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Type 1 diabetes mellitus is an autoimmune disorder in which a lack of
insulin is detrimental to the regulation of blood glucose. People with the
disease must take doses of insulin to compensate. However, many
endogenous and environmental stimuli alter glucose metabolism and
sensitivity to insulin in the day to day life of the individual. The ability to
understand, quantify and model such factors has great potential to improve
glycaemic control.
The individualised nature of both the presence of and response to everyday
stimuli inclines the research needs towards models that can be used in the
outpatient environment. The unique challenges around the quantity and
quality of outpatient data necessitates consideration to the practical
identifiability of behaviours and parameters in the model. Hence, this work
works towards modelling everyday life effects in a manner that is robust to
poorer data. In particular:
Chapter 1 introduces the clinical concepts around type 1 diabetes
along with some of the underlying physiological concepts of glucose
homoeostasis.
Chapter 2 briefly reviews the history of mathematical modelling of
glycaemia.
Chapter 3 introduces concepts around model fitting, identifying model
parameters, and especially the need for considering practical identifiability.
Chapter 4 reviews the literature for justification and explanation of
the effects of nutritional variation, psychological state, physical activity and
metabolic rhythms on glycaemia. The review also covers current methods
iv
and technologies for quantifying the presence or effect of these factors and
mathematical models developed to date.
Chapter 5 introduces the high quality clinical data that has been
obtained for model building and evaluation.
Chapter 6 details a range of models developed for the appearance of
plasma insulin from subcutaneous insulin infusion, and an extensive
analysis to compare the performance of the models.
Chapter 7 presents a data-driven modelling technique used to
ascertain the nature of the effect of mild to moderate exercise on plasma
insulin and glucose concentration.
Chapter 8 builds on the data-driven information with simplistic
differential models for insulin and glucose using basis functions to model
the effects of exercise.
Chapter 9 explores in silico the potential for everyday life effects to be
identified in diary-style outpatient data.
Chapter 10 presents a method for further in silico analysis of the
identifiability during model recovery.
Chapter 11 details a preliminary exploration of a potential method for
evaluating a priori practical identifiability.
Chapter 12 analyses the effect of pre-analytical glucose decay on
diagnosis rates of gestational diabetes.
Chapter 13 summarises the findings of the research.
Chapter 14 suggests opportunities for future work.
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Insulin therapy for type 1 diabetes mellitus is used to manage and
maintain near normal blood glucose. However, this therapy balances
treating hyperglycaemia and avoiding hypoglycaemia, both of which have
negative health consequences. Optimal insulin doses are often uncertain in
everyday life. Factors that are often overlooked can noticeably alter the
metabolism of glucose and insulin, which can confound glycaemic control.
Four major categories of everyday life factors have been reviewed in depth
in the literature: nutritional variability, psychological effects, physical
activity and metabolic rhythms.
Physiological mathematical models have long been used to study, observe
and control glycaemia. However, relatively little physiological modelling of
everyday outpatient factors has been carried out. Clinical data of subjects
with type 1 diabetes experiencing everyday life events such as exercise,
meals, snacks and insulin boluses was used as the basis for model
development. In particular, the inclusion of the appearance of insulin from
subcutaneous infusion, and the effect of exercise on plasma insulin and
glucose concentration have been modelled. The insulin system was
modelled with multiple physiological compartments while the effect of
exercise was initially modelled with a data-driven autoregressive technique
before basis models were developed.
Practical identifiability was considered to be a mathematically limiting
factor for model complexity and specificity given that high quality data is
generally not available in the outpatient environment. Hence, model
development strongly considered practical identifiability. For example, a
number of analyses were employed to determine which of multiple options
for the insulin model had the optimal complexity. The result was that one
of the simpler models had the best compromise between fit, parameter
vii
robustness and prediction ability. Furthermore, since practical
identifiability is a relatively new field with no formal analyses, two possible
evaluation techniques were explored. One technique with an analytical a
priori nature and the other using retroactive computational methods.
An in silico Monte Carlo analysis was carried out to test the potential
model recovery of exercise, stress fatigue and insulin sensitivity in
outpatient glycaemia. It was found that sparse, irregular and noisy data
could be overcome as the data accumulated to provide a clearer picture of
patient status. Variation in parameters decreased with increasing data
according to the 1/
√
n rule, indicating that measurement error and other
sources of noise introduced did not obscure parameter estimation. This
proof of concept represents a pathway toward personalisable glycaemic
models that can be fitted to the individual’s responses, and be used to
predict their response to treatment. Ultimately, sound modelling of
everyday life factors would improve the quality of life for sufferers of
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Type 1 diabetes mellitus (T1DM) is a metabolic disorder resulting from the
autoimmune destruction of pancreatic β-cells and subsequent lack of insulin
secretion (Atkinson and Eisenbarth, 2001). Insulin is necessary to regulate
blood glucose, without which high glucose levels result. Untreated, T1DM
is fatal. Hence, exogenous forms of insulin are usually injected or infused
subcutaneously. The disease often onsets in childhood, although it can
develop at any age, and is estimated to account for 5-10% of all cases of
diabetes (American Diabetes Association, 2006).
Prior to the 1850s diabetes was diagnosed by tasting urine, since the large
quantities of glucose cleared by the kidneys was easily detectable. The
1920s saw both commercially available urinary glucose tests and the
emergence of laboratory-based blood glucose measurement (Gale, 2002).
More recently, testing the presence of particular antibodies has proved to
be a good predictor of T1DM onset prior to the presentation of other
clinical symptoms (Sosenko et al., 2013; Atkinson and Eisenbarth, 2001).
Both reported and apparent incidence of T1DM has significantly increased
over the last couple of centuries (Gale, 2002) and even in the last couple of
decades (The DIAMOND Project Group, 2006). The pathology of T1DM is
considered to arise from a complex interaction between both risk-increasing
and protective genetic factors and a variety of environmental influences,
ultimately resulting in the production of auto-antibodies that target and
destroy β-cells (Atkinson and Eisenbarth, 2001). The environmental factors
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in particular are not well understood but the primary areas investigated are
viral infections, infant diet and toxins. The fast increasing disease incidence
draws much research interest to uncovering and therefore responding with
preventative measures for environmental risk factors (The DIAMOND
Project Group, 2006).
A related and much more common disorder is type 2 diabetes mellitus
(T2DM) which is likewise characterised by high blood glucose and accounts
for 90-95% of diabetes cases (American Diabetes Association, 2006). Unlike
T1DM, this form of diabetes is usually due to a combination of insulin
resistance and defective insulin secretion. Recent research indicates onset of
T2DM to be caused by over-production of insulin (Pories and Dohm, 2012).
Basal glucose production is subsequently higher to compensate for chronic
hyperinsulinaemia. Combined with other environmental and genetic risk
factors affecting insulin secretion and sensitivity, the postprandial insulin
response becomes blunted, resulting in hyperglycaemia. As the disease
progresses, β-cell production deteriorates and insulin secretion reduces.
Hence, late-stage T2DM presents similarly to T1DM.
1.2 Glucose homoeostasis
Glucose is a simple monosaccharide sugar with the molecular formula
C6H12O6. Glucose is an essential nutrient for humans and absorbed as a
major component of most dietary sources of carbohydrates. Glucose is also
synthesised in the liver from other non-carbohydrate substrates. The
circulatory system delivers glucose to all other organs in the body where it
is metabolised to release usable energy. The central nervous system,
smooth muscle and red blood cells are able to absorb glucose directly, but
most other tissues such as skeletal muscle and fat rely on insulin to
facilitate glucose transport into the cell (Cherrington, 1999). Since glucose
is primarily transported throughout the body via the bloodstream, it is
critical that glucose is present in the blood in appropriate concentrations.
The normal (euglycaemic) range for glucose is pictured in Figure 1.1.
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Figure 1.1: A diagram representing the full range of blood glucose,
showing euglycaemia, hypoglycaemia and hyperglycaemia. Note that the
euglycaemic range is relatively small and off-centred compared to the full
range (Kovatchev et al., 1997).
Glucose < 3.9 mmol/L is hypoglycaemia (Kovatchev et al., 1997) which can
be caused by excess exogenous insulin, and is generally accompanied by
unpleasant symptoms such as anxiety, cognitive dysfunction and seizures
(Cryer et al., 2003). Hypoglycaemia can be fatal or cause permanent brain
damage due to energy starvation of the central nervous system. Frequent
exposure to these blood glucose levels reduces an individual’s
hypoglycaemic awareness and therefore reduces their ability to take
corrective action (Cryer et al., 2003). Glucose > 10 mmol/L is considered
hyperglycaemia (Kovatchev et al., 1997). Chronic but mild hyperglycaemia
tends to result in complications such as neuropathy, kidney disease,
hypertension and heart disease (De Boer et al., 2008; Shankar et al., 2007;
Retnakaran and Zinman, 2008; Rubin and Peyrot, 1999). Extreme
hyperglycaemia associated with ketoacidosis and cerebral edema can be
fatal (Atkinson and Eisenbarth, 2001).
Glucose concentration requires constant bodily regulation to remain at
euglycaemic levels. The large quantity of incoming glucose from ingested
meals is typically the most major disturbance. In healthy individuals,
fasting glucose levels are around 4-5 mmol/L. Following a meal, blood
glucose concentration may reach 7-10 mmol/L or higher for some
individuals consuming meals with a large glycaemic load. Within 1-2 hours
the concentration will be under 7 mmol/L again, progressing to fasted
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levels. This glycaemic regulation is achieved through multiple concurrent
mechanisms (Figure 1.2).
1.2.1 Insulin and peripheral uptake
Insulin is a peptide hormone secreted from the β cells of the pancreas. The
primary function of insulin is to facilitate glucose transport into muscle and
fat tissue to be stored and metabolised for energy. Insulin therefore has the
dual primary purpose of reducing blood glucose concentration and thus
mitigating postprandial hyperglycaemia. Secretion of insulin typically
increases in response to sensory information from the gut (Cernea, 2011)
and rising glucose levels (Cherrington, 1999). Likewise, low blood glucose
and also high insulin concentrations reduce insulin secretion.
From the plasma, insulin diffuses into the extracellular interstitial space in
peripheral muscle and fat tissues. There it docks to insulin receptors on the
surface of a cell. Through a complex process, the insulin acts on the
receptor to stimulate a new glucose transporter to be expressed in the cell
membrane. The new transporter increases the rate of glucose transport into
the cell, also promoting glycogen formation. After the insulin molecule has
fulfilled its purpose it may be degraded by the cell or released. The liver
and kidneys clear most of the insulin in circulation.
The efficacy of insulin in increasing glucose transport into insulin sensitive
tissues at a given time is dependent on a large number of factors, generally
lumped together as a single whole-scale notion termed insulin sensitivity.
The equivalent but inverse property termed insulin resistance was more
commonly referred to in historical literature. In the short term, insulin
sensitivity is influenced by the likes of daily metabolic rhythms (Hinshaw
et al., 2013), stress (Rizza et al., 1982), physical activity (Borghouts and
Keizer, 2000), and menstrual cycles (Lunt and Brown, 1996). Longer term
insulin sensitivity changes are correlated to factors such as age, obesity
(Montastier et al., 2014), puberty (Hannon et al., 2006), and pregnancy
(Cousins, 1991).
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As previously stated, individuals with T1DM lack insulin. Autoimmune
destruction of the insulin-creating β cells in the pathogenesis of T1DM may
occur over a short or long period of time (American Diabetes Association,
2006). Shorter onset is more typical of children and adolescents while
longer onset is more typical in adults. Those with established T1DM have
negligible insulin secretion. Without insulin, hyperglycaemia persists and
insufficient glucose reaches insulin-sensitive tissues.
1.2.2 Hepatic and renal balance
At the basal state, the liver and the kidney produce and release glucose into
the plasma from stored sources (Cherrington, 1999). The liver performs
this endogenous glucose production (EGP) though two metabolic processes:
glycogenolysis and gluconeogenesis. Glycogenolysis cleaves glucose
monomers from glycogen, a glucose polysaccharide. Gluconeogenesis
metabolises non-carbohydrates such as pyruvate, lipids and lactate into
glucose. The kidney only produces glucose through gluconeogenesis but
also reabsorbs glucose back into the bloodstream that would otherwise be
destined for the urine (Gerich, 2010).
Following a meal containing carbohydrates, a third of incoming glucose is
taken up as it passes through the liver, both stored as glycogen and utilised
for energy (Cherrington, 1999). The high gradient of glucose in the portal
vein (from the intestine to the liver) compared to arterial concentration, as
well as the increased presence of plasma insulin and glucose all promote
hepatic glucose uptake. Insulin also reduces EGP in the liver by decreasing
glycogenolysis directly and gluconeogenesis indirectly. Therefore net
hepatic glucose output remains negative until plasma glucose, plasma
insulin and the portal vein glucose gradient have lowered.
Several other hormones regulate the action of the liver, post-prandially and
otherwise. Glucagon is a hormone secreted in α cells of the pancreas that
promotes hepatic EGP (Cherrington, 1999; Gerich, 2010). Glucagon serves
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to protect against hypoglycaemia, for example being secreted more when
insulin is released due to fat intake rather than glucose absorption (Carr
et al., 2008). Thus insulin and glucagon together mediate much of the
liver’s glucoregulatory response. The catecholamines, secreted from the
adrenal glands in a state of stress, also have a range of effects on both the
liver and kidney such as promoting renal glucose release, insulin
suppression, and glucagon secretion (Gerich, 2010). Additionally, in
Cherrington (1999)’s animal model, epinephrine and norepinephrine
independently promoted glycogenolysis, and epinephrine also promoted
gluconeogenesis.
As previously stated, people with T1DM must rely entirely on exogenously
administered insulin. As a result, EGP is less tightly controlled, though
still regulated by the remaining mechanisms. Furthermore, people with
diabetes of both types tend to have hyperinsulinaemia. The effect of this is
perhaps most notable during moderate aerobic exercise. High insulin
concentrations that are not down-regulated for exercise tend to cause a
shortfall in EGP that eventually results in hypoglycaemia (Yardley et al.,
2013; Sonnenberg et al., 1990). On the other hand, in the absence of
sufficient insulin, glucose uptake in the liver and kidney are vital for
ameliorating the extent of postprandial hyperglycaemia.
1.2.3 The incretin effect
Incretins are glucoregulatory hormones secreted from the enterocyte cells
lining the small intestine in response to the presence of nutrients (Hayes
et al., 2014; Ahrén, 2013; Cernea, 2011). The two main incretins are
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP). The primary effect of both incretins is to stimulate
glucose-dependent insulin secretion (Cernea, 2011; Karstoft et al., 2015).
The ’incretin effect’ is defined as fraction of insulin secretion after an oral
dose of glucose that does not appear for an equivalent intravenous infusion
(Ahrén, 2013; Hayes et al., 2014). The magnitude of the response is




















Figure 1.2: A schematic of healthy glucose homeostasis showing the
movement of glucose into and out of various tissues through the plasma,
as well as hormonal signalling between organs.
carbohydrate all stimulate the secretion of both incretins (Rijkelijkhuizen
et al., 2010; Carr et al., 2008; Kameyama et al., 2014).
The effects of both GIP and GLP-1 are complex and multifaceted. Both
stimulate glucose dependent insulin secretion (in those with functioning β
cells) and likewise decrease glucose-dependent glucagon secretion (Cernea,
2011; Hayes et al., 2014). Although in some conditions GIP can instead
increase glucagon secretion (Carr et al., 2008; Hayes et al., 2014). Beyond
pancreatic effects, GLP-1 decreases the gastric emptying rate and increases
satiety (Hayes et al., 2014; Cernea, 2011). GLP-1 also appears to increase
insulin-independent muscular glucose uptake (Hayes et al., 2014; Karstoft
et al., 2015; Abdulla et al., 2014; Johnson et al., 2007; Meneilly et al., 2001)
and may suppress EGP (Hayes et al., 2014; Prigeon et al., 2003; Karstoft
et al., 2015). GIP also potentially increases blood flow (Karstoft et al.,
2015). There are mixed opinions in the literature as to whether individuals
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with T1DM have normal or impaired incretin secretion (Vilsbøll et al.,
2003; Kamoi et al., 2011; Lugari et al., 2000; Zibar et al., 2015).
1.3 Diabetes therapy
The discovery of insulin in 1921 heralded the treatment of T1DM (Atkinson
and Eisenbarth, 2001). Initially, insulin was thought to be a cure, however
the complexity of treatment soon became clear. Prior to this point the
disease was considered to have 100% mortality for children in particular.
Younger children typically survived for less than 2 years after onset, and
older children sometimes survived 3-6 years (American Diabetes
Association, 2006). T1DM is still fatal in some developing countries such as
in Sub-Saharan Africa where treatment is not readily available or
affordable. Even in developed countries fatalities still occur, especially in
cases of delayed diagnosis in young children (Atkinson and Eisenbarth,
2001).
Initially, people were treated with porcine insulin which is very similar in
structure to human insulin. In the years following, a number of
manufactured human insulins were developed. Manufactured insulins vary
in structure to achieve different purposes. Human insulin is typically stored
in the pancreas as a hexameric group (Kang et al., 1991). However, the
monomer is the active form used elsewhere in the body. While the hexamer
is the most stable form of insulin, it takes some time to break into dimers
then monomers. Hence, some manufactured insulins have certain sequences
in the protein structure altered to discourage hexamer formation and
therefore act more rapidly (Home et al., 1999). This is particularly useful
to administer in conjunction with a meal. Other insulins are further bound
in crystalline structures to slow breakdown into monomers (Roach and
Woodworth, 2002). These longer-acting insulins are useful for mimicking
the basal rate of insulin release throughout the day observed in healthy
individuals.
The most common therapy involves multiple daily subcutaneous (SC)
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injections of these different types of insulin (Atkinson and Eisenbarth,
2001). Outpatients consult with clinicians regularly to monitor and
optimise their treatment regimes. The goal with longer-acting insulins is to
create a smooth basal profile to minimise differences throughout the day.
Depending on the half life of the insulin, this may require more than one
injection per day. Outpatients will also inject quantity of rapid-acting
insulin with meals based on the estimated quantity of carbohydrates in the
meal. At any other time, rapid-acting insulin may also be injected to lower
blood glucose according to a ratio of glucose levels to insulin units.
More recently, insulin pumps have become a mainstream form of treatment
(Stephens, 2015). These pumps are installed with a needle into the
subcutaneous tissue that is replaced every few days. Pumps tend to contain
only a rapid-acting form of insulin but have the ability to titrate the
contents at a slow rate throughout the day for a basal profile, as well as
being able to deliver large boluses for meals or correction. The pumps can
be programmed to supply a variable basis profile throughout the day in
accordance with a person’s circadian rhythm of glucose tolerance. The
pumps also store the owner’s insulin ratios and are able to make basic
recommendations based on input information.
A significant amount of research has been carried out in the field of decision
support based on mathematical modelling, both for self managed blood
glucose monitoring with multiple daily injections (Wong et al., 2008c,
2009), clinically monitored care for the critically ill (Chase et al., 2011;
Pappada et al., 2013; Lin et al., 2011; Pielmeier et al., 2010), and for a
closed loop system utilising insulin pumps and continuous glucose monitors
(Bequette, 2012; Cobelli et al., 2011; Hovorka et al., 2011, 2013; Kovatchev
et al., 2009). Mathematical modelling will be covered more extensively in
Chapter 2. The goal of decision support in T1DM is to reduce the burden
of disease management and improve patient safety. The burden of disease
management is associated with decreased perceived quality of life (Rubin
and Peyrot, 1999, 2001). Additionally, fear of hypoglycaemia tends to
result in those with T1DM tending toward hyperglycaemia and missing out
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on the benefits of euglycaemia (Atkinson and Eisenbarth, 2001).
Despite the amount of research carried out to date, many challenges remain
for delivering effective and personalised care to those with diabetes. In
particular, there are a vast number of variable stimuli that an individual
encounters throughout the day in an outpatient environment. Examples
include differing levels of glucose demand depending on physical activity,
changes in insulin sensitivity based on mood, and different patterns of
incoming glucose from ingested food. Research around these factors is
reviewed in Chapter 4. The manner in which many environmental stimuli
affect glycaemia is complex and often not well understood. The
uncertainties created by such factors continue to confound treatment at
times for most individuals. Some people, termed by clinicians as being
”brittle”, are particularly susceptible to poor glycaemic control due to daily
variabilities. These individuals would benefit most from advances in





Mathematical modelling of physiological processes has become a standard
method for studying these processes and developing new integrated
technologies. This is particularly true in the field of diabetes research and
glycaemic control. This chapter overviews some of the historical
development of glycaemic models. By no means is the content covered
exhaustive, due to the sheer quantity of research carried out in the field.
Additionally, the overview will focus mostly on insulin kinetics and
glucose-insulin dynamics rather than insulin secretion models.
2.1 Early models (1960s-1970s)
There have been a lot of glycaemic models developed over the years and it
can be difficult to trace them all through the literature. Some of the earliest
research was carried out in the 1960s by the Ackerman group (Ackerman
et al., 1964; Gatewood et al., 1968). This group fit linear differential models
to oral glucose tolerance tests with the purpose of distinguishing between
healthy and mildly diabetic responses. Ackerman et al. (1964) defined their
system as:
Ḣ = −l1H + l2 + l3G (2.1)
Ġ = −l4G+ l5 − l6H − I (2.2)
where H is plasma insulin concentration, G is plasma glucose
concentration, l1 is the insulin clearance rate, l2 is basal insulin secretion, l3
is the glucose-dependent insulin secretion rate, l4 is the insulin-independent
glucose disposal rate, l5 is glucose production, l6 is the insulin-dependent
glucose disposal rate and I is the appearance of glucose from oral loads. An
estimate was used for the plasma glucose profile from oral loads, despite a
12
relative lack of data to validate the model (Gatewood et al., 1968).
Much of the subsequent research into modelling insulin and glucose utilised
multiple tracer technologies to measure the contributions of different organs
in the production and disposal of insulin and glucose and under certain
conditions. These types of experiments significantly increased the inherent
complexity involved. By 1974, three compartment models had been
proposed for each of insulin and glucose by the group of Sherwin et al.
(1974) and Insel et al. (1974). The insulin model compartments described
hepatic, plasma and extra-vascular concentrations. Sherwin et al. proposed
three different model arrangements for the interactions between and
clearances from each of the compartments. Insel et al. fit tracer data to the
three compartment model that included insulin dependent and independent
glucose disposal. Some other early contributors to insulin models were
Frost et al. (1973) and Tranberg and Dencker (1978). The model of Frost et
al. was non-linear having both linear and saturable clearance from the
plasma compartment. In contrast, Tranberg and Dencker used only linear
clearance from the plasma. Another contributor to glucose models in this
period was Radziuk et al. (1978) who simplified prior 3-compartment
glucose tracer models to a 2-compartment model.
2.2 The Bergman Minimal Model (1979)
In contrast to many of the complex models prior, perhaps the most notable




= −(p1 +X(t))G(t) + p1Gb (2.3)
dX
dt
= −p2X(t) + p3(I(t)− Ib) (2.4)
dI
dt
= −n(I(t)− Ib) + γt|G(t)− h| (2.5)
where G is the plasma glucose concentration, X is the insulin action, and I
is the plasma insulin. The b subscript indicates a basal level parameter,
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while the p and n terms are rate constants, and h is the target glycaemia
relating to a critical glucose level for insulin secretion. The associated
insulin sensitivity (SI) can be calculated as p3/p2.
The Minimal Model has formed the basis for a large amount of glycaemic
modelling research and application. The model and variations of it are in
use (Campioni et al., 2009; Cobelli et al., 2014; Breton, 2008; Roy and
Parker, 2007; Erichsen et al., 2004). However, the Minimal Model has
drawn much criticism. This criticism is partially directed at just how
minimal the model is in terms of some of the physiological assumptions and
simplifications made (Chase et al., 2006; Palumbo et al., 2013) but also in
terms of the lack of robust parameter solutions obtained when fitting the
model to experimental data (Palumbo et al., 2013; Docherty et al., 2011;
Cobelli et al., 1998; Quon et al., 1994). More recent legacies of the Minimal
Model have addressed concerns around parameter robustness by using
Bayesian estimation methods which penalise parameters for taking on
values outside an expected range (Cobelli et al., 1999; Pillonetto et al.,
2002, 2003).
2.3 The Sorensen physiologic model (1985)
Sorensen (1985) developed an incredibly extensive whole-body glucose
metabolism model using a large number of simultaneous differential
equations, based on the earlier work of Guyton et al. (1978). The model
includes mass balances of glucose throughout several compartments: brain,
heart and lungs, gut, liver, kidney, and periphery. Sources and sinks for
glucose mass are considered in each compartment. An example of this






GGG −QGLGL + rHGP − rHGU (2.6)
where V GL is the glucose distribution volume of the liver, GL is the glucose
concentration in the liver, QGA is the blood flow rate in the hepatic artery,
GH is the glucose concentration in the heart and lungs, GG is the glucose
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concentration in the gut and QG the blood flow rate in the gut, QL is the
blood flow rate in the liver, rHGP is the hepatic EGP while rHGU is the
hepatic glucose uptake.
This equation alone hints at the complexity of the entire model with the
interactions between the various organs. In particular, Sorensen (1985)
modelled glucose in the brain, heart and lungs, gut, liver, kidney, and
periphery. In addition to glucose balance equations, there are insulin
balance equations for all of the same areas, as well as a mass balance for
plasma glucagon. Altogether there are sixteen differential equations.
Sorensen calibrated the model to a 70 kg male and populated the vast
number of variables with information from the literature. This is an
example of a bottom-up modelling approach that focuses on including all
contributing physiological processes, big or small, to achieve the observed
outcomes. This is in contrast to more minimal approaches that aim to
include the major contributing factors and achieve concordance with
outcomes through model fitting to account for patient variability. The
bottom-up approach tends to be less conducive to dealing with patient
variability. The inherent complexity in the Sorensen model has resulted in
comparatively sparse use in research (Kovacs et al., 2008). However, some
independent research utilised a modified version of the model (Parker et al.,
2000; Kovacs et al., 2008) or used it for simulation (Markakis et al., 2008).
2.4 Intensive care (2000s)
Much of the more recent research dedicated to glycaemic model
development has been motivated by the need for safe and effective
glycaemic control in intensive care units. The bodies of the critically ill are
under sufficient medical stress to cause substantial insulin resistance and
associated hyperglycaemia. Hyperglycaemia in this cohort significantly
impacts on mortality and recovery times (Chase et al., 2006). Thus,
mathematical modelling has been used to optimise insulin therapy for
patient health and safety, recovery time, and nurse workload.
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Three notable models were developed for use in critical care in the 2000s
(Chase et al., 2006). The first by Chee et al. (2003) is not a physiological
model as such but a proportional-integral-derivative control model. The
model prescribes different doses based on the patient’s blood glucose. The
dose characteristics are subject to change according to integral and
derivative control tactics.
The second model was physiological model developed for T1DM control
model by (Hovorka et al., 2004), and later modified for critical care (Plank








Q1(t) + k12Q2(t)− FR + UG(t) + EGP0(1− x3(t))
(2.7)






























ẋ1(t) = −ka1x1(t) + kb1I(t) (2.15)
ẋ2(t) = −ka2x2(t) + kb2I(t) (2.16)
ẋ3(t) = −ka3x3(t) + kb3I(t) (2.17)
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where Q1 and Q2 are accessible and inaccessible glucose compartments, k12
is the transfer rate between these compartments, VG is the distribution
volume of Q1, y and G are the measurable glucose concentration and EGP0
is the equivalent EGP with no insulin present. F c01 is total
non-insulin-dependent glucose flux for ambient glucose concentration while
FR is renal clearance above 9 mmol/L. UG is the incoming glucose from the
gut based on digested carbohydrates (DG), carbohydrate bioavailability
(AG) and the time period until maximum appearance in Q1 (tmax,G).
Insulin is modelled with two compartments (S1 and S2) to describe the
absorption of subcutaneous short-acting insulin, where u(t) the insulin
infusion, tmax,I is the time period until maximum appearance in the plasma
(I), ke is the elimination rate and VI the plasma insulin distribution
volume. The remaining compartments on which insulin acts are the EGP
(x1), distribution (x2) and disposal (x3), according to the activation and
deactivation rates given by the ka and kb terms.
The final of the three models is that of Chase et al. (2006) which is based
on the Minimal Model. The model is described:
Ġ = −pGG− SI(G+GE)
Q
1 + αGQ
+ P (t) (2.18)
Q̇ = −kQ+ kI (2.19)
İ = − nI
1 + αII
+ uex(t)/V (2.20)
P (ti < t < ti+1) = P̄i+1 + (P (ti)− P̄i+1)e−kpd(t−ti) where P̄i+1 < P (ti)
(2.21)
P (ti < t < ti+1) = P̄i+1 + (P (ti)− P̄i+1)e−kpr(t−ti) where P̄i+1 > P (ti)
(2.22)
where G is plasma glucose above equilibrium glucose (GE), Q is the
interstitial insulin, cleared at a rate k, I(t) is the plasma insulin with
exogenous input (uex(t)), distribution volume (V ) and clearance rate n.
The action of insulin and insulin clearance are both saturated effects
modelled using Michaelis-Menten functions with saturation parameters αG
and αI . The endogenous glucose clearance is denoted pG and the insulin
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sensitivity is SI . Total plasma glucose is P (t), dependent on enteral feeding
where kpr and kpd are increasing and decreasing feed rates, and P̄i and ¯Pi+1
are steps in the enteral feed rates. The model has since been updated to
include more complex nutritional mechanics (Lin et al., 2011).
2.5 Summary and present
Glycaemic modelling has been carried out extensively over the last 50
years. The earliest models were descriptive but relatively simple compared
to some of the models that followed. As the models became more
sophisticated, different groups have decided on approaches that varied on
the scale of simple to complex. The Bergman et al. (1979) Minimal Model
is considerably simpler than the Sorensen (1985) physiologic model, which
has at least 22 differential equations. Glycaemic modelling was initially
motivated by studying and controlling diabetes but also gained a focus in
intensive care in the 2000s.
At present, work continues in earnest to develop a safe and effective
closed-loop control strategy for people with diabetes. A keyword search of
”artificial pancreas” in the abstract and citation database Scopus results in
over 800 hits for content published in the 2010-2016 period alone. Models
continue to be researched, developed and implemented in this field. Despite
the research efforts and promising clinical trials, adequate closed-loop
control for outpatients with diabetes has not yet been achieved, mainly
attributed to limitations in continuous glucose monitoring systems
(Hanazaki et al., 2016). Variabilities in glucose metabolism arising from the
outpatient lifestyle such as stress and physical activity are also considered
major challenges to control, closed-closed loop or otherwise (Ward et al.,
2011; Breton, 2008). Hence, models are beginning to incorporate more of
these types of features as research progresses.
The goal of the present work is not to focus on the fundamental modelling
of glucose dynamics, but rather on incorporating everyday life effects into
an existing model, and to address these particular challenges in glycaemic
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control for the individual with T1DM. By nature, less fundamental aspects
of glucose metabolism encountered in the outpatient environment are
subject to large inter-patient variability. Hence, modelling strategies for
this purpose require a high level of personalisability to be effective. This
requires that such models be able to handle the kinds of behaviour and
variability anticipated, and on top of that work effectively with outpatient
data. Both criteria contribute their own sets of challenges. However, this
work represents a natural progression of the long and wide legacy of
glycaemic modelling to date.
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Chapter III
Parameter identification and identifiability
This chapter introduces the ideas and methodologies around identification
of model parameters and the identifiability of those parameters. Both
concepts are used extensively throughout this thesis.
3.1 The inverse problem
The ’inverse problem’ in science and engineering is the use of observational
data to calculate an underlying causative factor in a representative model.
In the context of physiological modelling, inverse problem methodologies
optimise variables in the model to some criteria based on the data of
measurable species. These optimised variables are the identified parameters
which govern underlying physiological behaviour in a manner specific to
that dataset. The value of identified parameters is dependent on the model,
data and application.
A model, especially in physiology, can only ever be an approximation of the
real processes occurring, due to the numerous inconsistent and variable
factors that can affect biological systems. When considering models
representing different approximations of the same system, it is perhaps
intuitive to assume that parameters identified from complex
approximations are more valuable and useful than those obtained from
simpler, more errant approximations.
However, it is important to note that the usefulness of model complexity is
entirely limited by the unique observability of modelled behaviours, with
respect to the quality and quantity of data available. There is no use trying
to quantify the underlying behaviour of effects that are too small compared
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to measurement noise, or too poorly timed relative to when data is
sampled. This is the essence of identifiability.
With regard to application, some parameters tend to be of high clinical
relevance (such as insulin sensitivity in glycaemia), while other parameters
tend to be less clinically relevant but support the optimisation process by
accounting for other inter- or intra- personal variabilities. On occasion, a




Optimisation of a parameter set, represented by the vector x, is often carried
out by minimising the 2-norm of an objective or cost function (Ψ). This
optimisation is described mathematically as:
xopt = argminx(||Ψ||2) (3.1)
In the context of fitting a model to a measured behaviour, for example blood
glucose concentration (G), the objective function is the residual modelling





(GS −G(tS )) (3.2)
where GS are the measured samples for S = 1 . . . n, where n is the total
number of samples. Likewise, G(tS) is the modelled blood glucose at the
sample times.
A successfully obtained least squares solution will have minimal positive or
negative bias in the residual error. For ideally formulated models, the
residual error corresponds exactly to the measurement noise. Hence, least
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squares optimisation is effective when noise in the measured behaviour is
zero-mean with no significant outliers, and when all observable behaviours
that do not correspond to noise are otherwise modelled.
3.2.2 Algorithms
Due to the typical non-linearity of inverse problems in physiological
modelling, least squares optimisation cannot be carried out through simple
linear regression. An iterative approach is required since the optimised
parameters depend on the model forward simulation (Equation (3.2)) which
in turn depends on the parameters in a way that cannot be simplified and
resolved. For the blood glucose example, xopt = f (G(tS) = f(x)).
The present work has extensively utilised gradient descent algorithms to
identify optimised parameters. Essentially, gradient descent operates on an
objective surface of ||Ψ||2 = f (x) (Figure 3.1). At each iteration (i), ||Ψ||2
is evaluated a step in the direction of each parameter from the current set
(xi). This information is used to decide which direction on the objective
surface is downhill, and how far to step in that direction for the next set
(xi+1). As with all numerical methods, the perturbation must be suitably
small to attain acceptable accuracy in xopt. However, it must also be large
enough relative to the quality of the forward simulation to avoid
convergence to a local minima in a noisy objective surface that does not
represent the least squares solution at the global minima.
The simplest gradient descent method is known as steepest descent, and
takes a step downhill in proportion to the steepness. The method is
relatively slow to converge but also very stable. Gauss-Newton is a second
order gradient descent algorithm that converges must faster but is
sometimes less stable. Levenberg-Marquardt is a further development on
Gauss-Newton that improves stability by tending toward steepest descent
































Figure 3.1: A contour plot (left) and surface plot (right) of an example
objective surface for two parameters. Higher dimension objective surfaces
(with three or more parameters) are harder to conceptualise visually but
follow the same mathematical principles.
3.2.2.1 Gauss-Newton
Gauss-Newton iterations are carried out as follows:

































· · · ∂Ψn
∂xp
 (3.4)
where j is the parameter index (j = 1, 2, . . . , p) for p total parameters.
It is most simple to use a first order numerical approximation for the









The Levenberg-Marquardt algorithm iterates to xopt using Equation (3.6)
and 3.7.
xi+1 = xi + A
−1(JTi Ψi(xi)) (3.6)
A = JTi Ji + λidiag(J
T
i Ji) (3.7)
where λ is the damping parameter. Depending on the desired properties
of the algorithm, λ is assigned different values as identification progresses.
The larger it is, the closer to first order descent. The smaller it is, the
closer to Gauss-Newton. Generally it is recommended to have some initial
value, λ0 with subsequent assignment of λi = λi−1/v (where v > 1) if it
achieved a greater decrease in ||Ψ||2 than λi−1. If either option increased
||Ψ||2 , λi = λi−1vk would be assigned, increasing k until ||Ψ||2 could be
decreased. The revised parameter set xi would therefore only be accepted
once ||Ψi ||2 < ||Ψi−1 ||2 .
3.2.3 Convergence
Since nonlinear inverse problems are solved iteratively, there is typically
some criteria which define how many iterations are carried out. If there is a
real solution and the system is stable, the parameter estimates will
converge towards this real solution. A maximum number of iterations can
be prescribed indiscriminately but it is usually more beneficial to include a
tolerance-based convergence criterion as well. If satisfactory convergence
occurs sooner than the maximum number of iterations, no unnecessary
computational time is spent, and the maximum iterations can be assigned a
conservatively large number.
Convergence is best measured in the object of interest, the parameter set
itself, rather than a secondary feature like the modelled behaviour, which
would be less sensitive to parameter convergence. Though there are many
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When the criterion is true, the appropriate tolerance is reached and
iterations cease. This criterion normalises convergence by the scale of each
parameter. Thus, it ensures approximately 4 significant figures are reached
in each parameter.
3.3 Identifiability
Identifiability is concerned with successfully modelling and identifying
uniquely observable behaviours. The field of identifiability can be broadly
split into two categories: structural and practical.
3.3.1 Structural identifiability
Structural or a priori identifiability is a well established field (Audoly
et al., 1998, 2001; Bellman and Åström, 1970; Bellu et al., 2007;
Pohjanpalo, 1978). This kind of identifiability is concerned with the model
formulation and whether there is a unique solution of optimised
parameters. Structurally identifiable models have a single global minima on
the objective surface. Structural identifiability analysis methods assume
perfect data, with at least as many observations as there are parameters.
Insufficient observations for the number of parameters results in an
under-defined solution.
A simple mathematical example of structural non-identifiability would be
to use the model Ẋ = −(x1 + x2)X and attempt to identify both x1 and x2
as separate parameters. Least squares estimation of these parameters would
result in a non-unique solution since there is no ability to distinguish the
individual effects of the parameters. Whatever value x1 was, x2 could take
on a value such that the desired net effect, as seen in the output behaviour,
was modelled to the best fit. On the objective surface, this would be seen as
a valley with an infinite line of solutions reaching minimum residual error.
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Structural identifiability is reasonably intuitive, especially in such a simple
example. Indeed, the formulation of the example model appears very
redundant. However, in large models, non-identifiability can be subtle and
hidden amongst the model complexity. Hence, several methods of detecting
and confirming a priori identifiability have been developed (Audoly et al.,
1998, 2001; Bellman and Åström, 1970; Bellu et al., 2007; Pohjanpalo,
1978). Model simplification can be used to remove a non-identifiable
feature if necessary. In some scientific fields it is practical to combine
several parameters into one non-dimensionalised parameter that can be
identified, such as the Reynolds number in fluid mechanics. However, this
approach may not be helpful when seeking to identify a specific
physiological parameter.
3.3.2 Practical identifiability
Practical identifiability is an emerging field (Raue et al., 2009, 2012, 2014;
Docherty et al., 2011; Saccomani, 2013). Though not as prevalent in the
research community, it is arguably more important than structural
identifiability, especially because of its less obvious and therefore more
subversive nature. The concept of practical identifiability takes into
consideration the role of data quality in the unique observability of
behaviours (Raue et al., 2009; Docherty et al., 2011). While structural
identifiability is discrete with either an affirmative or negative outcome,
practical identifiability can be viewed somewhat more continuously.
Parameters that are practically non-identifiable can be unique in terms of
model formulation, and thus pass as structurally identifiable. Therefore, for
perfect data, there is a global minima on the objective surface. However,
parameters prone to practical non-identifiability will tend to have large
regions of shallow gradients surrounding the minima, spanning a large
range in parameter values. The implication is that the noise in (inevitably)
imperfect data obscures the true location of the global minima in the
shallow region, and a wide range of parameter outcomes could result,
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depending on the exact properties of the dataset.
To illustrate this concept, consider the model y = x1 sin(t) + x2 sin(t + φ)
where x1 = 0.3 and x2 = 0.7. If the phase (φ) is
π
2
then the contributions of
the curves to y would be most apparent since one is at a maximum while
the other is at zero and vice versa. If φ is either 0 or π then the model could
be simplified to y = (x1 ± x2) sin(t). The contributions of x1 and x2 would
then be indistinguishable and thus structural non-identifiability is present.
However, as the phase approaches but does not equal 0 or pi, practical
non-identifiability increases and parameter estimates would become poorer.
Figure 3.2 shows a selection of parameter outcomes identified from data at
three different phases. For each dataset, seven datapoints between 0 and 2π
were taken with 20% noise applied. At φ = 0.5π there is maximum
practical identifiability since this represents the greatest possible phase
difference. Hence, the objective surface is conical and a relatively tight,
circular grouping of identified parameters results. As the phase approaches
π, the objective surface becomes progressively more elliptical. At φ = 0.95π
the objective surface is an extremely long ellipse, though appears as a
continuous valley within the reasonable range of parameter estimates. The
identified parameters now cover a large range of possibilities and thus are
no longer accurate or particularly useful.
In the example, when the phase was actually assigned to π, the parameter
identification algorithm failed to identify either parameter, producing NaN
results instead. This demonstrates how the effect of a structural
non-identifiability tends to be obvious to a person using the model. In
contrast, the φ = 0.95π model, with very low practical identifiability, still
produced parameter estimates, many of which could appear reasonable to
the model user in the context of use. However, the values obtained in
practice could be very different from the underlying behaviours, negatively
affecting treatment outcomes. Furthermore, the parameter identification
also resulted in good adherence of the model to the data (not shown).
Hence, the researcher could be deceived into believing that the model is
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Figure 3.2: Decreasing practical identifiability from left to right as the phase
approaches π. Top row: the simulated model (black) from the summed
components (grey). Bottom row: The no-noise objective surface (—) with
parameter estimates for 50 noisy datasets sampled from the model (+).
suitable for the given data, and that results are valid and useful when this
is far from true.
Early research describing practical identifiability was presented by Raue
et al. (2009). They presented a method for analysing both practical and
structural identifiability for all parameters in an arbitrary model based on
the flatness of likelihood profiles. Likelihood profiles are used in an
alternative parameter identification process known as Maximum Likelihood
Estimation. The likelihood profiles are similar to an objective surface in
that the minimal value indicates the optimum parameter value. However,
likelihood profiles are a more holistic representation of an individual





























Figure 3.3: A demonstration of the method of Raue et al. (2009) to
determine identifiability of a parameter using the maximum likelihood profile.
An identifiable parameter (left) has a likelihood profile that exceeds the
reference value (Ψ∗) outside the confidence interval. A practically non-
identifiable parameter (middle) has a distinct optimum but does not reach
the reference value outside the confidence interval. A structurally non-
identifiable parameter (right) has a flat maximum likelihood profile as there
are infinite optimum values.
Therefore, a totally flat likelihood profile indicates a structural
non-identifiability the same way that an infinite trench does on a
two-parameter objective surface. Likewise, if the likelihood function spans
indefinitely from either end of the minima without exceeding a certain
tolerance criterion, the parameter can be considered practically
non-identifiable. Raue et al. uses a threshold corresponding to a
likelihood-based 68% confidence interval, i.e. a parameter is considered
practically non-identifiable if the 68% confidence interval is infinite.
Figure 3.3 shows how the thresholds are used to determine identifiability.
Docherty et al. (2011) presented a graphical method for understanding and
evaluating identifiability in mathematically separable behaviours scaled by
the identified parameters. These behaviours are normalised by their
respective means and compared graphically. The closer the normalised
behaviours are, in particular at the sample times of the output data, the
poorer the practical identifiability. This method has more limitations than
that of Raue et al. but the advantage is that it can provide a clear picture
(literally) of why some datasets are more suitable than others and which
parameters might be better off as a single identified parameter. Docherty et
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al. also demonstrates that the method lends itself toward tailoring clinical
tests to optimise sampling times for accuracy and cost.
3.4 Implications
Solving the inverse problem is not always a simple matter of having a
model and using it to quantify the desired properties. Obviously, some
models are better approximations of real behaviours than others but the
story is far from ending there. Appropriate and robust parameter
identification methods are required to achieve good estimation.
Additionally, the implications of practical identifiability are far reaching for
the inverse problem. Some groups in the scientific community appear to
prefer complex models, since they have the best chance to describe the
system accurately. While it is generally true that model adherence to data
is improved with complexity and parameterisation, parameter robustness
suffers. Thus the sought after accuracy is not always upheld in the key
parameter outcomes. In some cases, it is not the degree of complexity but
an aspect of the model formulation that produces practical
non-identifiability, such as with the Minimal Model of glucose dynamics. In
either case, a good understanding of practical identifiability can prevent a
model being used inappropriately, which is especially important where
physiological modelling informs clinical decision making.
In the context of developing glycaemic models for outpatient use, practical
identifiability is a hugely important consideration. The type of data that
can be collected in the outpatient environment is incongruous with clinical
or research-grade data. Hence, models developed using research-grade data
cannot be translated directly to the outpatient and expected to perform in
the same manner. Hence, the present work retains an awareness of the








This chapter reviews so-called ”grey-noise” effects that, when
unaccounted for, can introduce non-random systemic errors into glycaemic
modelling outcomes. This review was published in the journal of
Biomedical Signal and Processing (Mansell et al., 2017b) and presents
physiological evidence to justify the presence of these grey-noise effects,
technologies and methods that exist to quantify their presence or effect in
some way, and previous efforts to model them by others in the field.
4.1 Motivation
Injecting exogenous insulin to restore normoglycaemia after a postprandial
excursion is a necessary therapy for those with T1DM and is often
beneficial for those with T2DM (Rubin and Peyrot, 2001). However,
estimating optimal insulin doses can be difficult. The traditional factors
determining a postprandial dose are meal carbohydrate content and
nominal SI. However, a host of small confounding influences accompany
these factors (Lovell-Smith et al., 2010; Lloyd et al., 1999; Nathan et al.,
1981; Sonnenberg et al., 1990; Lunt and Brown, 1996; Van Cauter et al.,
1997; Yardley et al., 2013; González-Ortiz et al., 2000). Uncertainty
introduced by confounding factors can cause individuals to take
conservative doses for fear of hypoglycaemia (Rubin and Peyrot, 2001),
reinforcing mild hyperglycaemia and increased incidence of diabetic
complications (Rubin and Peyrot, 2001; De Boer et al., 2008; Retnakaran
and Zinman, 2008; Shankar et al., 2007).
Physiological modelling tends to involve identification of patient-specific
physiological parameters from available data, either for a population or
specific to the patient at that time. For glycaemic control applications,
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these parameters are used in conjunction with measured data and
prediction algorithms to determine an appropriate insulin dose to remediate
glycaemic excursions to pre-defined targets. Thus, unmodelled, non-random
factors that affect this identification impact control safety and quality, and
thus compliance.
Comparatively simple models that contain few variables have proven to be
effective for glycaemic prediction and control in critical care (Chase et al.,
2008; Evans et al., 2011). These simple models work primarily because they
can be robustly identified (Docherty et al., 2011; Saccomani, 2013).
However, in outpatient diabetes there are significantly more environmental
stimuli present. These stimuli have the potential to contribute confounding
behaviours and variability to the glycaemic signal that are not measured or
included in the model.
For example, psychological factors, such as stress and depression, have been
shown to influence glycaemic outcomes, tending patients toward
hyperglycaemia (Rubin and Peyrot, 2001; Surwit et al., 1992; Räikkönen
et al., 1996; Lustman et al., 2000), and exercise is a major source of
glycaemic disturbance and can potentially cause hypoglycaemia (Breton,
2008; Dalla Man et al., 2009; Roy and Parker, 2007). When factors such as
exercise and stress are not modelled, they contribute to non-random grey
noise’ in the data and confound attempts to capture the patient’s true
glycaemic metabolism. Hence, capturing grey noise would ultimately lead
to more precise prediction in glycaemic levels and thus, improved glycaemic
control.
To fully and effectively model the glycaemic excursions of diabetes
outpatients, the models employed should attempt to minimise (by design)
the grey noise by including additional behaviours in conjunction with
patient-specific parameters. However increasing the size and complexity of
the models also increases risk of model structural (Audoly et al., 2001,
1998; Bellman and Åström, 1970; Bellu et al., 2007) and practical
(Docherty et al., 2011; Saccomani, 2013; Raue et al., 2009, 2014)
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non-identifiability. Parameters must be robustly identified for sensible
estimation, and effective model-based treatment.
Glucose-insulin dynamic models are the core element of any glycaemic
control algorithm and have already been extensively reviewed in the field
(Carson and Cobelli, 2001; Chase et al., 2006, 2010; Palumbo et al., 2013).
This chapter seeks to draw attention to important grey-noise effects in
diabetes that can significantly affect management and interpretation of
data, and to provide a qualitative assessment and comparison of the
representative modelling efforts to date and their applicability to the
outpatient environment. The background of literature evidence for each of
these effects and any methods of measuring their presence are also
explored, given that these aspects are critical for mathematical modelling
and control strategies. The specific grey-noise effects considered are:
variability in nutritional intake, psychological effects, physical activity and
metabolic rhythms.
A literature review was carried out through extensive searches on the
academic database Scopus, which includes access to PubMed and a range of
other citation sources. Due to the wide range of topics within the scope of
the research, no single or few search criteria were strictly applied. A more
thorough and expedient approach was required where the focus of criteria
shifted between the different grey-noise factors, and also between the fields
of clinical research, development and use of measurement technologies, and
mathematical model development and validation. The goal was to locate
the foundational models for all general strategies used to model a specific
grey-noise effect, as well as supporting measurement and evaluation
technologies and science. This chapter therefore compiles and reviews the
detectability, measurability and practical identifiability of certain grey-noise
factors, relevant to modelling, understanding and predicting the glycaemic
excursions of outpatients with diabetes.
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4.2 Nutrition
4.2.1 Physiological sources of variability
The gastro-intestinal tract is a complex system for extracting nutritional
components from ingested food. Meals typically contain differing quantities
of water, carbohydrate, fat, protein, essential vitamins and minerals. After
mastication, ingested food is ground into smaller particles in the stomach
by gastric acid, digestive enzymes and mechanical contractions (Reinus and
Simon, 2014). Gastric emptying (GE) then delivers the food to the
intestine where it is combined with bile and pancreatic enzymes. Muscular
contractions in the intestine mix, propel and further break-down the food
(Reinus and Simon, 2014). Absorption of glucose and two other notable
monosaccharide sugars, fructose and galactose, occurs through the intestine
walls to the bloodstream via transporter proteins in the cell walls (Reinus
and Simon, 2014; Bornhorst and Singh, 2014).
Many factors affect GE. Food composition and quantity has a large effect
due to feedback signals for optimising intestinal nutrient absorption (Reinus
and Simon, 2014; Goldenberg and Cummins, 1971; Macdonald, 1996). In
particular, higher quantities of fat, glucose, energy, and acids in the food
reduce GE rate (Reinus and Simon, 2014; Bornhorst and Singh, 2014;
Goldenberg and Cummins, 1971; Macdonald, 1996; Velchik et al., 1989;
Schvarcz et al., 1997). Studies appear to generally support these same
observations in T1DM and T2DM (Schvarcz et al., 1997; Lodefalk et al.,
2008; Gentilcore et al., 2006; Fraser et al., 1990; Samsom et al., 1997;
Folwaczny et al., 2003; Kong et al., 1996). Food structure also has a large
impact on GE. Starches with expanded or disperse matrices like bread and
potato have been shown to empty faster than rice or pasta whose matrices
are denser (Mourot et al., 1988; Mishra and Monro, 2012; Torsdottir et al.,
1986).
GE rates also exhibit significant variability across and within individuals for
equivalent meals (Lartigue et al., 1994). Those with diabetes are especially
prone to variability, with 20-50% experiencing abnormally slow GE (Clark
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and Nowak, 1994; Horowitz et al., 2002). This condition is known as
gastroparesis and is perhaps due to chronic hyperglycaemia more than
neuropathy (Folwaczny et al., 2003; Liu et al., 2007). However, its impact is
variable across individuals and over time creating a grey-noise bias.
Most carbohydrates are not ingested as monosaccharides. Disaccharides,
such as sucrose and lactose, must be cleaved by enzymes anchored to the
cells lining the intestine before absorption can occur (Reinus and Simon,
2014; Mourad and Saadé, 2011). Starches are long, branching chains of
covalently bonded glucose. These polysaccharides must be digested into
oligosaccharides by pancreatic amylases before being processed further into
singular glucose molecules at the intestinal wall (Reinus and Simon, 2014).
Amylase access to the starch substrate is a primary determinant of starch
digestive rate and thus plasma glucose appearance (Mishra and Monro,
2012; Englyst et al., 2003; Englyst and Englyst, 2005). High levels of
processing, weak and porous starch structures and low levels of dietary fibre
typically contribute to rapid availability of glucose (Mishra and Monro,
2012; Englyst et al., 2003; Englyst and Englyst, 2005; Monro, 2013).
Resistant starch and non-starch polysaccharides (e.g. cellulose) cannot be
digested and absorbed as glucose, and are instead fermented by gut
bacteria in the large intestine and absorbed as short-chain fatty acids, thus
their effect is non-glycaemic (Reinus and Simon, 2014; Englyst and Englyst,
2005).
Absorption of monosaccharides is moderated by the expression of
transporter proteins in the cells of the intestinal wall (Reinus and Simon,
2014; Mourad and Saadé, 2011). Transporter expression increases in
response to intestinal glucose presence and insulin secretion (Mourad and
Saadé, 2011). Studies have found diurnal rhythms of transporter expression
in rats (Mourad and Saadé, 2011; Douard and Ferraris, 2008; Ferraris,
2001) and similar expression is hypothesised in humans. Increased
transporter expression has been observed in diabetes Dyer et al. (2002) and
obesity (Nguyen et al., 2015). Consequently, a common treatment for
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T2DM involves partial transporter repression (Tahrani et al., 2013).
Finally, once absorbed, galactose and fructose provide limited contributions
to glycaemia. The liver converts approximately 10-20% of galactose into
free glucose (Gannon et al., 2001; Sunehag and Haymond, 2002; Ercan
et al., 1993) and 29-54% of fructose into free glucose. However, reported
rates vary widely, potentially depending on gender, exercise condition and
health status (Sun and Empie, 2012), again contributing grey-noise and
uncertainty.
4.2.2 Measurement of glucose appearance
Scintigraphy (gamma imaging of radio-labelled food) is considered the gold
standard method to measure GE (Kar et al., 2014; Szarka and Camilleri,
2009). Studies show that GE of liquids typically follows exponential decay
functions and is thus often described by half-emptying times (Reinus and
Simon, 2014; Bornhorst and Singh, 2014; Lartigue et al., 1994; Siegel et al.,
1988). Solids tend to exhibit a lag’ period of slow emptying before
exponential emptying takes over (Collins, 1991; Siegel et al., 1988;
Bornhorst and Singh, 2014).
Glucose appearance trajectories from the intestine are difficult to measure
or infer via plasma or capillary glucose concentration measurement, due in
part to the obscuring effects of the hepatic regulatory response to meal
ingestion. In particular, the hepatic glucose balance shifts from a steady
output of glucose in the basal state to a net uptake during post-prandial
periods (Cherrington, 1999). Insulin dynamics also obscure glucose
appearance modelling when plasma glucose measurements are interpreted
without consideration of specific insulin measurements. Thus, plasma
glucose data provides only a net effect across these variable endogenous
responses.
Glucose appearance can be modelled using data from double-tracer
methods (Mari et al., 1994), which typically involve infusing one type of
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labelled glucose ([3H]glucose) intravenously while giving an oral dose that
contains a different tracer element ([14C]glucose) Mari et al. (1994).
Together, the tracers allow the glucose appearance rate (Ra) to be
distinguished from glucose clearance and EGP. This type of Ra data is
considered to be gold-standard in the measurement of glucose appearance
and has been used by multiple groups to validate candidate models (Wong
et al., 2008c; Dalla Man et al., 2006). Ra can be expressed in units of
mmol/min or mg/min, but in clinical trials is most often normalised by
subject weight with units of mol/kg/min or mg/kg/min (Mari et al., 1994;
Dalla Man et al., 2006; Elleri et al., 2013). Ra trajectory (Ra(t)) calculation
requires glucose kinetic models, such as Steele’s one-compartment model
(Steele, 1959) or Mari’s two-compartment model (Mari et al., 1994).
Evaluating the effect of food type on variability in glycaemic effect can be
carried out through multiple methods. Glycaemic index (GI) is a
long-standing and simple method that gives the relative area of a glycaemic
excursion caused by a food normalised by that of a reference food of
equivalent carbohydrate content, either glucose or white bread
(Foster-Powell et al., 2002). Each food type must be tested across multiple
subjects to mitigate the effect of inter-patient variability. In such studies, a
cohort of subjects with diabetes are also often tested to account for
physiological differences (Foster-Powell et al., 2002).
Glycaemic load is a later extension of GI that takes into account the
carbohydrate density of a food for a more practical evaluation of glycaemic
effect for regular portion sizes (Foster-Powell et al., 2002). Carbohydrate
bioavailability’ is another, more extensive, classification that divides
carbohydrates into portions of rapidly available glucose, slowly available
glucose and resistant starch (Mishra and Monro, 2012; Englyst et al., 2003;
Englyst and Englyst, 2005; Monro, 2013). These quantities were
determined via in vitro digestion rate measurements. Ultimately, solely
carbohydrate focused evaluations have limited usefulness for mixed meals.
In particular, a clinical study found no correlation between estimation GI
and measured GI of common breakfasts due to the influence of fat and
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protein content (Flint et al., 2004).
Elleri et al. (2013) calculated Ra(t) for complex sugars and carbohydrates
with high and low GI foods using a double tracer method with an enriched
oral meal load. In a follow-up protocol, a controller was used to titrate
intravenous glucose at a rate that would match the oral glucose excursions.
The study itself did not propose novel model formulations for these food
types, but noted the potential to do so. It appears to be the first study to
quantify multiple modes of glucose absorption from different carbohydrates
in vivo. The results are reproduced in Figure 4.1 to show the effect of
slower available glucose compared to rapidly available glucose on Ra
trajectories.
4.2.3 Models for glucose appearance
A summary of the nutritional models can be found in Table 4.1.
4.2.3.1 The minimal model
The minimal model of food absorption was developed by Worthington in
1997 (Worthington, 1997). Validation of Worthington’s model was carried
out using measured plasma glucose excursions in a subject with T1DM.
Hence, insulin-mediated glucose clearance was assumed negligible.
Worthington fitted models of varying complexity to glycaemic data for high
and low GI meals, and proposed the one-compartment model with a delay
(D) due to its minimal parameterisation and general adherence to data.







where C1 is a combined stomach and intestinal compartment, PX is the
mass of the ingested meal, GV corresponds to the fraction of available
glucose, VG is the glucose distribution volume and ka is the turnover rate.
Ra is thus calculated as kaC1, normalised by subject mass if preferred.
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The model is relatively minimal and does not aim to directly model
observed physiological compartments, such as the stomach and intestine.
Furthermore, the model was not validated on gold-standard Ra data as it
was developed using glycaemic excursion data. The goal of the model was
to develop measures for the specific glycaemic impact of different foods by
characterising D, ka and GV , as opposed to GI, which is impacted by
glucose-insulin dynamics. A representative simulation of this model is
pictured in Figure 4.1.
4.2.3.2 Piecewise emptying model
The Lehmann and Deutsch (1992) model features a piecewise stomach
emptying function (Gempt) based on a linear increase to a maximum
emptying rate (Vmax), followed by constant rate and then linear decrease
back to zero. Ascending and descending times (Tasc and Tdec) are usually 30
minutes each. Thus time spend at the maximum rate (Tmax) based on the




− (Tasc + Tdec) (4.2)





t; t < Tasc
Vmax; Tasc < t ≤ Tasc + Tmax
Vmax − VmaxTdec (t− Tasc − Tmax); Tasc + Tmax < t ≤ Tasc + Tmax + Tdec
(4.3)
The model is adjusted for small carbohydrate loads (approximately <10
grams) as there is too little food to allow time for the emptying rate to
plateau. Thus there is no Tmax and instead Tasc and Tdec are both defined
as 2Ch/Vmax, rather than 30 minutes. The resulting function is triangular
rather than trapezoidal.





= Gempt(t)− kabsGgut(t) (4.4)
where kabs is a constant emptying rate and thus the appearance rate would
be kabsGgut(t). An example of Ra from this model is included in Figure 4.1.
The model was developed to simulate a virtual patient for education in
diabetes management as well as computational testing and analysis of
treatment regiments (Lehmann and Deutsch, 1992). Thus all model
parameters are defined at fixed values except for the input quantity of
carbohydrate. The model accounts for some food-related variability by
adjusting the model form with meals of low carbohydrate content, though
an adjustment was mathematically necessary anyway. Further variability
could be captured by altering the maximum emptying rate and intestinal
absorption parameters. Moreover, using a fixed Vmax would not account for
strong GE dependence on factors such as quantity of carbohydrate, fat and
protein and energy, demonstrated in the literature (Bornhorst and Singh,
2014; Reinus and Simon, 2014; Velchik et al., 1989; Goldenberg and
Cummins, 1971; Schvarcz et al., 1997; Macdonald, 1996).
4.2.3.3 2-compartment model
Wong et al.’s model for clinical use in T1DM is a 2-compartment model
that is based partially on the minimal model of Worthington (1997) and
was validated on mixed-meal tracer glucose appearance data (Wong et al.,
2008c). The first compartment (STO) represents the stomach, while the
second (GUT ) represents the gut with each emptying in an exponential decay.
The model also includes a rate limitation in glucose/carbohydrate intake in
the gut (GABSmax) based on experimental results. The model is defined as:
dSTO(t)
dt
= −k6STO(t) + uCHO(t) (4.5)
dGUT (t)
dt
= GABS (t) + k6STO(t) (4.6)
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GABS (t) = −min(k7GUT (t),GABSmax) (4.7)
where uCHO is an impulse containing the carbohydrate mass in the meal, k6
is the GE rate, and k7 is the gut absorption rate. Ra can therefore be
calculated as GABS (t)/0.18, and potentially further divided by subject
mass.
This glucose appearance model aims to use a priori estimated values for all
constants to inform therapeutic doses of insulin in conjunction with a wider
model that includes glucose-insulin dynamics. The chapter discusses; but
ultimately did not model, the effect of slowly digested carbohydrates due to
the difficulty in predicting the various glycaemic indices of mixed meals.
Figure 4.1 includes a representative simulation of this model.
4.2.3.4 3-compartment model
Dalla Man et al. (2006) developed a model to capture more complex digestive
behaviours. Two compartments are used for solid (qsto1) and liquid (qsto2)
phases in the stomach. The solids undergo grinding and enter the liquid
phase and the liquid empties into the intestine. A third compartment (qgut)
is used for the small intestine. The model is defined:
q̇sto1(t) = −k21qsto1(t) +Dδ(t) (4.8)
q̇sto2(t) = −kempt(qsto)qsto2(t) + k21qsto1(t) (4.9)
q̇gut(t) = −kabsqgut(t) + kempt(qsto)qsto2(t) (4.10)
Ra(t) = fkabsqgut(t) (4.11)
where k21 is the grinding rate, D is the glucose content, δ(t) is an impulse
function, kabs is the absorption rate in the intestine and f is the fraction
of glucose that appears from absorption. The kempt parameter is a complex
function of the stomach contents defined:
kempt(qsto) = kmin +
kmax − kmin
2











qsto = qsto1 + qsto2 (4.15)
where kmin and kmax are the minimum and maximum values of kempt, c and
b are shape parameters that specify when changes in kempt occur relative to
the fraction of the meal remaining in the stomach.
The complex changing emptying rate produces a secondary hump on Ra(t)
(seen in Figure 4.1) that is often observed experimentally. Initially, kempt is
large, but is quickly reduced, presumably imitating the feedback control
from the small intestine as the first amount of glucose is absorbed. As the
stomach empties, kempt returns to its maximal value.
Dalla Man et al. (2006) optimised values for kmax, kmin, c, b and kabs to fit
the model to Ra data. The assumptions k21 = kempt and kempt > kabs were
made for structural identifiability. Still, it is worth noting that the authors
found that for a quarter of the subjects, the c parameter was near zero,
indicating that kempt was initially at its minimal value. Assuming that
c = 0 allowed the model to be simplified in these particular cases.
Dalla Man et al. noted that the second stomach compartment alone did not
adequately fit the model to Ra data. Thus, the non-linear emptying rate
function, rather than the additional compartment, is the defining feature of
the model. Given a constant kempt value, the two stomach compartments do
not appear to produce significantly different Ra(t) curves to a single
compartment (seen in Figure 4.1).
4.2.3.5 Gastro-intestinal transit model
Salinari et al. (2011) presents a very thorough gastro-intestinal transit
model for modelling Ra in Oral Glucose Tolerance Tests (OGTTs) that
considers motility of carbohydrates along the small intestine. Glucose is
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delivered to the intestine according to a GE function and then absorbed to
the blood stream as it moves along the intestine. The authors present a
simple form of the model, as well as a more extensive one that considers
regional differences in transporter protein expression along the intestine
(both seen in Figure 4.1). Like the 3-compartment model, the latter case
accounts for the hump frequently observed on the descending path of Ra
trajectories experimentally. Overall, it appears to be the first model that
aims to capture the contributions of more complex behaviours in the






−γt − e−kt); 0 ≤ t ≤ L/u
fD kγ
k−γ (e
−γL/u−k(t−L/u) − e−kt); t > L/u
(4.16)
where D is the glucose bolus ingested, f is the loss coefficient, k is the GE
rate constant, and γ is the intestinal glucose absorption rate. L is the
length of the small intestine and u is the velocity of the glucose along the
length. Thus, if the time exceeds L/u, some glucose will enter the large
intestine and will not be absorbed.
Salinari et al.’s more complex model includes a power term in the gastric
emptying function and two glucose transporters with different regional





where the absorption rates (γ(z)) are a function of a space co-ordinate (z)
and q(z, t) is the quantity of glucose in the intestine as a function of space

















where u is the velocity of the glucose as with the uniform case and q0 is
the intestinal content at the entrance of the intestine, which is a function of
gastric emptying, defined:




where η is the delivery of glucose to the intestine due to power-exponential




where β is the power constant. For the non-uniform case, the absorption
rate is considered to be the sum of absorption rates for two separate
transporters: γ(z) = γ1(z) + γ2(z). Gaussian functions can be used to
approximate γ1−2 in the absence of data.
Salinari et al. intended for the model to be used for identification of
physiological parameters from OGTT data. A priori values had to be
assumed for most constants in the nutritional model, except the GE rate
(k), which was identified, and a scaling factor (c) for the Gaussian
transport rate functions (γ1−2). The scale of γ2 was identified (c2 = c) and
the scale of γ2 was assumed to be half that value (c1 = 0.5c2).
4.2.4 Implications for modelling nutritional intake
Appearance of glucose from nutrition is subject to a wide range of
grey-noise variability and uncertainty due to the complexity of
gastro-intestinal processes, inter- and intra- subject variation, and effects
from the food structure and composition. These factors, when unmodelled,
increase grey noise in model-based identification and prediction. Models of
varying complexity were presented. Overall, each candidate nutritional
models exhibits similar behaviour (in Figure 4.1). Since control of
glycaemic excursions is of primary interest to researchers, the integrated
form of Ra(t), is particularly relevant, and more effectively demonstrates
the similarity of the models.
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The general glucose appearance trajectory can be captured even with the
comparative simplicity of the minimal model of Equation (4.1). Modelling
complex behaviours can give insight into the rates of particular and
important physiological processes, especially in the presence of high quality
time (min)
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Figure 4.1: A summary comparison of six model types for 75g carbohydrate
inputs and an 80kg subject: the minimal model (Worthington, 1997); the
piecewise emptying model Lehmann and Deutsch (1992) both as in the
literature and with a modified emptying rate; the 2 compartment model
(Wong et al., 2008c); the 3 compartment model with complex GE rate
(Dalla Man et al., 2006); the 3 compartment model with constant GE rate
(Dalla Man et al., 2006) with parameters modified for comparison to the
Wong et al. (2008c) model; the uniform and non-uniform absorption transit
models (Salinari et al., 2011). Also included is the tracer data for high and
low glycaemic meals (Elleri et al., 2013), scaled to achieve a similar overall
glucose appearance per subject mass to the simulated models.
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clinical data. Furthermore, complex modelling approaches can yield insight
into particular dysfunctions or etiologies. However, predictive capabilities of
a model for post-prandial glycaemic outcomes will likely be limited by
intra-individual and food variability, rather than the complexity of the
model, as these uncertainties significantly outweigh the added precision.
This concept is demonstrated in Figure 4.1, which also includes scaled
versions of Elleri et al.’s tracer data for high and low GI meals. Most model
simulations are similar to each other and the high GI data. The exception
to this is the piecewise emptying model, which is largely due to the author’s
choice of fixed emptying rate coupled with a simulated carbohydrate load
larger than generally prescribed for that model. Using a modified emptying
rate brings the simulated model trajectory closer to those of the other
models (Figure 4.1). In contrast to the majority of the models, the low GI
data stands out with a significantly different trajectory. Hence, food
structure and composition contributes to potentially recoverable grey noise
in the measured data. If the influence of GI and other such factors is not
modelled, this variance in glycaemic excursions will be incorrectly captured
in other overall metabolic model parameters, and prediction precision will
be harmed.
The many physiological and environmental sources of nutritional variability
could perhaps be lumped into variables that capture the general behaviour.
In this case, it appears that nominal appearance rate and glucose quantity
are dominant features that could be parameterised to capture the general
trend in glucose excursion caused by nutritional and subject variability,
utilising a priori information, where possible, for prediction applications.
At present, tools such as GI and carbohydrate availability are used to study
and predict the glycaemic effect of a given meal (Englyst et al., 2003;
Englyst and Englyst, 2005; Flint et al., 2004; Mishra and Monro, 2012;
Monro, 2013). The fat and protein content of nutrition has shown a
confounding effect on GI (Flint et al., 2004). Hence, the nature of the
confounding effects needs to be quantified to provide the necessary a priori
information to fully capture the glucose appearance of typical meals.
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4.3 Psychological effects
4.3.1 Stress and similar factors
It is well recognised that medical and emotional stress affects glucose
regulation (Klonoff, 2007; Lloyd et al., 1999; Räikkönen et al., 1996; Surwit
et al., 1992; Xiu et al., 2014; Ramkissoon and Veh́ı, 2015). These effects are
attributed to the release of a number of hormones, particularly cortisol (Xiu
et al., 2014). More than three decades ago, Rizza et al. (1982) observed
glycaemic responses alongside a cortisol infusion, which reduced hepatic
and peripheral insulin sensitivity. A number of other experiments have also
been carried out to determine the relationship between stress stimuli and
glycaemia in T1DM subjects (Lloyd et al., 1999; Surwit et al., 1992; Ward
et al., 2011; Rizza et al., 1982). While clear correlation was found between
medical stress and hyperglycaemia, mixed results exist for the effect of
psychological stress. Surwit et al. (1992) found some studies showed that
psychological stress correlated with both hyperglycaemia and
hypoglycaemia, while other studies exhibited no effect. This discrepancy
could potentially be due to differing or ambiguous definitions of stress
across studies and the possible presence of autonomic neuropathy in some
individuals, which can reduce sympathetic responses to stress (Surwit et al.,
1992).
In general, stress appears to be consistently associated with poor glycaemic
control (Lloyd et al., 1999). Studies using exogenous cortisol as a stimulus
found reduced insulin sensitivity signals (Surwit et al., 1992; Ward et al.,
2011; Rizza et al., 1982). Depression is also associated with poor glycaemic
control and a high incidence of hyperglycaemia (Nathan et al., 1981;
Lustman et al., 2000). Since cortisol levels are elevated in depression and
linked to insulin resistance (Nathan et al., 1981), it follows that depression
would be linked to insulin resistance, although the strength of this link is
unconfirmed.
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4.3.2 Measurement of stress
The effect of stress has been measured by calculating SI values changing in
response to a cortisol stimulus (Ward et al., 2011). Ward et al. tested a
stress-compensating closed-loop glycaemic control algorithm in subjects
taking oral hydrocortisone doses that were equivalent to moderate stress
(Ward et al., 2011). Their results showed that model-identified SI was
reduced by around 40-50% several hours after hydrocortisone doses leading
to significant changes in insulin requirements for glycaemic control.
Stress levels can be measured using a number of methods other than
subjective surveys. Recent technological advances have seen a rise in in the
ability to measure indicators of stress in an outpatient environment.
Several groups have performed research into measuring galvanic skin
responses, which are altered in response to psychological stress as a
sympathetic nervous response (De Santos Sierra et al., 2011; Saha et al.,
2014; Luharuka et al., 2003). Their devices are able to provide continuous,
digital data and can also be combined with heart rate monitors for very
successful stress detection (De Santos Sierra et al., 2011). This technology
would be less effective in diabetes due to reduced sympathetic nerve
response and reduced skin moisture (Surwit et al., 1992; Goetsch et al.,
1993). However, it could be useful in younger individuals and those that
have little neuropathy. Another technology has emerged that can take
quick and easy salivary cortisol measurements with a small device
connected to a smartphone (Zangheri et al., 2015; Choi et al., 2014). The
simplicity and cost effectiveness of the technology both add to outpatient
usability. Therefore, there is great potential to measure stress and similar
psychological disturbances on a day to day or more frequent basis, if
necessary, in the near future.
4.3.3 Implications for modelling psychological effects
Stress and depression have significant impact effect on glycaemic regulation.
Some studies have shown that stress is often concurrent with reduced SI
(Surwit et al., 1992; Lloyd et al., 1999; Rizza et al., 1982). However, there
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appears to be a lack of glycaemic models that incorporate stress, and thus
this important contribution to grey-noise is typically overlooked.
Mansell et al. (2015d) modelled stress as a constant multiplicative
reduction in SI appearing on certain days (Chapter 9). Considering more
short-term effects, Ward et al. (2011) shows a delay between the
administration of oral hydrocortisone and changes in SI. It is apparent
that the specific bioavailability of the hydrocortisone compared to
endogenous forms of cortisol has a significant but not yet quantified effect
on glycaemic control. Given the mixed results of clinical studies of the
effect of psychological stress and the emergence of sensors to measure its
indicators, this research area may soon attract more interest and see the
development of data-driven models. Accounting for psychological effects
could reduce a large source of grey noise and enable tangible improvements
in model-based glycaemic control in diabetes.
4.4 Physical activity
4.4.1 Physiological effects of physical activity
The acute effect of exercise is a major metabolic disturbance and thus can
contribute grey noise in diabetes modelling. Moderate or aerobic exercise
typically burns muscle glycogen stores in the first 5-10 minutes before
relying on glucose released from the liver and fatty acids from fatty tissue
(Yardley et al., 2013). In healthy individuals, insulin levels decrease and
glucagon levels increase to stimulate the additional hepatic EGP required
to maintain normoglycaemia (Yardley et al., 2013; Sonnenberg et al., 1990).
During and after prolonged exercise, glycogen stores become depleted and
hypoglycaemia can occur.
However, individuals with diabetes are typically in a state of
hyperinsulinemia that prevents adequate hepatic response resulting in more
readily occurring exercise induced hypoglycaemia (Yardley et al., 2013;
Sonnenberg et al., 1990). Even post-exercise, elevated muscle clearance of
glucose can persist for 2 hours and increased SI has been observed for
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upwards of 16 hours due to increased peripheral sensitivity and increased
non-insulin mediated uptake (Borghouts and Keizer, 2000; Magkos et al.,
2008). These factors can lead to hypoglycaemic events hours after exercise
has ended. High intensity anaerobic or resistance forms of exercise are less
dependent on insulin and glucagon reactions, since the release of
catecholamines stimulates a 5-10-fold increase in hepatic EGP (Yardley
et al., 2013). Therefore, anaerobic and resistance forms of exercise, even
included in routines with aerobic exercise, can reduce the likelihood of
acute or late hypoglycaemia (Yardley et al., 2013).
4.4.2 Measurement of physical activity
Measurement of exercise is generally thought of in terms of energy
expenditure (EE) and intensity. EE for aerobic respiration can be evaluated
by measuring the gas exchange occurring within an individual. The rates at
which oxygen is inspired and carbon dioxide is expired are highly correlated
with energy consumption (Schrack et al., 2010). However, anaerobic
respiration does not rely on O2 and does not produce CO2, so other
methods must be used to estimate anaerobic EE (Scott, 2006).
Traditionally, the Douglas Bag method has been used as the gold-standard
test for aerobic EE over a range of intensities. This method involves
collecting exhaled gas via a face mask and analysing the oxygen and carbon
dioxide content. However it is limited to a clinical environment due to the
necessity of physical or chemical analysis of exhaled gas (Wenzel et al.,
1990). Recent advances in technology have enabled portable, real-time
analysis of gas exchange with a device known as the K4b2 (Schrack et al.,
2010). The device is considered effective and reliable for measurement in an
outpatient environment (Veluswamy et al., 2015). However, the K4b2
requires that exercise is undertaken while wearing a face mask and is thus
not feasible for daily outpatient use.
Other less direct measures of physical activity can estimate EE. Heart rate
is considered to have reasonable correlation with EE (Strath et al., 2000)
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and can be supplemented with motion sensors for improved precision
(Strath et al., 2002). Accelerometers have reasonable overall correlation
with EE, but lack accuracy across different activities (Bassett D.R et al.,
2000; Yumiko et al., 2002). Furthermore, measurements are dependent on
the sensor location on the body relative to the activity (Kim et al., 2014).
Regardless, accelerometers may be accurate enough to evaluate a level of
EE in the average non-athlete individual depending on the application
(Yumiko et al., 2002).
Self-recorded physical activity questionnaires have also been shown to
correlate reasonably well to EE for moderate and vigorous exercise (Kurtze
et al., 2007) and thus may be suitable for capturing the effect of exercise on
glycaemia. Pedometers can give a good indication presence of physical
activity, but cannot effectively delineate intense exercise from low-intensity
walking (Dai et al., 2008). The ActiReg system combines body position
sensing with motion sensing to estimate EE during low intensity activities
and can also be supplemented with heart rate measurement for better
estimation during higher intensity activities (Hustvedt et al., 2004). The
advantage of movement monitors is the relative ease of data collection in an
outpatient environment. In particular, the recent prevalence of
smart-phones containing accelerometers vastly improves this data collection
ability. However, the disadvantages of movement monitors are the low
accuracy and precision. Those involving additional heart rate measurement
appear to be the most accurate (Hustvedt et al., 2004; Strath et al., 2002).
The relative intensity of aerobic exercise is usually evaluated as a
percentage of either peak oxygen uptake (VO2max) or the oxygen uptake
reserve (VO2R = VO2max − VO2rest) (Mann et al., 2013). Direct
measurement of V O2max is time-consuming, difficult and not done daily
(Beutner et al., 2015; Kumar et al., 2012). Thus, several other methods of
indirect measurement have been developed (Beutner et al., 2015; Sykes and
Roberts, 2004; Uth et al., 2004). Notably, the heart rate reserve can be
used to estimate VO2max (Uth et al., 2004) and heart rate relative to the
heart rate reserve can be used as a measure of exercise intensity on its own
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(Mann et al., 2013).
4.4.3 Models of exercise
A summary of exercise models can be found in Table 4.1.
4.4.3.1 Heart rate model
Breton (2008) developed a functional exercise model as an extension to the
minimal model of glycaemic dynamics . The model was tested on a patient
with T1DM and utilised a heart rate monitor as a measured input for exercise.
Based on heart rate (HR), energy consumption (Y ) is modelled:





(HR − HRb) (4.21)
where the subscript b indicates a basal heart rate and the rate parameter
τHR was set as 5 minutes for a delay.
Insulin action (Z, synonymous with SI) can be modelled to mimic
activation of glucose transporters, which increases with exercise, increasing


















Both n and τ are used to filter out random non-exercise induced changes in
heart rate (Breton, 2008). These effects of energy consumption and
modified insulin action appear in the plasma glucose (G) compartment that
also includes insulin action (X) and glucose appearance from food (D):




where α and β modify the size of the effects and were intended to be
identified along with other glycaemic parameters, such as p1, Vg, and Gb,
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using a combination of least-squares and Bayesian influence (Breton, 2008).
The use of Bayesian adaptation of parameter values implies that this
model, as defined by Breton (2008), can yield impractical results due to low
practical identifiability (Docherty et al., 2011; Cobelli et al., 1998; Erichsen
et al., 2004; Cobelli et al., 1999; Pillonetto et al., 2002).
Figure 4.2 shows an example simulation of the effects of this exercise model.
Breton notes that their experimental data did not cover enough time to
explore the dynamics of post-exercise recovery in insulin sensitivity.
Dalla Man et al. (2009) augmented it with increased peripheral tissue
glucose utilisation post-exercise and a dependency of insulin action on the





















































































Figure 4.2: An example simulation of the Breton et al. model for 30 minutes
of exercise with the SI multiplication factor (1 + αZ) pictured left, the rate
of perturbation in plasma glucose (βY G) pictured middle and the resulting
plasma glucose trajectory from a non-basal starting value pictured right.
4.4.3.2 PVOmax2 model
Roy and Parker developed an exercise model as an extension of the minimal
model Roy and Parker (2007). The power at maximum oxygen consumption
(PVOmax2 ) was used to modulate the insulin signal. Additionally, rather than
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use PVOmax2 as a measured quantity, it was modelled:
dPVOmax2
dt
= −0.8PVOmax2 (t) + 0.8u3(t) (4.25)
where u3(t) is ultimate exercise intensity (ranging from 0-92%) above basal
(8%). Equation (4.25) effectively models a small delay between the targeted
exercise intensity and the actual PVOmax2 . The plasma insulin compartment









2 (t)− a6Ie(t) (4.27)
where u1 is the exogenous insulin input. Population values were used by
Roy and Parker for parameters n and p4, while a5 and a6 were identified
from plasma insulin assays in healthy individuals undergoing exercise in a
clinical trial.
Roy and Parker also modelled hepatic EGP (Gprod) and peripheral glucose












2 (t)− a4Gup(t) (4.29)
where a1−4 were identified from multiple tracer data of EGP and glucose
disappearance in healthy subjects undergoing exercise in a clinical trial.
Model simulations were then compared to subjects with T1DM in a similar
trial. Roy and Parker also modelled the decrease in EGP as a result of
glycogen depletion (Ggly) as a function that was zero until a critical
threshold was reached and also returned to zero in the post-exercise period.
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where W is weight of subject.
Figure 4.3 shows an example simulation of the model. It is evident from the
figure and Equations (4.28) and (4.29) that Gprod and Gup cannot be easily
delineated using data of their net effect on glycaemia if multiple tracer data
were not available. Hence, for outpatient application, only one, rather than





















































































Figure 4.3: An example simulation of the Roy and Parker model for 30
minutes of exercise with the plasma insulin pictured left, glucose perturbation
rates (note that Ggly is neglected) pictured middle and the resulting plasma
glucose trajectory pictured right.
The reduction in plasma insulin with exercise is debated. Some literature
indicates this behaviour occurs as a glucoregulatory response in healthy
individuals to stimulate additional hepatic production, but cannot be
regulated in individuals with T1DM (Sonnenberg et al., 1990; Yardley
et al., 2013). Furthermore, increased plasma insulin has been observed
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during exercise in T1DM suggesting increased mobilisation from
subcutaneous depots of slow acting exogenous insulin (Mallad et al., 2015).
Thus, the validation of the plasma insulin model against healthy
individuals is not necessarily directly transferable across into diabetes.
4.4.3.3 Curviliniear insulin resistance model
Magkos et al. (2008) measured insulin resistance (IR, inverse to SI) the day
after intense exercise in a clinical study. Reduced IR the morning after
evening exercise was proposed to be related to EE as a curvilinear function
shown in Figure 4.4. There was also a tendency for higher initial IR values
to reduce to a greater extent (Magkos et al., 2008). It should be noted that
there was a substantial amount of inter-subject variability.
While the model indicates that exercise reduces IR, a large portion of the
subjects experienced an increase. The authors also noted that a large EE
was required for appreciable changes. In the context of the study, this
information led to the conclusion that relying on acute effects of exercise
was not a practical means of improving insulin sensitivity. Overall, the
study was underpowered to yield a statistically significant means of
predicting changes in IR the day after exercise. However, the data shows a
probable effect of exercise, and may be useful in further development of
exercise models for glycaemic control, especially if more rigorous validation
can be carried out.
4.4.4 Implications for modelling physical activity
The effect of exercise on glycaemia has been well recorded (Sonnenberg
et al., 1990; Yardley et al., 2013; Mallad et al., 2015; Mayer-Davis et al.,
1998; Borghouts and Keizer, 2000). Exercise is a particularly important
factor due to its tendency to cause hypoglycaemia even well after exercise
has ended (Sonnenberg et al., 1990; Yardley et al., 2013; Borghouts and
Keizer, 2000). Clinical experiments have shown that compensating for
exercise with planned reductions in insulin dose is an effective means of
reducing hypoglycaemic risk (Sonnenberg et al., 1990). Such trials
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Figure 4.4: Data (+) and model (—) for changes in next-day insulin
resistance as a function of EE in exercise in healthy subjects. Figure
reproduced from Magkos et al. (2008)
demonstrate the benefit of a reduction in exercise-induced grey noise. Thus,
including exercise in model-based prediction has great potential for
safe-guarding patients with diabetes against hypoglycaemia and giving
greater confidence in engaging in physical activity.
Some of the exercise models considered here use data that is unlikely to be
available in an outpatient setting, such as PVOmax2 (Roy and Parker, 2007)
or insulin resistance (Magkos et al., 2008). Given the sparse sampling
regimen that could be expected in outpatient diabetes glucose control,
models that capture the effects of exercise on glycaemia must be sparsely
parameterised. However, the exercise model of Breton (2008) utilises the
heart rate input data and thus could potentially be incorporated into an
algorithm for the control of glycaemia. The model is also relatively simple
and does not require a great deal of parameterisation and thus would not
require prohibitively large data sets to confidently identify. Hence, the
model is likely to be practically identifiable.
Some aspects of the effect of exercise have been explored in the models
reviewed. Both Breton’s heart rate-based model and Roy and Parker’s
PVOmax2 -based model are validated in high resolution, short term data that
does not extend particularly far beyond the exercise period. The need for
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models that capture post-exercise glucose excursions is highlighted by
Magkos et al.’s clinical data and model for next-day IR. However, next day
IR does not provide a precise picture of the whole post-exercise effect
either. To capture exercise-induced grey noise in outpatient diabetes,
further understanding of the immediate and delayed effects of exercise on
glycaemia is needed.
Anaerobic exercise has a confounding influence and has not been modelled
as often as aerobic exercise. In particular, anaerobic exercise does not
correlate well with traditional means of measuring EE (Scott, 2006).
Furthermore, anaerobic exercise seems to have a contrary glycaemic effect
to aerobic exercise as it has been shown to reduce the risk of hypoglycaemia
(Yardley et al., 2013). Thus, anaerobic exercise still presents a significant
source of grey-noise that should be accounted for to improve glycaemic
control.
4.5 Metabolic rhythm
Glucose regulation is also subject to circadian and other metabolic rhythms
(Van Cauter et al., 1997). This section focuses on circadian rhythms in SI
as a dominant, and thus measurable effect.
4.5.1 Circadian rhythms in glycaemic indicators
Section 4.2.1 described the presence of circadian rhythms in glucose
transporters in the intestine. Overall glucose tolerance also tends to be
lower in the afternoon and evening than in the morning in healthy
individuals. Thus the term ’afternoon diabetes’ emerged to describe the
increased possibility of a false-positive diagnosis of glucose intolerance in
the afternoon (Van Cauter et al., 1997). There are mixed results regarding
the role of insulin sensitivity in this phenomenon (Sensi and Capani, 1976;
Carroll and Nestel, 1973), but the evidence generally supports a reduced SI
in the afternoon, along with reduced glucose utilisation and insulin
secretion (Van Cauter et al., 1997). Oddly, this pattern appears to be
reversed in diabetes with glucose tolerance and insulin sensitivity improving
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from morning to evening for both T1DM and T2DM (Van Cauter et al.,
1997; Visentin et al., 2015). This observation is part of the so-called ’dawn
phenomenon’.
4.5.2 Measurement of circadian rhythms
Circadian metabolic rhythms tend not to be directly measurable. Early
observations arose from differing glucose tolerance results to the same oral
glucose challenge at different times of day (Van Cauter et al., 1997). More
recently, mathematical models and multiple tracer methods have been used
to study changes in SI and EGP and uptake at different times of the day
(Van Cauter et al., 1997; Sensi and Capani, 1976; Carroll and Nestel, 1973;
Visentin et al., 2015).
Hinshaw et al. (2013) recently calculated distinct SI values for breakfast,
lunch and dinner in subjects with T1DM compared to healthy subjects.
The mean result for the cohort with diabetes showed a large increase in SI
from breakfast to lunch and a slight decrease by dinner, an opposite pattern
to the healthy cohort. Hinshaw et al. noted that the unexpectedly large
inter-subject variability in SI patterns reduced the power of the study to
make conclusions for the whole T1DM population. However, this variability
also perhaps suggests a greater need for personalisation in control
algorithms using identifiable models and easily obtained data to minimise
the impact of this effect.
4.5.3 Models of circadian SI rhythms
Several circadian SI models have been utilised (Toffanin et al., 2013; Fabietti
et al., 2006; Mansell et al., 2015d). A summary of these models can be found
in Table 4.1.
4.5.3.1 Piecewise model
Toffanin et al. (2013) used many literature references to determine several
fixed points for their multiplication factor (y) . The y(t) function was created
by interpolating t and y with a cyclic piecewise cubic Hermite interpolating
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polynomial based on:
t = [0, 2, 3, 8, 11.5, 15, 22, 24] (4.31)
y = [1.4, 0.8, 0.6, 0.4, 0.8, 1, 1, 1.4] (4.32)
where t is the time in hours.
The model was not used in any identification scheme, but as part of a
virtual patient and control algorithm for in silico trials. Toffanin et al.
parameterised the model via reference to various published reports. They
noted the proposed model was for cases when patient-specific information
was not available, but would become redundant with patient-specific
clinical testing.
4.5.3.2 Sinusoidal model
Fabietti et al. (2006) used a simple sinusoid to model circadian SI. SI is
multiplied by a function:







where Ac is the amplitude and Pc is the phase and t is the time in hours.
Ac, Pc and the nominal SI parameters were all identified from available
data. Fabietti et al. noted problems with identifying Ac since the
experiments were only 4-6 hours and the parameter would sometimes
exceed 1, indicating a negative SI at some times. This result strongly
suggests practical non-identifiability occurred in this study due to a lack of
information in the data set. In particular, with only a small portion of the
SI path recorded, there would be a greater trade-off between all of the
parameters due to the nature of the function and not being able to observe
the entire function. A longer experiment, in particular one lasting several
days, would be required to remediate this issue (Mansell et al., 2015d).
Importantly, the resultant time of lowest identified sensitivity averaged
around 6am, which is consistent with literature (Fabietti et al., 2006),
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providing some confidence.
4.5.3.3 Variable basis model
Mansell et al. (2015d) used a series of linear basis functions to model a
circadian rhythm in SI:
SI(t) = SI1g1(t) + SI2g2(t) + SI3g3(t) (4.34)
where g1−3 are overlapping triangular basis functions, pictured Figure 4.5,
and SI1−3 are parameters that can be identified from sparse diary data
stretching over weeks or months.
The model prioritises flexibility for identifying patient-specific rhythms.
More basis functions could be added to create a more detailed model, but
at the expense of identifiability. Since there are typically 3 meals during the
day, there are 3 unique glycaemic disturbances with which to perform
parameter identification, particularly for sparse data. Hence, the model was
designed to maximise practical identifiability of its parameters, while
maintaining flexibility to capture various SI profiles.
time (hours)










Figure 4.5: Basis functions for Mansell et al.’s variable-basis circadian SI
model
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time from midnight (hours)

























Figure 4.6: A comparison of circadian SI models: Toffanin et al.’s piecewise
model, Fabietti et al.’s sinusoidal model and our variable basis model, with
the latter two models fit to the first
4.5.4 Implications for modelling circadian rhythms in SI
Some models for circadian rhythms in metabolic function, particularly its
effect on insulin sensitivity, have been developed. Figure 4.6 shows a
comparison of the Fabietti et al. and Mansell et al. models fit to the
Toffannin et al. piecewise model. The Toffanin et al. (2013) model uses
information from the literature to populate all hours of the day with
specific values for SI. This approach could be effective if the information
proves to be applicable to a wide range of individuals, or if reliable clinical
measurements of individual circadian rhythms could be taken and then
used in diabetes outpatients. However, despite the specificity of Toffanin et
al.’s piecewise model, the literature suggests a great deal of uncertainty in
the shape of individual circadian SI rhythms (Van Cauter et al., 1997).
Due to the range of effects that could influence SI over the course of any
single day, data would ideally be captured over multiple days to achieve
sensible estimation of the rhythm. Both Fabietti et al.’s sinusoidal model
and Mansell et al.’s variable basis model could be used effectively with
long-term data. Since patient data and the majority of glycaemic
excursions occur during waking hours, the data is not necessarily
distributed in such a way that would benefit identification of Toffanin et
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al.s’ sinusoidal approximation (Toffanin et al., 2013; Docherty et al., 2011).
Thus, model features occurring during the night would suffer from practical
non-identifiability. The Mansell et al. model overcomes this issue by design,
by placing identified features during the daylight hours.
4.6 Discussion
This chapter yielded information on several distinct, highly variable,
grey-noise factors in outpatient diabetes, and their implications for
modelling and control. In particular, a representative selection of
foundational models for postprandial appearance of glucose in the
bloodstream were identified and discussed, along with similar foundation
models for the effects of exercise, stress, and circadian metabolic rhythms.
A summary of these models is found in Table 4.1. While the models vary
significantly in complexity, each are well suited for a particular purpose,
though not all would be useful in the context of outpatient diabetes
management.
This chapter has also examined the critical and relevant methods of
quantifying and measuring these variables or their effect in terms of which
are well suited for outpatients, which is relevant to the kinds of models that
could be used in practice. Thus, models that rely on clinically available
methods and data would be limited to use in clinical environments.
Equally, very complex models with respect to the quality or quantity of
data available tend to be vulnerable to mathematical non-identifiability,
thus leading to clinical misinterpretation and prediction error, and are thus
not easily suited for use in regular glycaemic management for inpatients or
outpatients.
There is potential to capture contributions to grey-noise in glucose
appearance from nutrition. Food structure affects the digestibility of
carbohydrates and their resulting bioavailability. In general, more processed
foods result in smaller particle size and thus, more rapidly available glucose
(Mourot et al., 1988; Mishra and Monro, 2012; Torsdottir et al., 1986;
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Englyst et al., 2003; Englyst and Englyst, 2005). Composition of a meal,
particularly the fat and protein content, affects the rate of gastric emptying
due to physiological feedback control from the small intestine (Bornhorst
and Singh, 2014)(Reinus and Simon, 2014; Velchik et al., 1989; Goldenberg
and Cummins, 1971; Schvarcz et al., 1997; Macdonald, 1996; Lodefalk
et al., 2008; Gentilcore et al., 2006; Fraser et al., 1990; Samsom et al., 1997;
Folwaczny et al., 2003; Schvarcz et al., 1997; Kong et al., 1996). Intra- and
inter- subject variability is large, especially in diabetes where gastroparesis
occurs (Clark and Nowak, 1994; Fraser et al., 1990; Horowitz et al., 2002;
Kong et al., 1996; Lartigue et al., 1994). The nutritional models of glucose
appearance considered here vary in complexity (Worthington, 1997; Wong
et al., 2008c; Dalla Man et al., 2006; Lehmann and Deutsch, 1992). When
considering the sparse nature of data expected in outpatient diabetes, only
models that require few patient-specific parameters may be of use when
attempting to capture the patient state. While each of these models has
been developed using differing data resolution and quality, all analyses used
data that was of a higher quality and resolution than may be expected in
clinical practice. Hence, further research must be undertaken to establish
the optimal model and a priori parameter combination that could capture
patient state under the limited measurements available in an outpatient
setting.
Psychological states, such as stress and depression, are a source of grey
noise as they are known to affect glycaemia but are infrequently modelled
in control applications (Klonoff, 2007; Lloyd et al., 1999; Räikkönen et al.,
1996; Surwit et al., 1992; Xiu et al., 2014; Ramkissoon and Veh́ı, 2015). It
is suspected that stress and depression cause elevated levels of cortisol and
other hormones which reduce SI (Rizza et al., 1982). However, there are
conflicting results in clinical trials as to the glycaemic effect of stress and
depression (Surwit et al., 1992). Recent advances in measuring the presence
of stress by simple, non-invasive means (Zangheri et al., 2015; Choi et al.,
2014; De Santos Sierra et al., 2011; Saha et al., 2014; Luharuka et al., 2003)
may allow further adaptations to model based capture of glycaemia.
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Physical activity frequently results in hypoglycaemia in diabetes (Yardley
et al., 2013; Sonnenberg et al., 1990; Borghouts and Keizer, 2000). This
hypoglycaemia is thought to be the result of insufficient compensation by
EGP to meet increased demands during exercise due to general
hyperinsulinaemia (Yardley et al., 2013; Sonnenberg et al., 1990), as well as
increased peripheral insulin sensitivity and glucose uptake lasting many
hours after exercise (Borghouts and Keizer, 2000; Magkos et al., 2008). To
maximise the applicability of exercise models in outpatient settings, they
should utilise physical activity metrics such as heart rate or motion sensing
(Strath et al., 2000, 2002; Bassett D.R et al., 2000; Yumiko et al., 2002;
Kim et al., 2014). Additionally, the models should be extended over a
post-exercise period of at least 16 hours, and must be robustly identifiable.
None of the models reviewed completely fulfil these criteria. In particular,
both the Breton and the Roy and Parker models were not validated beyond
an hour post-exercise. Additionally, the Roy and Parker model required
gold standard multiple tracer data to identify certain parameters, and
would thus be too detailed and over-parameterised for outpatient data.
Magkos et al.’s model had some clinical relevance but lacked validation
power and seemed too sparsely parameterised.
Studies suggest that in diabetes, the insulin sensitivity is often lower in the
morning than the evening (Van Cauter et al., 1997)Visentin et al. (2015).
Clinical trials show substantial inter-subject variability in patterns of
model-identified SI between breakfast, lunch and dinner (Visentin et al.,
2015; Hinshaw et al., 2013). Several models that aim to capture or simulate
circadian rhythms in SI are considered (Fabietti et al., 2006; Toffanin
et al., 2013; Mansell et al., 2015d). The Toffanin et al. model was
constructed with fixed points based on clinical studies while the Mansell et
al. and Fabietti et al. models were created for data-driven identification.
Given the large amount of inter-subject variation, useful models should be
flexible and able to be identified over a number of days to increase the
certainty of results and minimise grey noise. Furthermore, practical
identifiability could be optimised by identifying parameters describing
day-time behaviours, as the glycaemic perturbations which allow SI to be
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identified are largely driven by meal times.
To maximise prediction capability, it is critical to ensure that model
parameters are identified with confidence. Hence, candidate models must
be as practically identifiable as possible, while maintaining the ability to
capture the important characteristics of glycaemic excursions. In general,
identifiability is maximised when there are a minimum of parameters in the
candidate model (Raue et al., 2009, 2012, 2014). However, the necessity of
modelling factors to reduce grey noise is apparent in this chapter. The
challenge is to balance minimal parameterisation with capturing as many
observable factors as possible. Ultimately, this modelling strategy should
reduce uncertainties allowing for lower and more precise control targets.
Increased confidence in glycaemic control protocols and a corresponding
reduction in chronic hyperglycaemia should improve the quality of life for
individuals living with diabetes.
4.7 Summary
This chapter examines several important and often overlooked grey-noise
factors that affect glycaemia and glycaemic management in outpatient
diabetes. Clinical literature has clearly shown that sources of variability
around nutritional intake, physical activity, emotional stress and circadian
metabolic rhythms are physiologically relevant factors affecting individual
glycaemic excursions in diabetes. Hence, ignoring the presence of these
factors could contribute significant and systemic grey noise to analytical or
predictive modelling outcomes, as well as to management in general.
Therefore, there is significant potential benefit to be gained from including
these factors in models when it is possible to measure the relevant stimuli.
Methods to detect or measure the presence of these factors have been
reviewed and discussed with respect to their applicability in aiding
modelling and their potential clinical use in care. Previous efforts modelling
these grey-noise factors are presented, compared and discussed with regard
to applicability in outpatient diabetes. Practical identifiability is considered
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to be a mathematically limiting factor for model complexity and specificity
given that high quality data is generally not available in the outpatient
environment. Hence, not all models would perform well in an outpatient
context. However, each model considered may be effective when used for
the purpose it was developed, whether that be for clinical diagnosis, disease
pathology, or inpatient care.
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Table 4.1: A summary of grey-noise effect models and their defining features








1992 • trapezoidal piecewise GE function
• single linear gut compartment
Wong et al.’s 2
compartment model
2008 • linear stomach and gut compartments
Dalla Man et al.’s 3
compartment model
2006 • two stomach compartments for solid to
liquid phases
• non-linear GE rate function depending on
total stomach content




2011 • stomach compartment with power-
exponential GE function
• partial differential equation for gut with
movement/absorption along one spatial
direction
• regional expression of two gut glucose
transporters approximated with Gaussian
functions
4.3.3 Mansell et al.’s stress
model
2015 • simple step function for multiplicative




2008 • energy consumption modelled from heart
rate
• insulin action increased with exercise




2007 • PVOmax2 modelled from prescribed exercise
intensity
• glucose production and uptake
compartments based on PVOmax2 affecting
plasma glucose
• glycogen depletion function for prolonged
exercise affecting plasma glucose
Magkos et al.’s
curvilinear IR model
2008 • next day change in IR correlated to EE




2013 • piecewise interpolation of values interpreted
from literature over 24hr period
• lowest in early morning, middle in afternoon
and evening, peak at midnight
Fabietti et al.’s
sinusoidal SI model
2006 • simple sinusoid with 24hr period
Mansell et al’s variable
basis model
2015 • sum of three overlapping triangular basis
functions over 24hr period
• each basis function scaled by different value
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Chapter V
Everyday life events data
This chapter describes the data used for the remaining chapters in Part II.
The data was collected as part of a study designed by a group of clinicians
and modellers in Denmark, and was kindly provided to us in the spirit of
collaboration. Hence, this chapter is essentially the content of their work
published in Schmidt et al. (2012) and Duun-Henriksen et al. (2013).
As Schmidt et al. (2012) describes in their paper, mathematical modelling
is invaluable to the diabetes research field, and is used for developing
control algorithms, performing research simulations, and predicting glucose
for decision support. However, much of the data used historically for
developing models has not reflected the everyday life of a heterogeneous
cohort of individuals with T1DM, and the inherent variabilities therein.
Hence, Schmidt et al. (2012) aimed to collect data for model-building that
observed subjects with T1DM on subcutaneous infusion of insulin




Twelve subjects were recruited from an outpatient diabetes clinic (subject
characteristics given in Table 5.1). All patients had been treated with a
SC infusion of insulin aspart (IAsp, Novo Nordisk, Bagsværd, Denmark) via
pump for at least six months.
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1 F 51 43 23.1 46 0.45 58
2 M 41 8 22.2 52 0.61 62
3 F 35 26 26.9 52 0.50 68
4 F 26 13 21.4 50 0.72 49
5 M 31 23 23.5 40 0.73 64
6 M 49 7 25.1 43 0.47 69
7 F 25 8 23.8 52 0.76 63
8 F 29 19 32.6 53 0.67 52
9 F 38 13 20.3 51 0.57 73
10 F 34 12 34.7 54 0.78 60
11 F 29 14 24.4 49 0.66 53
12 F 23 12 23.3 54 0.62 47
5.1.2 Protocol
Each subject attended two study days, providing a total of 24 separate sets
of data. On each of these study days, subjects participated in a unique
schedule of three main events at 0, 150 and 300 minutes. These events
varied in type (meal with or without insulin, insulin bolus, exercise or
snack) and some events varied in magnitude (large or small insulin bolus,
mild or moderate exercise). The possible schedules can be traced through
the three tiers pictured in 5.1.
Out of the 24 study days, twenty included an exercise event, half at mild
and half at moderate intensity. Thirteen of the exercise events occurred at
Event 2 and the remaining seven at Event 3. Eight schedules contained a
snack at Event 3. The remaining 2nd and 3rd events were insulin boluses,
half of which were small and half large.
Subjects arrived two hours before the first event for a stabilisation period
(-120 to 0 minutes). During this time glucose levels were brought to stable
euglycaemic levels if necessary using small insulin boluses or intravenously
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Figure 5.1: The trial structure indicating the possible combinations of first,
second and third tier events
was also used to stabilise subjects (300 to 420 minutes). The total
observation time was nine hours, from 8am to 4pm.
The meal provided at Event 1 contained one gram of carbohydrate per
kilogram of the subject’s body weight, and had an energy composition of
52% carbohydrates, 18% protein and 30% fat. The snack scheduled for
some subjects at Event 3 contained 0.4 grams of carbohydrate per kilogram
of body weight, and an energy composition of 89% carbohydrates and 11%
protein. The carbohydrates in both the meal and snack have a high
glycaemic index.
Exercise was carried out by treadmill running, where the speed of the
treadmill was adjusted to achieve a prescribed HR. Prescribed HR for each
of mild and moderate exercise intensity was chosen as a fraction of the HR
reserve, i.e. HR = HRrest + %intensity(HRmax − HRrest) where HRrest is the
resting heart rate and HRmax is the maximum heart rate, and the intensity
for mild and moderate exercise is 50% and 75%, respectively.
At Event 1, insulin boluses with meals were either absent or given at half
the required amount based on the subjects normal insulin to carbohydrate
ratio. Boluses separate to meals (Event 2 or 3) were either small or large,




A large range of variables were measured over the course of the study days.
Subjects wore a continuous glucose monitor (Paradigm Real-Time,
Medtronic) which gave a glucose reading every five minutes. Subjects also
wore an ActiHeart R© (CamNtech Ltd., Cambridge, UK) heart rate
measurement device with readings every minute.
Blood samples were drawn at regular intervals to measure other relevant
species. Blood glucose was analysed every ten minutes using the YSI2300
STAT Plus (Yellow Springs Instruments, Yellow Springs, OH). Three
ten-minute insulin measurements were analysed after an event, otherwise
every 30 minutes, using LOCI-technology (Novo Nordisk A/S, Måløv,
Denmark). At the same time as insulin, the concentrations of glucagon,
cortisol, growth hormone, epinephrine and norepinephrine were analysed.
Other relevant information was recorded for anything taken by the subjects
during the study day. These inputs were food intake, intravenous glucose,
subcutaneous insulin infusion, along with prescribed exercise. All
measurements and inputs were recorded with respect to the relevant time.
5.2 Data and discussion
Figure 5.2 and Figure 5.3 are examples of the kind of input and output
data obtained from two separate test days for the same subject. The type
of data is ideal for the development of mathematical models. The data is of
clinical-grade quality, considering the range of measured species, the
equipment used, and relatively high sampling frequencies, but aims to
capture much of the everyday variabilities expected in an outpatient
environment. The large range of measured species, especially the various
hormones analysed, provides numerous avenues for research for the effect of
various environmental stimuli on these hormones, and the subsequent effect
of the hormones on blood glucose and insulin dynamics.
From a dynamic modelling perspective, the variety in order of events is
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useful for distinguishing different effects. For example, having some meals
without boluses, some with, and some boluses alone allows for good
observability of the independent effects of the meal and insulin boluses on
blood glucose. For an event like exercise, it occurs at a variety of glucose
and insulin concentrations across and within subjects, again providing a
range of contexts to distinguish the effect of exercise specifically.
A disadvantage is the long postprandial period from the Event 1 meal.
Rate of appearance studies have shown that the tail end of glucose from a
meal with highly glycaemic carbohydrates can still be entering the
bloodstream 300-400 minutes after initial ingestion (Elleri et al., 2013;
Dalla Man et al., 2006). Since this event is present in all datasets, it could
be more difficult to distinguish the effects of some other events occurring
during this post-prandial period. However, this reflects everyday outpatient
reality that, aside from first thing in the morning before breakfast, most
hours of the day are spent well within 300-400 minutes of some form of food
ingestion.
The sampling frequency of all the measured species appears to be
appropriate for capturing most important glycaemic and insulinaemic
dynamics reasonably well. While more data is generally better, the burden
of cost for an increased sampling rate is a limiting factor. Additionally,
since the primary dynamics appear to be reasonably observable as is,
additional data may contribute mostly to further observation of
measurement noise more than anything else.
Overall, the high quality data from Schmidt et al. (2012) and
Duun-Henriksen et al. (2013) provides a unique opportunity for model
development in T1DM. The subjects had T1DM and experienced a range of



























































Figure 5.2: A visual representation of results from trial 2a (subject 2,
study day 1) reproduced from Duun-Henriksen et al. (2013). Note that the





























































Figure 5.3: A visual representation of results from trial 2b (subject 2,
study day 2) reproduced from Duun-Henriksen et al. (2013). Note that the





This chapter presents the model-building and evaluation process for a
continuously infused subcutaneous insulin aspart model. While the
underlying pharmacokinetics are inevitably complex, it is recognised that
model complexity does not always contribute positively to model
performance. Hence, a range of models of increasing complexity are
compared and evaluated for performance with the available data. The
content of this chapter is in review at the Journal of Pharmacokinetics and
Pharmacodynamics.
6.1 Motivation
Subcutaneous administration is the typical route of insulin therapy for
outpatients with T1DM and is sometimes used in T2DM. Appearance of
insulin in plasma and the active interstitial regions is slower than
intravenous (IV) administration of insulin, which peaks briefly before
dissipating. Use of IV bolus administration for outpatients is unfeasible due
to health risks and practical difficulties. Modelling IV insulin appearance is
trivial. In contrast, modelling the appearance of insulin in plasma after SC
insulin administration is difficult. In particular, SC insulin exhibits kinetic
delays that are difficult to predict and quantify.
An injected insulin bolus disperses rapidly into the small fluid volume
between fat cells (Rasmussen et al., 2014). The insulin is then subject to
self-association reactions in addition to absorption kinetics (Lindholm and
Jacobsen, 2001; Home et al., 1999). Pharmaceutical human insulin is
typically stored as a six unit hexamer (Kang et al., 1991). Hexamers are
thought to be either absorbed directly to the plasma at a slow rate (Kang
et al., 1991) or drained lymphatically (Rasmussen et al., 2014). More
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significantly, SC dilution cleaves hexamers to dimers, and single unit
monomers. Both dimers and monomers appear to be readily absorbed
(Kang et al., 1991; Rasmussen et al., 2014; Lindholm and Jacobsen, 2001;
Home et al., 1999). However, absorption rates are strongly dependent on
factors that affect blood flow. For example, temperature, injection depth
and physical activity have been known to affect the absorption rates (Kang
et al., 1991; Rasmussen et al., 2014).
The insulin analogue IAsp has been engineered with a molecular
substitution that discourages self-association into hexamers and therefore
exhibits a faster glycaemic response than soluble human insulin (Lindholm
and Jacobsen, 2001; Home et al., 1999). Thus, while hexamers are the
predominant insulin form in a vial of IAsp, these hexamers disassociate
rapidly post-injection (Rasmussen et al., 2014; Lindholm and Jacobsen,
2001). Kang et al. (1991) suggest that SC hexamers are negligible in IAsp,
that dimers become the predominant insulin form immediately and that the
latter phase of IAsp is likely entirely monomeric due to lower
concentrations. Furthermore, the monomer to dimer equilibrium constant
in IAsp has been found to be 200-300 times smaller than in human insulin
(Brems et al., 1992).
There have been multiple efforts to model the pharmacokinetics of various
insulin types and insulin delivery strategies (Wilinska et al., 2005; Wong
et al., 2008a,b; Li and Johnson, 2009; Lehmann et al., 2009; Nilam et al.,
2007; Song et al., 2014; Li and Kuang, 2009). A range of candidate models
have been developed for continuous SC IAsp infusion. These were
compared and validated on a heterogeneous dataset that was collected in a
clinical-grade environment that mimicked outpatient conditions
(Chapter 5). Effective models must be robust to the typical variation
expected within and between patients. Furthermore, models must be
well-suited to the quality of data they would be coupled with to ensure




6.2.1 Data selection and processing
Datasets that contained exercise in the second event tier were omitted from
the analysis. Only 11 data sets remained, and within these, datasets with
exercise in the third tier were truncated. These datasets covered 9 subjects
(2/7 M/F, 33±8 years).
6.2.2 Models
Literature suggests that a multi-compartmental, potentially non-linear
approach may be appropriate to represent the association and absorption
kinetics of insulin (Eaton et al., 1980; Kang et al., 1991; Home et al., 1999;
Lindholm and Jacobsen, 2001; Li and Johnson, 2009; Wilinska et al., 2005;
Li and Kuang, 2009). However, the intentional reduction in dissociation
half-life for IAsp could allow a much simpler model than required for other
insulin types. The models developed are permutations of a large, generic
model. This general model has three SC compartments (US1−3, [mU]),
modelled by:







− (k2 + k23)US2(t) (6.2)
U̇S3(t) = k13US1(t) + k23US2(t)− k3US3(t) (6.3)
UST (t) = k1US1(t) + k2US2(t) + k3US3(t) (6.4)
where k terms are transfer rates [min−1]; αU saturates the transfer rate
between US1 and US2 [mU
−1]; and UST is the transfer rate of all insulin
states from the subcutis to plasma [mU ·min−1].
Plasma and interstitial dynamics are modelled by the 3-compartment
model of Fisk et al. (2016) that was based on the 2-compartment ICING
model (Lin et al., 2011). Insulin diffusion occurs between plasma (I), active
interstitial (Q) and passive interstitial (QP ) compartments. Clearance
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occurs from the plasma and active interstitial compartments. The Fisk et

















where nK is the renal clearance coefficient [min
−1]; nL is the hepatic
clearance coefficient [min−1] that is saturated by αI [L · mU−1]; nC is the
interstitial clearance rate [min−1]; plasma-interstitium transport rates are
labelled nQ and nP for active and passive, respectively [min
−1]; VI , VQ and
VP describe plasma, active interstitium and passive interstitium volumes of
distribution, respectively [L].
The following candidate models were developed to represent specific

























Figure 6.1: Pathway diagram for the full model showing rates of mass transfer
between compartments
80
Model 1 (M1) is the simplest of all the models, including only a single
linear compartment for SC insulin, and a single plasma compartment with
linear clearance. Transport rate from the subcutis and hepatic clearance
rate from the plasma are identified: x = [k1, nL]
T
Model 2 (M2) retains the simplicity of the M1 plasma compartment but
insulin passes a second SC compartment before transportation to the
plasma. Transport rates for both SC compartments are equal and identified
as one parameter along with the clearance rate from plasma:
x = [k12, nL]
T, k2 = k12
Model 3 (M3) has the same SC structure as M2 but introduces an
interstitial insulin compartment paired with the plasma compartment.
Insulin is cleared hepatically and renally from the plasma and also in the
interstitium. Several functions interrelate interstitial-plasma transport and
clearance rates and only interstitial clearance is identified along with the
SC rate parameters: x = [k12, nC ]
T, k2 = k12
Model 4 (M4) introduces nonlinear transport across SC compartments and
identifies a transition from SC to the plasma. The saturation term creating
this nonlinearity is a priori but the SC transport rates are no longer
treated as equal and are identified separately: x = [k12, k2, nC ]
T
Model 5 (M5) introduces a priori nonlinear hepatic clearance from the
plasma but is otherwise the same as M4: x = [k12, k2, nC ]
T
Model 6 (M6) adds a passive interstitial compartment that contains, but
does not clear insulin. All passive compartment parameters are a priori.
Active interstitial clearance is still identified along with the SC transport
rates as before. Furthermore, the SC nonlinear saturation term is also
identified: x = [k12, k2, αU , nC ]
T
Model 7 (M7) returns to the plasma-interstitial system of M5, neglecting
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the passive interstitial compartment, but adds a third SC compartment.
The first two compartments feed into the third compartment identified at a
fixed ratio. The transport rate to the plasma, now from the third
compartment, is also identified: x = [k12, k13, k3, nC ]
T, k23 = 0.66k13
Model 8 (M8) contains the SC system of M7 but again includes the
passive interstitium of M6. M8 is the most complex model and contains
three SC compartments from which three parameters are identified, a
plasma compartment, a passive interstitial compartment, and an active
interstitial compartment from which clearance is identified:
x = [k12, k13, k3, nC ]
T, k23 = 0.66k13
Specifications for which parameters were identified and any a priori
assigned values for each model are given in Table 6.1. In all cases plasma
volume was assumed to be 3L, while interstitial volumes were predefined
fractions of the subject weight (Fisk et al., 2016; Lin et al., 2011).
Particular ratios (fnK , fnL and fnQ) defined relationships between clearance
and transport rates for the plasma-interstitial system for some model













Linear, un-paired differential equations were simulated via analytical
solutions with trapezoidal integration for computational simplicity. For
nonlinear differential equations, left-hand numerical integration was used
for nonlinear terms, while remaining terms were integrated trapezoidally.
This ensured rapid integration while retaining precision. For
interdependent compartments, i.e. plasma and interstitium, iterations were
carried out between the species until satisfactory convergence in plasma
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SC species were simulated for an additional few hours before the
experimental start time to utilise information recorded about boluses used
in the night or early morning. Starting point values for all species were
simulated as steady state values given the parameters and initial
concentrations in parent species.
6.2.3 Analysis methodology
6.2.3.1 Parameter estimation
Parameters were estimated for individual datasets using a
Levenberg-Marquardt gradient descent algorithm (Chapter 3).
Table 6.1: Specifications for parameters in each model permutation






k1 ID 0 0 0 0 0 0 0
k12 0 ID ID ID ID ID ID ID
k13 0 0 0 0 0 0 ID ID
k2 0 k12 k12 ID ID ID 0 0
k23 0 0 0 0 0 0 0.66k13 0.66k13
k3 0 0 0 0 0 0 ID ID
αU 0 0 0 0.002 0.002 ID 0.002 0.002
nK 0 0 fnK fnK fnK fnK fnK fnK
nL ID ID fnL fnL fnL fnL fnL fnL
αI 0 0 0 0 0.0017 0.0017 0.0017 0.0017
nI 0 0 fnI fnI fnI fnI fnI fnI
nC 0 0 ID ID ID ID ID ID
nIp 0 0 0 0 0 nI 0 nI
VQ 0 0 0.1w 0.1w 0.1w 0.058w 0.1w 0.058w
VP 0 0 0 0 0 0.09w 0 0.09w
VI 3 3 3 3 3 3 3 3
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(Is − I(x, ts))2 (6.12)
where xopt is the optimal parameter values, Is is the s
th insulin data
measurement and I(ts) is the modelled plasma insulin at the time of the s
th
sample.
Starting parameter values for the algorithm were
x0 = [0.01, 0.05, 0.05, 0.05, 0.5, 0.05]
T and perturbations were
∆x = [10−5, 10−5, 10−5, 10−5, 10−6]T. A maximum of 250 iterations were




6.2.3.2 Goodness of fit
The candidate models’ ability to capture the observed behaviour was
assessed. Overall goodness of fit was evaluated with the coefficient of
determination (R2) across all datasets and compared across models.
Additionally, residual error patterns in the post-bolus period were collated
from all datasets to investigate the presence of any consistent bias
indicating mismodelled behaviour.
6.2.3.3 Parameterisation
The degree of parameterisation was evaluated to ensure that the model did
not attempt to fit kinetics that were more likely to be measurement noise.
The Akaike Information Criterion (AIC) is based on information theory, and
evaluates the trade-off between fitting capability and complexity. Typically,
a model with the lowest AIC score is considered optimal. The AIC value for
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small sample sizes is given by:
AIC = 2k − 2 ln(L) + 2k(k + 1 )
n − k − 1
(6.14)







where k is the number of parameters, n is the sample size, σ is the reported
standard deviation of the measurement noise, derived from Petersen et al.
(2010).
AIC was calculated for individual datasets to compare medians and
interquartile ranges between models. In a related analysis, cumulative
distribution functions (CDFs) of residual error collated from all datasets
were created for each model and compared to the distribution expected
from assay error alone. In theory, a perfectly parameterised model would
yield a residual distribution that was just outside that of the reported
measurement error. Such an outcome would imply that real behaviours are
captured, and that the model was not adhering to measurement noise.
Knowledge of measurement noise was required for both parameterisation
analyses. Published information for assay variance at different serum
insulin concentrations (Petersen et al., 2010) was interpolated to simulate
error at the concentration of each measured data point. For AIC, variance
of this simulated error was calculated and averaged over 1000 simulations.
The mean CDF of 1000 error simulations was used in the CDF analysis.
6.2.3.4 Practical identifiability
Robust parameter estimation is essential for utilisation of models in
prescriptive clinical applications. Lack of robustness can be attributed to
practical non-identifiability. Identified model parameter values describing
similar but distinct behaviours can trade off if measurement noise in the
data is sufficient (Raue et al., 2009; Docherty et al., 2011). Few formal
methods of measuring practical non-identifiability have been developed. For
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this application a boot-strapping methodology was employed. Robust
parameters should be insensitive to small changes in the content of a
dataset. Thus, for a data set with n datapoints, n parameter identification
runs were undertaken with each run having one data point removed (i.e.
with n − 1 data). The coefficient of variation (CV) in x due to the
down-sampled datasets was calculated (CVi =
σxj
xj
× 100%). Median and
interquartile values of CV were calculated across the eleven datasets for
each parameter in each model.
6.2.3.5 Predictability
An analysis was carried out to test the predictive capabilities of each
model. M1-8 were fit to each dataset excluding the last two hours of output
data. Identified parameters were then used to predict the last two hours of
plasma insulin. Residual error between the predictions and a linear
interpolation of the data for all datasets was plotted for visual
interpretation. For quantitative evaluation, mean absolute residual error
over all datasets was calculated for each model.
6.3 Results
All models were successfully fit to the experimental data. Figure 6.2 shows
a typical result. M1 had the lowest R2 (Table 6.2), while the remaining
models achieved similar goodness of fit (Figure 6.3a). Goodness of fit
generally increased with complexity and M8 performed the best (R2 =
0.92). Post-bolus residual patterns exhibited insignificant bias for models
M2-M8 (Figure 6.4). However, M1 exhibited some consistent bias,
indicating failure to capture some dynamics.
M8 achieved the lowest median AIC score Table 6.2. However, M4 achieved
the lowest mean AIC score (Figure 6.3b). M2-8 have very similar AIC
scores. No model residual CDFs were within the reported measurement
noise (Figure 6.3c). Degree of conformity to the assay CDF increased
roughly in the order of model complexity with M1 being the most distant
from the assay error and M7 and M8 being very similar and the closest.
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Figure 6.2: A typical result for model fitting plasma insulin for a dataset.
Note log-scale in UX(t) and that the subject took a bolus not long before the
experiment began
The CV of parameter estimates across bootstrap permutations were lowest
for M2-3 (Table 6.3). M4-5 had similar results to M3 for the nC parameter
but higher CV in subsequent parameters. M6-8 had median CVs exceeding
20% in many parameters with large interquartile ranges.
On occasion, the convergence criteria was not reached before 250 iterations
had elapsed. This convergence failure occurred for M7 in one of the 11
datasets in the original parameter estimation exercise. During the
bootstrap analysis with 212 dataset permutations, convergence failure
occurred six times for M6 and 19 times for M7.
The predictability analysis yielded similar minimal prediction errors for
M2-8 while the errors for M1 were larger (Table 6.4, Figure 6.5). M3
predicted best with lowest mean error and tightest visible distribution of
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Figure 6.3: Analysis results: a) all (grey) and mean(black) R2 values for
datasets at each model; b) all (grey) and mean (black) AIC values for datasets
at each model; c) collated residual CDFs for each model against simulated
noise
residual trajectories. Convergence failure occurred once with each of M6-8
during this analysis.
6.4 Discussion
All models were generally capable of fitting the data. M8, the most
complex model, achieved highest goodness of fit (R2 = 0.92, Table 6.2).
M1, the least complex model, was worst fitting model (R2 = 0.53). This
finding follows the expected trend of fitting capability improving with
parameterisation and model detail. Post-bolus residuals (Figure 6.4)
provide information on the suitability of the model forms for the capturing
insulin responses and the efficacy of the identification process. As expected,
post-bolus patterns did not differ significantly across models with the same
underlying SC model. M1 yielded a repeated bias immediately after the
bolus, indicating it was incapable of capturing the kinetics of post-bolus
plasma insulin.
The net-zero bias of residuals shown in Figure 6.4 imply that the parameter
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Table 6.2: Median, lower (Q1) and upper (Q3) quartiles for R
2 and AIC
values for each model across the datasets
Model R2 (Q1,Q3) AIC (Q1,Q3)
M1 0.53 (0.32,0.61) 122 (89.7,159)
M2 0.85 (0.82,0.89) 101 (81.0,105)
M3 0.85 (0.82,0.89) 101 (81.1,105)
M4 0.87 (0.85,0.93) 99.1 (79.2,108)
M5 0.87 (0.85,0.93) 99.2 (79.1,108)
M6 0.89 (0.87,0.92) 102 (81.9,109)
M7 0.91 (0.88,0.94) 91.8 (82.4,109)
M8 0.92 (0.88,0.94) 92.1 (82.4,109)
identification process was generally robust and led to model simulations
that adhered to the measured data. However, the non-zero incidence of
failed convergence after 250 iterations for M6-8 during the bootstrapping
and prediction exercises implies isolated cases of unstable parameter
identification or that the particular parameter sets yielded practically
non-identifiable model parameters. Practical non-identifiability can occur if
the data contains insufficient information to quantify a particular model
parameter’s behaviour, or to delineate the behaviour of two or more model
parameters. Practical non-identifiability results in very high CV values for
some parameters. Models that produced a non-zero incidence of failed
converge (M6-8) yielded the highest parameter CV values (Table 6.3).
Thus, the parameter trade-off in M6-8 appears to have limited the ability of
the parameter identification methodology to determine accurate Jacobian
gradient directions, preventing descent on the objective surface with respect
to certain parameters. This means that M6-8 have insufficient practical
model identifiability to provide robust and reliable parameters.
The CDF comparison allowed a similar parameterisation analysis to AIC.
The Akaike criteria implies that ideal model parameterisation leads to
model fit residual CDFs as close as possible to the measurement error CDF.
Model fit residual CDF within the measurement error envelope implies that
the data has been over-fitted’ and thus that the model is over


























































































Figure 6.4: Post bolus residual trajectories of collated post-bolus residual
behaviour across all datasets and for each model
prediction, classification and diagnosis of parameter values. The CDFs in
Figure 6.3 indicated that none of the candidate models were over-fitted.
Despite the potential for further parameterisation, the AIC analysis
indicated that when trading off fit and model complexity M4 was the best
choice based on lowest mean result (Figure 6.3b) or M7 based on the lowest
median result (Table 6.2). This dichotomous outcome across summary
statistics for the AIC metrics demonstrates that the optimal model was
difficult to determine. A much larger sample size would be needed to
confidently rank the top models according to the AIC criterion. The close
AIC medians and ranges across the models, particularly M2-8, implied
similar performance. The CDFs and R2 results of M2-8 are also reasonably
close.
The bootstrap analysis revealed that M2 and M3 were the most robust
models (Table 6.3), with median parameter CVs not exceeding 2%. In
contrast, M6-8 yielded multiple median parameter CVs in excess of 20%
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Table 6.3: Median, lower (Q1) and upper (Q3) quartiles for CV [%] for
parameter estimates across all permutations of datasets for each model in
the bootstrap analysis
Model M1 M2 M3 M4 M5 M6 M7 M8
x1 nL nL nC nC nC nC nC nC
CVx1 1.2 0.6 0.6 0.7 0.6 1.6 23 12
Q1,Q3 0.7,1.7 0.5,0.9 0.5,0.9 0.5,1.0 0.4,1.2 0.8,14 20,28 3.1,27
x2 k1 k12 k12 k12 k12 k12 k12 k12
CVx2 8.0 1.7 1.7 5.1 5.8 40 16 11
Q1,Q3 6.4,13 1.5,2.1 1.5,2.2 2.6,10 2.7,12 27,157 11,28 4.3,18
x3 k2 k2 k2 k13 k13
CVx3 4.8 5.1 23 27 23
Q1,Q3 2.5,39 3.0,23 6.6,57 21,108 12,87
x4 αU k3 k3
CVx4 64 25 4.4
Q1,Q3 39,150 3.1,32 2.7,24
Table 6.4: Mean absolute residuals with each model for predicted outcome
of the last 2 hours of the experiment based on identification of prior data
Model M1 M2 M3 M4 M5 M6 M7 M8
|Ψ∗| [mU/L] 5.01 2.23 2.07 2.33 2.39 2.95 2.45 2.82
and large interquartile ranges. This indicates that these models are too
sensitive to small variations in data to yield unique parameter estimates
that are indicative of the underlying pharmacokinetic behaviour of the
participants. Hence, the M6-8 formulations lead to parameter estimates
that have ambiguous utility in prediction or diagnosis. Furthermore, these
models sometimes did not converge to the data within 250 iterations of the
Levenberg-Marquardt scheme used during the bootstrap-like and prediction
analyses. Levenberg-Marquardt is generally considered a robust parameter
identification system due to its ability to transition between quick second
order and robust first order convergence based on the behaviour of previous
iterations.


























































































Figure 6.5: Residual error between 2 hour predictions and the actual data
(at datapoints, black, at linear data interpolation, grey)
established T1DM. Thus, zero endogenous insulin secretion was assumed.
This allowed analyses that did not require determination of the endogenous
insulin signal. Even if undertaken with C-peptide data and an assumption
of equimolar secretion, determining endogenous secretion would ultimately
incorporate another contribution of measurement error into the analysis,
reducing clarity in the appearance of insulin in plasma. There is some
ambiguity whether the pharmacokinetics of SC insulin in T1DM is relevant
in T2DM. Individuals with T2DM often experience a period of insulin
hypersecretion prior to hyposecretion that occurs when the disease is
established (Pories and Dohm, 2012). Thus, determining appearance of SC
insulin in those with T2DM may require deconvolution of the appearance
profile from hypersecretion of endogenous insulin. It is possible that such a
deconvolution would introduce uncertainty greater than that caused by
assuming equivalent SC kinetics across individuals with T1DM and T2DM.
Insulin measurements were taken at 10 minute intervals immediately after
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the bolus administration. Higher data resolution would yield more robust
estimates of non-linear appearance effects. However, Figure 6.4 shows that
the general form of the plasma insulin excursions could be well quantified
by the sampling rate. The non-linear effects of appearance may be of
primary interest to pharmacokinetic studies of drug composition. However,
the general form of the plasma insulin excursion captured by M2-M8 is of
primary importance for projects aiming to control glycaemia. Changes in
glucose are approximately proportional to area under the insulin curve.
Hence, for glycaemic regulation, the most critical factors to determine are
appropriate insulin rise time, peak levels, and decay rate.
Eight models of differing nature and complexity have been analysed.
Models M1 to M7 are simplifications of M8 which contains terms for all
reported significant mechanisms of SC appearance in plasma. The
simplifications are achieved by fixing parameters a priori, defining
relationships between parameters and effectively removing compartments.
The models provided unique compromises of parameter robustness and
fitting accuracy. Table 6.5 summarises the outcomes for all of the models
highlights the value of M3 as the most robust model that also provides
acceptable R2 values. These outcomes imply that the best prediction and
control could be achieved with M3. Table 6.5 also shows that M8 adheres
to the measured data better than all other candidate models. However, M8
also exhibited relatively high parameter variance implying that it would
have limited use in determining robust parameter estimates.
6.5 Summary
This modelling exercise considered eight permutations of an insulin
pharmacokinetic model. The models had different levels of
parameterisation, and different compartmental approaches. Increased
parameterisation and complexity generally led to lower parameter
estimation precision but better adherence to measured data. In contrast,
models with fewer identified parameters had poorer model fitting, but led
to improved identified parameter precision, and associated improvements in
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plasma insulin prediction. The optimal model for parameter robustness and
prediction incorporated a two compartment SC depot and a two
compartment plasma-interstitial system.
Table 6.5: Summary of model performance across key metrics; underlined






Potential value based on
analysis
M1 0.53 122 5.01 1.2,8.0 systemic
bias
Too simplistic
M2 0.85 101 2.23 0.6,1.7 unbiased No benefits over M3
M3 0.85 101 2,07 0.6,1.7 unbiased Best prediction
and parameter
robustness
M4 0.87 99.1 2.33 0.7,5.1,4.8 unbiased Acceptable compromise
of robustness and model
fitting
M5 0.87 99.2 2.39 0.6,5.8,5.1 unbiased Reasonable compromise
of robustness and model
fitting
M6 0.89 103 2.95 1.6,40,23,64 unbiased Poor practical
identifiability
M7 0.91 91.7 2.45 23,16,27,25 unbiased Poor practical
identifiability





Autoregressive modelling of exercise
This chapter presents a data-driven autoregressive modelling approach to
reveal the effect of mild to moderate exercise on insulin and glucose
independently. This work was presented as a conference abstract and poster
at the New Zealand Society for the Society for the Study of Diabetes
Annual Scientific Meeting (Mansell et al., 2016)
7.1 Motivation
Exercise causes a disturbance to glycaemic control in T1DM and can result
in hypoglycaemia without compensatory treatment (Sonnenberg et al.,
1990; Brazeau et al., 2008). In healthy individuals, decreases in insulin
secretion during exercise signal the liver to increase EGP for additional
peripheral glucose demand (Sonnenberg et al., 1990). Since those with
established T1DM lack endogenous insulin, this pathway for modulating
hepatic EGP during exercise is impaired, though catecholamine hormones
are still active (Yardley et al., 2013). Furthermore, some literature suggests
that the plasma concentration of exogenous insulin increases during
exercise in T1DM Koivisto and Felig (1978); Sonnenberg et al. (1990),
further reducing glucose concentration. Hence, the insulin-glucose dynamics
during exercise have implications for glycaemic management in T1DM.
In this chapter, Nonlinear AutoRegressive eXogenous (NARX) modelling
has been used to delineate the effect of exercise on both insulin and glucose
concentrations in T1DM. NARX is a non-parametric form of modelling
that allows a model to be trained to imitate the relationship between model
input and output data without specific knowledge of the physiological




Of the 24 trials from 12 subjects (3/9 M/F, 34±9 yrs), only 20 contained
the necessary exercise periods for this study. During these trials, patients
ran on a treadmill for approximately 20 minutes at either a mild or
moderate level. These levels corresponded to target heart rates 50% and
75% of the interval between resting and maximum heart rate, respectively.
The glucose data was truncated to exclude three hours following the
morning meal and four datasets were excluded altogether due to a
scheduled afternoon snack. Thus, meal glucose appearance could be
neglected.
NARX is typically applied where input and output data sampling rates are
equal and consistent. This is mathematically appropriate since NARX
formulations are independent of time. The insulin and glucose
measurements (Idata and Gdata) were taken at sampling rates that were
much lower than the one-minute resolution of insulin pump data, meal
intake and prescribed exercise. Hence, the insulin and glucose data were
interpolated with a Hermite cubic polynomial to increase the resolution of
output data to equate the sampling rates.
Prescribed exercise was given in terms of a target heart-rate (HR(t)),
elevated during the exercise period and at resting (HRrest) otherwise.
Subject information for maximum heart rate (HRmax) was used to







Exercise data was then converted into an impulse located at the start of the





e(t)dt, at t = te0
zero, otherwise
(7.2)
where n − 1 is the total number of minutes in the experiment. Integrating
e(t) means that the impulse is essentially a measure of energy expenditure.
7.2.2 Model formulation
NARX modelling correlates output behaviour to input stimuli. Interpolated
insulin (I(t)) and glucose (G(t)) concentration were treated as the output
behaviours for the two respective models. Continuous SC infusion (U(t))
and the exercise function (E(t)) were treated as input stimuli for the
insulin model, as well as past insulin. The product of insulin and glucose
(I(t)G(t)), intravenous glucose (V (t)), E(t) and past glucose were input
stimuli for the glucose model.
The insulin model is described:









where aI is the insulin auto-correlative (AC) term, bUI,1→100 are
cross-correlative (CC) terms for SC insulin over 100 minutes, bEI,1→60 are
the CC terms for exercise over 60 minutes, and cI is the steady state offset.
The glucose model is described:










where aG is the glucose AC term, bIG is the CC term for the glucose-insulin
product, bV G,1→25 are the CC terms for intravenous glucose over 20
minutes, bEG,1→60 are the CC terms for exercise over 60 minutes, and cG is
the steady-state offset.
Multiple parameters were used to correlate present I and G to the input
stimuli legacy, since their effects were not expected to be instantaneous. In
particular, SC insulin has significant kinetic delays before plasma
appearance. The spike in glucose introduced by intravenous administration
was not adequately represented by interpolation of the 10 minute resolution
glucose samples. Hence, the interpolated behaviour needed to be modelled.
Exercise input was modelled as an impulse so that the response, both
during and after exercise, could be observed as one time-dependent effect.
In all these cases, a continuous set of correlation parameters accounts for
the appearance rate of these inputs in the output behaviours over a given
period of time.
7.2.3 Parameter identification
Multiple linear regression was used to solve the parameters in each model.
The Ax = b matrix equation for insulin model is described:
[It−1,Ut ,Ut−1, · · · ,Ut−99,Et ,Et−1, · · · ,Et−59,1]
∗ [aI ,bUI ,bEI , cI ]T = It
(7.5)
where all I, U and E terms are n − 1 × 1 arrays of data, bUI is a 1 × 100
array of parameters, bEI is a 1 × 60 array of parameters, and 1 is a
n− 1× 1 array of ones.
Likewise, the matrix equation for the glucose model is described:
[Gt−1, It−1Gt−1,Vt ,Vt−1, · · · ,Vt−24,Et ,Et−1,
· · · , Et−59,1] ∗ [aG, bIG,bVG ,bEG , cG ]T = Gt
(7.6)
where all G, I, V and E terms are n − 1 × 1 arrays of data, n is the
duration of the experimental data used, bVG is a 1× 25 array of parameters
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and bEG is a 1× 60 array of parameters.
Values for U−99 → U−1 were populated from pump settings and recorded
boluses that may have been administered before the experiment. Values for
E−59 → E−1 and V−24 → V−1 were zero. When no IV glucose was given, V
arrays and bVG were excluded from the glucose equation. In two cases, IV
glucose was administered within the 60 minute exercise observation
window, and at no other time. To avoid structural non-identifiability, these
datasets were truncated at the point of IV introduction. Identified CC
coefficients for exercise (bEI and bEG) for each dataset were compared
across datasets. Cumulative integrals of these coefficients were compared.
7.3 Results
The exercise-insulin CC terms are shown in Figure 7.1. During exercise,
bEI was generally positive, greater at first, and generally negative
post-exercise, tending toward zeros at the end. Distinct nodes are visible in
bEI at 10, 20, 30 minutes. The integrated bEI profiles show an approximate
net zero effect of exercise on insulin in most datasets.
The exercise-glucose CC terms are shown in Figure 7.2. The rate of glucose
deficit in bEG increases with exercise duration and returns to zero over the
post-exercise period. Nodes in bEG occur every 10 minutes. The integrated
bEG profiles show a net-negative effect of exercise on glucose.
Along with the sought after exercise CC coefficients, those for SC insulin
infusion and intravenous glucose boluses are shown in Figure 7.3 and
Figure 7.4, respectively. With the exception of one stray trajectory, most
datasets produced a SC profile with a positive rate in the first half an hour,
tapering to zero between 30 and 100 minutes. Therefore the integrated
effect of SC input was net-positive by 100 minutes for these datasets. For
the few datasets with IV glucose, the CC coefficients followed a somewhat
sinusoidal trajectory with a period of 10 minutes. The remaining AC and


















































































































































































































Figure 7.2: Exercise-glucose cross-correlative coefficients (top), and
integrated (bottom)
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Table 7.1: Median (Q2), lower (Q1) and upper (Q3) quartiles for remaining
parameters in both insulin and glucose models
parameter description Q2 (Q1,Q3)
aI AC insulin term 0.994 (0.990,0.997)
cI insulin offset term -0.0137 (-0.0997,0.0534)
aG AC glucose term 1.008 (0.995,1.013)
bIG insulin-glucose CC glucose term −3.99× 10−4 (−4.51, 0.60)× 10−4
cG glucose offset term -0.0611 (-0.0775,-0.0284)
Table 7.1.
7.4 Discussion
The present work applied NARX to a biological application with unequal
input and output sampling rates. Interpolation of data allowed the NARX
model to function on an appropriate time-scale. Exercise CC coefficients
across the subjects showed consistent patterns. This consistency in
outcomes across the heterogeneous cohort indicates the NARX approach
was valid and valuable. The variability in magnitude of the CC profiles
indicates the level of intra-subject variability.
The CC coefficients represent the instantaneous impact of exercise on
insulin or glucose over time. Thus, the integrated bEI profile is the
exercise-mediated excursion of pump-delivered IAsp, as it appeared in the
plasma. Insulin concentration generally increased during exercise, returning
to normal afterwards. Thus the net effect of exercise on insulin appearance
generally tends towards zero. This is expected due to the unchanged rate of
insulin delivery to the subcutis. Increased blood flow is likely to raise the
rate of SC absorption during exercise Kang et al. (1991). Temporarily
lowered SC insulin levels would then potentially decrease the post-exercise
appearance rate. If plasma or interstitial clearance rates were raised due to
exercise, a net negative effect would be expected. This factor may have
contributed to the few datasets tending toward net negative values.
Integrated bEG shows an exercise-mediated deficit in glucose. The
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Figure 7.4: Intravenous-glucose cross-correlative coefficients for the few
relevant datasets that used intravenous glucose.
magnitude of glucose deficit generally increased with exercise duration.
However, this effect would likely plateau for some time during extended
exercise periods, but would be dependent on factors such as the availability
of muscular and hepatic glycogen stores (Yardley et al., 2013). Glucose
deficit continued into the post-exercise period, which may be partly due to
refuelling of depleted muscle glycogen.
NARX modelling was an effective approach for this type of data. In
particular, the T1DM cohort lacks of endogenous insulin, thus negating the
need for more complex deconvolution. The CC terms used to investigate
the influence of exercise on plasma insulin yielded particular shapes that
were not necessarily intuitive. Since NARX is largely data-driven, it is an
operator independent approach that allowed these trajectories to be
discovered. This method is in contrast to typical approaches which often
compare and fit a hypothesised model. Therefore, such an approach may
have not as effectively found or utilised the remarkably consistent shapes
discovered by NARX.
The other parameters in the NARX models were not particularly useful and
did not take on expected values. For example, the aI term is related to the
combined hepatic and renal insulin clearance (nT ) in a form that could be
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approximately modelled by nT = 1 − aI . This relationship would provide a
median nT of 0.006 min
−1 based on the results as opposed to the expected
value on the order of 0.1 min−1. Furthermore, many of the aG parameter
outcomes exceed the value of 1, identifying a self-dependent growth in
glucose concentration rather than the decay seen physiologically. Likewise,
results for the bIG term which could be related to insulin sensitivity by
SI = −bIG was identified in the right order of magnitude but sometimes
positive, indicating insulin acting to increase rather than decrease glucose
concentration in those cases.
These inconsistencies and discrepancies in the other NARX parameters is
the result of trade-off between parameters and is due to practical
non-identifiability. In data not shown plasma insulin simulated using
Equations (9.2) and (9.3) also failed to get expected parameters from the
NARX algorithm, and aI was particularly sensitive to the rate of SC
delivery. However, a priori knowledge of physiology implies that insulin
clearance should be quite independent of SC delivery. In a typical
physiological model, trade-off would be minimised by assigning a priori
values to many parameters based on population averages from other clinical
or modelling studies. In this case, the clear consistency and observability of
the effect of exercise is not discounted by these other parameter outcomes.
However, the limitation highlights NARX efficacy as an interim modelling
method rather than a final representation of physiology.
A notable limitation to the method was the need for output interpolation.
Figure 7.1 and Figure 7.2 (also 7.3 and 7.4) indicate nodes in the CC
parameter trajectories at the sample times for insulin and glucose
measurements. These nodes are an artefact of the interpolation, due to the
presence of noise in the data and how that influenced the estimation of
values by the Hermite cubic polynomials. The broad trends in the profiles
are valid but the applicability of the higher resolution dynamics of the
trajectory are reduced due to these artefacts.
Another limitation to the method was the use of an impulse function in
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place of the step function that describes the period of exercise. This was a
necessary manipulation of the data to observe the effect of exercise.
Otherwise, the difference between the effects of starting, continuing,
finishing and being finished with exercise would have confounded the
NARX parameters. Impulse-based results are very useful anecdotally, but
require validation in different exercise durations to establish robustness.
This analysis was intended to act as a basis for further work. The use of
uniquely data-driven shape information and interpretation of physiological
processes involved should aid development of robust, differential models.
Any advances in modelling everyday events such as exercise will enhance
analysis and control of glycaemia in T1DM, improving the quality of life of
these individuals.
7.5 Summary
In subjects with T1DM, plasma appearance from SC IAsp increased during
exercise. This observation was likely due to heightened blood flow
quickening absorption from the subcutis. Following exercise, the plasma
appearance temporarily decreased, generally resulting in a near net-zero
effect overall. Lowered SC concentrations from exercise would slow
absorption afterwards once blood flow was normalised, explaining the
decreased appearance rate.
The subjects experienced a net-negative effect on plasma glucose due to
exercise, consistent with the observed tendency for exercising outpatients
with diabetes to become hypoglycaemic. The greatest rate of glucose deficit
was generally near the end of exercise, tending back toward zero in the
post-exercise period.
NARX modelling promotes data-driven outcomes, meaning that it allows
the data to drive the behaviours defined by the model. In contrast,
traditional modelling fits a completely a priori model to the data. In this
case, interpolated input data had to be used with the NARX model. This
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step resulted in some bumpy regions appearing in the results that are not
expected to be real phenomena. This outcome limits the applicability of
exact shapes discovered. However, the general form of the shapes are
valuable, especially for further research and model development.
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Chapter VIII
Basis modelling of exercise
This chapter details a differential model developed for the effect of
exercise on plasma insulin and glucose concentrations, respectively. The
models build on the work of the previous chapter that used data-driven
techniques to observe the effect exercise. These differential models are
evaluated for performance on the available data.
8.1 Motivation
In the previous chapter, an autoregressive modelling approach was used to
observe the effect that exercise had on the plasma concentration of
exogenous insulin administered in the subcutaneous tissue of the subjects
with T1DM. It was found that exercise was associated with an increase in
plasma insulin concentration that decreased again after exercise for a
net-zero effect overall. The observed behaviour was thought to be a result
of increased mobilisation from the subcutis due to increased blood flow and
agitation, followed by a relative deficit in SC concentration that slows
plasma uptake in the post-exercise period. This observation is in contrast
to the behaviour of endogenous insulin in healthy individuals that is
down-regulated during exercise to promote additional EGP (Yardley et al.,
2013; Sonnenberg et al., 1990).
The effect of exercise on glucose concentration was also observed with
NARX. It was found that exercise increased the rate of glucose disposal
during exercise. The disposal rate returned to zero after exercise but not
immediately. This increased glucose disposal caused a net reduction in
glucose due to exercise, as is expected with the increased peripheral glucose
demand for energy.
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The NARX model outcomes were useful for deconvoluting and therefore
observing the consistent patterns across the whole cohort. While the
outcomes of the NARX provided these indicative patterns they fail to
provide a model with meaningful parameters. Furthermore, the data
required interpolation to be compatible with NARX, introducing artefacts
not present in the data itself. Additionally, conversion of exercise input
information from step to impulse function was required for observing the
effect but would not therefore be robust to differing exercise durations.
Differential models are much more robust to these concerns. The current
chapter presents the next stage of exercise-insulin and exercise-glucose
modelling using differential equations with basis functions.
It can be anticipated that in an outpatient environment, plasma insulin will
not be measured at all. Therefore, it is important when developing a model
for this context to avoid unnecessary complexity. Parameters governing this
indirectly observed compartment will not be very practically identifiable
during optimisation. Hence a simplistic insulin model is used in this work.
There is no modelling of an interstitial compartment or nonlinear saturable
hepatic insulin clearance. The exercise itself is modelled using basis
functions for both glucose and insulin, that can be summed together in
their effect for simplicity and robustness.
8.2 Methods
8.2.1 Data
Nineteen out of 24 datasets described in Chapter 5 were used for the present
work. Four datasets were excluded due to the absence of exercise in the trial
schedule. One further dataset was excluded from insulin modelling due to
the absence of insulin boluses. In the remaining trials, all subjects ran on
a treadmill for approximately 20 minutes while aiming to maintain a heart
rate (HR∗) prescribed for either a mild or moderate exercise. Basal insulin
was administered by pump as per each subject’s normal daily pump settings,
and small or large boluses were administered with and/or without food as
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per the specific trial schedule.
8.2.2 Model and simulation
The insulin system was modelled with a single plasma compartment (I)
with linear clearance. Inputs to the insulin model include the appearance of
insulin from SC delivery (US) and the influence of exercise (EI). This
plasma compartment is modelled as a function of time (t, minute




+ εIEI(t)− nT I(t) (8.1)
where VI is the plasma insulin distribution volume, nT is the total linear
insulin clearance rate, and εI is the magnitude of exercise effect on insulin.
I(t) was calculated with the analytical solution of Equation (8.1) using
cumulative trapezoidal integration.
Each measure of insulin administered subcutaneously by the pump appears
as an equimolar curve in US over the following minutes. The curve shape is
described by the basis function array (fU), based on SC insulin appearance
models by Wong et al. (2008a).
fU = tku
2 e−kut (8.2)
t = [0, 1, 2, · · · , 600] minutes (8.3)
where ku is the SC rate parameter. To simulate the accumulative effect
of continuous SC infusion, each time point for SC insulin appearance was
therefore calculated with the dot product:
US(t) = fU · [UX(t), UX(t− 1), UX(t− 2), · · · , UX(t− 600)] (8.4)
where UX terms indicate the pump input. For indices less than zero (i.e.
before the experiment time began), information was used from pump
settings and experimental notes of early morning boluses.
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Like SC insulin, a sum of basis functions was used for the effect of exercise.
The functional array for exercise (fEI) is an impulse followed by an equal
area subtraction curve (Figure 8.1a), based on the results of Chapter 7.
fEI = [1,−tkeI2e−keIt] = [1, 0,−(keI2e−keI ), · · · ,−(600keI2e−600keI )] (8.5)
where keI is the exercise rate parameter in the insulin model. Thus individual
time points in the insulin exercise effect array (EI) are therefore calculated:
EI(t) = fEI · [HR∗(t),HR∗(t− 1),HR∗(t− 2), · · · ,HR∗(t− 601)] (8.6)
where HR∗ is target heart rate. An example of the exercise function and its
integrated form, to represent actual plasma insulin deviation, are seen in
Figure 8.1b-c.




































Figure 8.1: An indicative demonstration of the modelled effect of exercise
on insulin, showing (a) the basis function, (b) the exercise effect function for
20 minutes of exercise (arbitrarily at HR∗ = HRmax), and (c) the integrated
exercise effect function.
single glucose compartment (G) with both insulin-dependent and
insulin-independent glucose disposal. Inputs include glucose appearance
from ingested food (PS) and intravenous bolus (V ). The exercise function
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(EG) also impacts directly on the glucose compartment.
Ġ(t) = −pG(G−G0)− SI(GI −G0I0) +
PS(t) + V (t)
VG
+ εGEG(t) (8.7)
where SI is the insulin sensitivity, pG is the hepatic glucose balance, G0 is
basal plasma glucose, I0 is basal plasma insulin, VG is the volume of glucose
distribution and εG is the magnitude of the exercise effect on glucose.
Each measure of carbohydrate ingested appears as an equimolar curve in
the PS(t) function, based on the Mansell et al. model. This curve contains
some fast appearing glucose at a fixed ratio to the rest of the glucose. This
was achieved through the following basis function array:
fP,m = 0.9tkp,m
2e−kp,mt + 0.1t(0.072)e−0.07t (8.8)
where kp,m is the glucose appearance rate parameter, m = 1, 2 denoting
separate parameters and therefore basis functions for the meal (1) and the
snack (2). This difference in parameter accounts for the differing glycaemic
loads. The basis function is pictured in Figure 8.2a. This basis function is





fP,m · [PX,m(t), PX,m(t− 1), PX,m(t− 2), · · · , PX,m(t− 600)]
(8.9)
where PX,1 is the carbohydrate input function for the meal and PX,2 for the
snack.
As with the insulin model, the effect of exercise on glucose was modelled by
using a basis function fEG based on the results in Chapter 7. This
112
functional array is modelled:
fEG = −tkeG 2 e−keGt (8.10)
(8.11)
where keG is the exercise rate parameter in the glucose model. Thus
individual time points in the glucose exercise effect array (EG) are therefore
calculated:
EG(t) = fEG · [HR∗(t),HR∗(t− 1),HR∗(t− 2), · · · ,HR∗(t− 600)] (8.12)
An example of the exercise function and its integrated form, to represent
actual plasma glucose deviation due to the muscular demand for glucose, are







































Figure 8.2: A demonstration of the modelled effect of exercise on glucose,
showing (a) the basis function, (b) the exercise effect function for 20 minutes
of exercise (arbitrarily at HR∗ = HRmax), and (c) the integrated exercise
effect function.
8.2.3 Parameter identification
The insulin model was fitted to individual datasets by identifying variables
in the parameter set xI = [nT , ku, VI , keI , εI ]
T. An alternative insulin model
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was also fit to the datasets that excluded the effect of exercise, i.e.
εI = keI = 0, (xI = [nT , ku, VI ]
T). These two modelling cases are henceforth
referred to as the exercise insulin model and no-exercise insulin model,
respectively.
The glucose model was also fitted to datasets and the identified variables
were those in the parameter set xG = [SI, kp,1, kp,2, εG]
T. If no snack was
consumed, kp,2 was set to zeros and omitted from the parameter set. Like
insulin, a no-exercise glucose model was also fit to the datasets, i.e.
εE = keE = 0, (xG = [SI, kp,1, kp,2]
T). In the no-exercise and exercise
glucose models, the following a priori assumptions were made for other
parameters: pG = 0.004, VG = 16.7L, keG = 0.15min
−1, G0 = 4.5mmol/L,
I0 = min([10,min(I (t))])mU/L (Mansell et al., 2015d; Lin et al., 2011).
The I(t) function for the glucose model was a Hermite cubic polynomial
interpolation of the data, and V (t) was simply taken as the data input for
IV glucose.
Optimally fitted model parameters (xopt) were estimated by solving the
least squares solution to the residual error in plasma insulin and plasma
glucose for the respective models. The optimisation was undertaken with
variants of the Levenberg-Marquardt-like gradient descent algorithm
(Section 3.2.2.2). For the insulin model, the damping factor (λ) was
initially, λ0 = 10
−4 but λi = 10λi−1 if ||Ψi || > ||Ψi−1||, otherwise
λi = max[0.9λi−1, 10
−4]. If the parameter set yielded any NaN results,
initial x was reinstated with λi = 10λi−1. For glucose, λ was simply kept at
0.1.
Starting parameter values were xI0 = [0.01, 0.05, 0.05, 0.05, 0.5, 0.05]
T and
xG0 = [0.0003, 0.02, 0.05, 0.1]
T, and perturbations were
∆xI = [10
−5, 10−5, 10−5, 10−5, 10−6]T and xG0 × 10−4. A maximum of 250





Due to the poor practical identifiability of the keI parameter, it was identified
in the exercise model using a hierarchical identification method (Schranz
et al., 2011). In particular, keI was excluded from initial identification, fixed
at 0.05, until the convergence criterion was first reached with the remaining
parameter set (Schranz et al., 2011). Convergence of the full parameter set
was continued. In this second stage, keI was bounded 0.01 ≤ keI ≤ 0.1 and
if instability repeatedly occurred in the parameter set (i.e. NaN results more
than three times) keI was once again fixed to 0.05. This allowed most datasets
to benefit from an optimised keI parameter but recognised the limitations
inherent for some datasets.
8.2.4 Model performance analysis
R2 was the primary goodness of fit measurement for each dataset. For both
exercise and no-exercise models. R2 was evaluated over entire experimental
time, and separately for the two hour peri-exercise period (t− te0 ≤ 2 hours
where te0 indicates time of exercise commencement). Median, upper and
lower quartiles for these results across the datasets are presented.
Additionally, a collation of peri-exercise residual error profiles (Ψ(t − te0))
for all datasets are presented for each of the exercise and no-exercise
models.
A parameterisation analysis was also carried out. The CDF of peri-exercise
residual errors in all datasets was computed for both the exercise and
no-exercise models. These residual CDFs were compared against a CDF of
expected measurement noise. Published intra-assay variance data at
different insulin concentrations Petersen et al. (2010) was used to simulate
expected measurement error. An over-parameterised model would have a
residual CDF steeper than measurement noise, indicating that features
caused by noise are modelled as if they were real phenomena. Thus,
residual CDFs of an ideally parameterised model would be slightly
shallower than that of measurement noise, and with an unbiased halfway
crossover at Ψ = 0.
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8.2.5 Model result interpretation
Mean and lower, median and upper quartile statistical outcomes for the
identified exercise-related (keI , εI and εG) parameters were calculated.
Additionally, correlations between the magnitude of exercise-mediated
insulin excursion (εI) and other known variables across the cohort were
determined. As part of this investigation, the relationship between εI and
plasma insulin at the start of exercise Ie0 was studied by calculating the
correlation coefficient (R) and using variance analysis (ANOVA).
Since outcomes from two datasets were excluded as outliers when
correlating εI and Ie0, a separate analysis was carried out to justify this
decision. This analysis was similar to the concepts presented in the
so-called bootlier (bootstrap-based outlier detection) plots of Singh and Xie
(2003) which show that sampling from distributions containing outliers
produces multimodal histograms. Ten thousand bootstrap iterations were
carried out in which a randomly selected n∗ = 14 subset from the original
n = 19 datasets was chosen, and R between εI and Ie0 calculated. This
process was repeated three more times, still with n∗ = 14 but out of a
dataset pool excluding the two designated outliers, then with a pool
excluding two other points that could otherwise be considered outlying if
the designated outliers were not, then excluding all four of these points.
This particular bootlier analysis variation was developed to determine
whether the two designated outliers contributed disproportionately to the




Figure 8.3 shows typical insulin model fitting results for two datasets. The
exercise and no-exercise insulin models generally exhibited similar
performance for SC insulin appearance. The exercise-model captured the
increase in insulin during exercise and subsequent decrease after exercise
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observed in the data. Conversely, the no-exercise model was not capable of
capturing this excursion.
t (min)





























Figure 8.3: A typical fitted result for two separate datasets showing the data
(×), modelled without exercise (grey) and modelled with exercise (black).
Goodness of fit, as evaluated by R2, was reasonably good for both insulin
models when evaluated over the full experimental period (Table 8.1).
However, a noticeable improvement (12%) in median fit was achieved using
the exercise model compared to the no-exercise model. By comparison,
peri-exercise fit was very poor for the no exercise model (R2 = 0.31) with a
lower quartile R2 less than zero. In this two hour period, modelling exercise
substantially improved the fit.
The no-exercise insulin model shows a distinct pattern in the peri-exercise
residual trajectories for the cohort (Figure 8.4a) with large positive residual
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Table 8.1: Median, lower (Q1) and upper (Q3) quartiles of R
2 values in the
insulin model variations, considering both the full experimental period and




modelled 0.91 (0.88,0.95) 0.86 (0.80,0.94)
unmodelled 0.81 (0.72,0.89) 0.41 (-0.13,0.57)
error in the first hour and smaller but negative residual error in the second
hour. The exercise model was generally successful in attenuating both
positive and negative residual error biases (Figure 8.4b), maintaining an
approximately zero median residual error. Figure 8.4c shows that the
no-exercise model has the shallowest rise in CDF and is biased toward
positive residual errors. The exercise model CDF is much closer to the
estimated measurement noise CDF but still shallower in rise. Unlike the
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Figure 8.4: Analysis of peri-exercise residuals: (a) residual profiles for all
datasets using the no-exercise insulin model; (b) residual profiles using the
insulin exercise model; (c) CDFs for all-dataset collations of peri-exercise
residuals, compared to distribution for expected measurement error.
Mean identified εI was 1.04 and the quartiles were 0.35, 0.78 and 1.36. The













R2 = 0.40 outliers not included in
correlation calculation
Figure 8.5: Plasma insulin at exercise commencement compared to exercise-
induced excursion magnitude with linear trend. Each different marker style
denotes a different patient. Marker colour denotes mild (grey) and moderate
(black) levels of exercise.
algorithm in the methodology. Mean keI was 0.0496 for all datasets, and
0.0492 for datasets excluding those with fixed keI . Quartiles for keI were
0.041, 0.050 and 0.052 for all datasets, and 0.016, 0.045, 0.070 excluding the
fixed case.
No significant relationships were found between εI and a range of
population variables, with one exception: plasma insulin concentration
immediately prior to exercise (Ie0). An appreciable correlation between the
two variables was found (with outliers removed), giving an R value of 0.66
and corrected R2 of 0.40. ANOVA calculated a p-value of 0.004 for the
relationship compared to a constant εI . Figure 8.5 shows that all
intra-patient pairs of datasets exhibited exclusively positive correlation
between Ie0 and εI .
The bootlier plots (Figure 8.6) show that when using the full dataset pool
for sampling bootstrap populations (left) most R values fall into one of two
bands. Both bands have poor correlation, one centred around a mean value
of R̄ = 0.25 and the other R̄ = 0.03. A small band of well correlated
outcomes is also present around R̄ = 0.68. Removing the two outliers at
Ie0 = 43 and Ie0 = 52 mU/L from the available pool of datasets yields a
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Figure 8.6: Distributions of correlation outcomes between Ie0 and εI for same-
sized subsets of the datasets. The left two cases exhibit the effect of removing
the designated right-hand outliers from the available pool of datasets. The
right two cases again exhibit this effect but with another two possible datasets
removed that could be considered outlying if the righthand outliers were not.
R at the first 1000 bootstrap iterations are plotted (top) and histograms for
outcomes of all iterations (bottom).
single well-correlated band, R̄ = 0.67. Further removing the two other
possible outlying points at Ie0 = 29 and Ie0 = 33 mU/L yields similar
results to the initial analysis but with slightly tighter distributions. The
correlation bands were located at R̄ = 0.66, R̄ = 0.25 and R̄ = 0.06 for a
pool just excluding these two possible outliers. Excluding all four potential
outliers, both designated and possible, yields a single band of
well-correlated outcomes at R̄ = 0.66. Since the analysis wherein the two
high Ie0 outliers are removed was the only trial to achieve a consistent
correlation band, the theory of Singh and Xie (2003) recommends that
these points should be declared outliers.
8.3.2 Glucose model
Figure 8.7 gives two examples of the glucose model performing well with
the inclusion of the exercise basis. One of the examples shows quite a large
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Table 8.2: Median, lower (Q1) and upper (Q3) quartiles of R
2 values in the
glucose model variations, considering both the full experimental period and




modelled 0.97 (0.93,0.99) 0.50 (0.17,0.90)
unmodelled 0.93 (0.83,0.98) -0.12 (-1.11,0.66)
exercise-mediated excursion while the other has only a small change. In the
rest of the cohort, some datasets showed small or even negligible changes
due to exercise while other patients were highly effected. Median εG was
0.33 with lower and upper quartiles of 0.12 and 0.63 respectively. Figure 8.8
gives two examples of the glucose model performing less well. One example
demonstrates an overly magnified exercise excursion immediately next to an
ill-fitted intravenous glucose bolus. The other shows some unmodelled
effects from the ingested meal.
The no-exercise glucose model has a median R2 of 0.93 over the entire
experimental period (Table 8.2) and the exercise glucose model improves
this to 0.97. These goodness of fit measurements are higher and less
variable than for the insulin model but the R2 values have not been
adjusted for the relatively higher sampling frequency. The improvement in
the peri-exercise period from modelling exercise was comparable to insulin
but the fit achieved was not as good overall, with a median R2 of 0.50.
There were some particular outlying residuals that remained even after
exercise was modelled (Figure 8.9a-b,d-e). It should be noted that unlike
most datasets, these sets contained IV boluses during the experimental
time. Several datasets experienced a large improvement in model residual
with exercise modelled but many which had smaller residuals to begin with
did not experience much improvement. Over the dataset collation, the
peri-exercise residual distribution was significantly positively biased when
exercise was not modelled (Figure 8.9c). When exercise was modelled this
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Figure 8.7: Typical good fitting results for two separate glucose datasets
































Figure 8.8: Typical poor fitting results for two separate glucose datasets
showing the data (+), modelled without exercise (grey) and modelled with
exercise (black).
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distribution was very close to the expected measurement noise distribution.
Over the whole experimental time, modelling exercise brought the
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Figure 8.9: Analysis of peri-exercise residuals: (a) residual profiles for all
datasets using the no-exercise glucose model; (b) residual profiles using the
glucose exercise model; (c) CDFs for all-dataset collations of peri-exercise
residuals, compared to distribution for expected measurement error. Plots
(d-f) are equivalent to (a-c) but for the full experimental time.
8.4 Discussion
The mathematical model for the effect of exercise on plasma insulin
concentration was effective in the cohort of subjects with T1DM treated by
SC pump. Table 8.1 demonstrates that the exercise-model improved the
goodness of fit in insulin from R2 = 0.81 to 0.91 over the full experimental
time in the median case. Focusing on the peri-exercise period specifically,
two hours from the start of exercise, goodness of fit improved substantially
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by modelling exercise, from R2 = 0.41 to 0.86. Modelling the effect of
exercise on plasma glucose concentration also improved fit with
peri-exercise R2 increasing from -0.02 to 0.50. Full dataset R2 increased
from 0.93 to 0.97 when the exercise terms were used.
In addition to the R2 metric, the residual collation in Figure 8.4a-b shows
that residuals for the no-exercise insulin model have a distinct positive then
negative trajectory. In contrast, the exercise model shows little positive or
negative bias, as confirmed by the peri-exercise residual CDF of
Figure 8.4c. Furthermore, this CDF is slightly shallower than that expected
from noise, indicating that the model is not over-parameterised.
Over-parameterised models can adhere to the data closer than the
measured accuracy should allow. In these cases, the model is capturing
effects that are dependent on measurement noise and have no relevance to
the underlying behaviour. These outcomes of good fit, no bias and
appropriate parameterisation demonstrate the efficacy of the exercise basis
function model as an addition to the basic insulin model.
The glucose model was not as effective as the insulin model with some large
excursions in the model residual, despite the improvements. This appeared
to be largely due to limitations in the general form of the glucose model
other than with the specific exercise basis. In particular, the observed effect
of the IV glucose was inconsistent with the modelled effect, causing
trade-off with exercise magnitude in some datasets. This physiological
observation is likely due to an acceleration of glucose disposal from plasma
in response to IV glucose bolus, unaccounted for by the model.
Additionally, the glucose appearance basis from the ingested meal was not
effective for some datasets. In the peri-exercise period, the residual
distribution analysis indicates that the model may be close to
over-parameterisation, which may be consistent with some observations of
trade-off between behaviours.
The structure of the basis models was simple and easy to apply to existing
models. The equitable plus and minus portions of the insulin basis function
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reflect well the fact that there is no expected change in the insulin entering
the system via the SC pump or leaving the system (assuming that clearance
rates are unchanged). For glucose, an increasing but saturated rate of
glucose disposal in response to exercise seemed a reasonable approximation
of physiological processes. In the post-exercise period, this rate took time
to return to zero, consistent with observation of continued muscular uptake
to refuel glycogen stores. The ability to sum the basis functions together
makes it robust to variable exercise duration. However, the models should
be validated on longer exercise periods to check that no additional
physiological effects are influenced by exercise duration.
The intra-subject magnitude of the exercise effect on insulin was not always
consistent. This motivated further investigation into what influenced the
magnitude (εI). Figure 8.4 shows positive correlation between the plasma
insulin concentration immediately prior to exercise (Ie0) and εI when
excluding two particular outliers (R = 0.66, p = 0.004). A suggested reason
for the correlation is that high plasma insulin indicates a high SC
concentration that is more responsive to exercise-induced agitation and
high blood flow. It should be noted that a dataset excluded for the absence
of SC boluses also showed negligible changes in the peri-exercise period.
This observation further supports the notion that SC concentration, and
the effect of boluses in particular, affects exercise-induced plasma insulin
excursions.
The outlier exclusion in the Ie0 to εI correlation is supported by the
evidence in the bootlier analysis of Figure 8.6. The literature notes that
outlying data tends to create multi-modal distributions when performing
bootstrapping analyses (Singh and Xie, 2003), which is observed in the
lefthand plots of the figure. Removing the two outliers removes the
multi-modal distributions, leaving only the higher correlation outcomes. To
further the validity of this bootlier analysis, the same procedure was carried
out with two other potential outlier data points. Removing these datasets
did not alter the outcomes sufficiently to define these points as outliers.
While this validates the R̄ = 0.66 correlation, the consistency of results
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shows that the core datasets do produce a strong correlation. It should be
noted that even in the outliers, all intra-subject dataset pairs had positive
Ie0 to εI correlations.
The Levenberg-Marquardt variant was generally successful in optimising
parameters in the insulin and glucose models, evidenced by the achieved
goodness of fit (Table 8.1 and 8.2). The particular method of fixing and
then allowing ke to be optimised under certain conditions allowed the best
compromise between identification stability and fit for insulin. The ke
exhibited behaviours often associated with lower practical identifiability,
especially in some datasets. When identified, ke had a median value of
0.045 with lower and upper quartiles of 0.016 and 0.070. These outcomes
support the a priori value of 0.050 that was used for the remaining
datasets.
The combination of R2, residual trajectory bias analysis and residual CDF
analysis provide a clearer overall picture of model performance than just R2
alone. Models must have a good compromise between fitting ability and
practical identifiability. If effects are modelled beyond their ability to be
observed in the available data (i.e. the signal-to-noise-ratio is too low) then
the model outcomes are useless, or worse, misleading. This is especially
true if there is no recognition of the limitations in the unique observability
of features, since the realistic expectations of the model and data can be
lost amongst the mathematics (Docherty et al., 2011; Raue et al., 2009;
Saccomani, 2013).
If the present insulin model were to be used in an outpatient setting, all
parameters relating to exercise would have to be a priori since the plasma
insulin compartment is not observed directly. Hence, the importance of
uncovering causative mechanisms that could inform a priori parameter
estimates. Though the glucose model could be made significantly more
complex to achieve an improved fit, such a directive would need to be
balanced by recognition of the limitations of outpatient data.
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The correlation of plasma insulin concentration and exercise excursion
magnitude relied on the exclusion of two outliers, which were from the same
subject. The bootlier analysis justified this exclusion, but at the risk of
seeming like a manufactured outcome, appropriate caution should
accompany the R̄ = 0.66 correlation. The correlation should be seen as
suggestive rather than definite, and certainly not causative. However, the
correlation does prompt interest for further investigation. In particular, if a
correlation were established, a single plasma insulin measure could be used
to provide a patient-specific a priori estimate of εI .
In future, the insulin model would benefit from well-informed parameter
estimates for ε in particular. Hence, further work could be carried out to
link SC properties to the exercise effect. Additionally, successfully
modelling the effect of exercise on insulin is only a precursor to successfully
modelling the overall effect of exercise on glucose, which is significantly
more complex. This was shown in the increased number of behaviours,
species and parameters used in the glucose model, yet still inviting room for
an improvement in fitting accuracy. Whether the glucose model were
improved or not, both models should be tested with longer durations of
exercise to see if the physiological principles determined in this analysis can
be extrapolated beyond 20 minutes of exercise.
8.5 Summary
This chapter introduces an effective basis model for the effect of exercise on
subcutaneously administered IAsp in individuals with T1DM. The exercise
model fits well with the data, with R2 = 0.86 around the exercise period
compared to R2 = 0.41 when exercise is not modelled. Analysis of the
model residuals around this period collated across all datasets indicate that
the exercise model is not biased and is appropriately parameterised.
Additionally, another basis model was developed for the effect of exercise
on glucose. This model performed adequately, improving fit proximal to the
exercise period from R2 = −0.02 to R2 = 0.50 but other aspects of the
glucose model limited the overall performance.
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The identified magnitude of exercise-mediated excursion in plasma insulin
appeared to be correlated to the concentration of plasma insulin
immediately prior to exercise. This was suspected to be due to higher SC
concentrations resulting in both higher plasma insulin and higher
responsiveness to exercise-induced agitation and high blood flow. These
correlations are strong for most datasets (R = 0.66) but tentative due to







Identifying secondary effects in increasing data
This chapter details an in silico analysis proving the potential for identifying
everyday life (or secondary) effects on glycaemia in sparse, outpatient diary
data. Monte Carlo analyses are used to compare identified model parameters
to those in the underlying virtual patient for increasingly large datasets.
The content of this chapter was published as an article in the Journal of
Mathematical Biosciences (Mansell et al., 2015d), and a simplified version
of the research presented at the 15th Annual Diabetes Technology Meeting
(Mansell et al., 2015a). Note that this work preceded the model-building of
previous chapters. Hence, the model used in this and the subsequent chapter
does not include the updated features.
9.1 Motivation
There is significant potential benefit in developing effective glycaemic
control mechanisms for individuals with T1DM similar to those used for the
critically ill (Chase et al., 2011; Plank et al., 2006). However, there are
many social and psychological factors that confound the type of regimented
glycaemic control used successfully in the critically ill who are typically
sedated. In particular, some social situations induce over consumption.
Furthermore, stress, anxiety and frustration can affect glycaemic behaviour
and occur intermittently. Stress and related factors can be caused by
self-monitored blood glucose, regimented lifestyles, and unpredictable
glycaemic variability (Rubin and Peyrot, 2001). Thus, a further, necessary
goal of glycaemic control algorithms for outpatients should be mitigating
the psychological impact of the control algorithm itself by allowing greater
flexibility in daily activities.
There are many secondary effects that influence glycaemic control. It is
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well established that emotional (as well as medical) stress results in
hyperglycaemia in individuals with T1DM (Surwit et al., 1992; Lloyd et al.,
1999). This hyperglycaemia is due to insulin resistance caused by the
endogenous release of corticosteroids and catecholamines (Ward et al.,
2011). Sleep deprivation is also responsible for changes in insulin sensitivity
without significant changes in cortisol levels (González-Ortiz et al., 2000).
In contrast, moderate-intensity (aerobic) exercise can lower blood glucose
significantly, and eventually causes hypoglycaemia if care is not altered
(Sonnenberg et al., 1990; Yardley et al., 2013). These factors provide
challenges for self-managed glycaemic regulation. Furthermore, they are
capable of confounding model-based control algorithms due to the lack of
quantitative evidence or direct identification of their effect on glycaemia.
The use of physiological modelling has emerged in the field of glycaemic
control for the critically ill (Pappada et al., 2013; Pielmeier et al., 2010;
Chase et al., 2011). Inter- and intra- patient variability provides challenges
to maintaining glycaemic control for individual patients. Thus, these
modelling methods identify a number of patient-specific parameters as well
as using a priori population-average parameters (Chase et al., 2011).
Recent developments have also been made in the field of automated
treatments for outpatients with T1DM that are using CGMs (Hovorka
et al., 2013; Bequette, 2012; Cobelli et al., 2011). Some of these
developments also include compensation for stress hyperglycaemia (Ward
et al., 2011). However, this type of treatment is still experimental and has
high cost and complexity (Khovanova et al., 2013; Bequette, 2012). Hence,
it may be more practical to improve upon conventional approaches such as
self-monitored glucose with multiple daily insulin injections (Wong et al.,
2008c, 2009). Knowledge of relevant patient-specific parameters would
benefit model-based therapy support for insulin dosing information.
Sparse, irregular data provides challenges in uncovering clear trends. Thus
the purpose of this research was to test parameter estimation in such data,
identifying some of the key patient-specific secondary effects on glycaemic
dynamics: stress, fatigue and exercise. The data was generated in silico
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with efforts to mimic self-reported, diary-style data with simulated
self-monitored glucose measurement and omission errors. The results
obtained from parameter identification were assessed in accumulating
data-sets over a Monte Carlo (MC) population. Finally, the methods were
tested for their ability to handle long-term changes in insulin sensitivity
(SI) that occur due to changes in a patient’s metabolism (Mayer-Davis
et al., 1998; Abate et al., 1995; Wu, 2005).
9.2 Methods
9.2.1 The virtual patient
To test the estimation of factors affecting glycaemic dynamics, a virtual
patient with T1DM was simulated in silico. The patient ingested regular
meals and the occasional snack. They took insulin boluses with meals as
well as a constant insulin infusion to mimic slow acting insulin. The virtual
patient also participated in moderate exercise several times a week and
experienced days of stress or fatigue several times per month.
The model used to simulate the glycaemic dynamics of the in silico patient
is a variation of the clinically validated DISST model (Lotz et al., 2010).
The adaptations include a nutrition model (Wong et al., 2008c, 2009; Lin
et al., 2011) and effects of exercise, stress, fatigue and SI drift. The model
consists of a priori parameters (definitions in Table 9.1), time-dependent
inputs (definitions in Table 9.2) and identified variables (Table 9.1). A
flowchart showing the order of dependent species in the model can be seen
in Figure 9.2.
First, subcutaneous insulin concentration (US) was modelled as a kinetic
delay from regular bolus doses and a basal infusion (UX):
U̇S(t) = UX(t)− kXUS(t) (9.1)
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Interstitial insulin concentration (Q) was modelled as being co-dependent
with plasma insulin (I) which is a function of US:




Q̇(t) = −(nI + nC)Q(t) + nII(t) (9.3)
A linear model was used to predict gut glucose (PS). The gut glucose model
included regular meals of varying glucose content (PX) and randomly timed





Circadian rhythms are known to influence insulin sensitivity but there are
conflicting reports on the nature and shape (Van Cauter et al., 1997;
Carroll and Nestel, 1973; Sensi and Capani, 1976). In absence of consensus
in reported profile, SI was modelled in Equation (9.5) with overlapping
triangular basis functions (g1−3). These functions produce daily rhythms
with morning, midday and afternoon peaks, SI1−3. The bases and resulting
SI profile are pictured in Figure 9.1. Additionally, SI is influenced by the
presence of stress (σ), fatigue (ϕ) and long-term drift:







where D(%) is the yearly percentage increase in insulin sensitivity (defined
in the analysis methodology, Section 2.5) and ty is 525600 minutes per year.
The modelled species Q, PS and SI were introduced into the blood glucose
model (G), along with the effect of exercise (ε) (Yardley et al., 2013):
Ġ(t) = −pG (G(t)−G0 + ε(t))− SI(t) (G(t)Q(t)−G0Q0) + k2PS(t) (9.6)
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time (hours)




























Figure 9.1: The shape of the daily basis functions g1−3 (a) and resulting
SI profile determined by Equation (9.5) (b) with time measured from 12am
midnight
Stress, fatigue and exercise contributions were the product of a peak value
and a time-dependent function:
ε(t) = εmaxfε(t) (9.7)
σ(t) = σmaxfσ(t) (9.8)
ϕ(t) = ϕmaxfϕ(t) (9.9)
where the functions fi define when each of the effects occurs and the intensity,
fi ∈ {0, 0.5, 0.6, 0.7, 0.8, 0.9, 1}. Thus, the max values indicate the maximal
contributions possible from each of the effects.
9.2.2 Simulation
The model was simulated for either one or two years with time-varying species
using one minute resolution. Analytical solutions to the model equations were
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Figure 9.2: The flow of dependency in the model, also indicating the order
in which the species needed to be simulated
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Table 9.1: Parameter constants used to simulate the virtual patient glycaemic
profiles in the model. The * indicates parameters which were identified as
variables from virtual data
Parameter Description Value Unit
nI Plasma to interstitium transport rate 0.02 min
−1
nT Plasma insulin clearance rate 0.1 min
−1
nC Cell metabolism of insulin 0.02 min
−1
Vp Volume of distribution of plasma insulin 4.3 L
pG Glucose dependent balance 0.004 min
−1
VG Glucose distribution volume 12.4 L
k1 Stomach to gut glucose transfer rate 0.05 min
−1
k2 Rate of glucose absorption from gut 0.008 min
−1
kX Rate of insulin injection site dispersal 0.01 min
−1
G0
∗ Basal glucose concentration 4.5 mmol · L−1
Q0 Basal interstitial insulin concentration 4.23 mU · L−1
εmax
∗ Exercise coefficient 6.5 mmol · L−1
σmax
∗ Stress coefficient 0.3
ϕmax
∗ Fatigue coefficient 0.1
SI1
∗ Morning (8.30am) SI peak 0.8× 10−3 L ·mU−1 ·min−1
SI2
∗ Midday (12pm) SI peak 1.0× 10−3 L ·mU−1 ·min−1
SI1
∗ Afternoon (3.30pm) SI peak 0.6× 10−3 L ·mU−1 ·min−1
was used to find the analytical solution to the more complex interdependent
species of Equations (9.2) and (9.3). The full set of analytical solutions for








ek1t (PX(t) + PC(t)) dt
)
(9.10)














The interstitial insulin solution is described:

























ρ1 = nC + 2nI + nT (9.16)
ρ2 =
√
n2C − 2nCnT + 4n2I + n2T (9.17)












pG + SI(t)Q(t)dt (9.19)
All integrals were calculated with trapezoidal numerical integration.
Numerical instabilities meant that simulations had to be undertaken in
sections of seven days at a time and concatenated.
Each run within the MC analyses generated a patient using the same
Table 9.1 parameter values, but with variation in certain input vectors (PX,
PC, fε, fσ, fϕ). PX took on random values between 72-90 grams of
carbohydrate at mealtimes, which corresponds to 400-500 mmol of glucose.
PC was 30 grams carbohydrate (160 mmol glucose) at 52 random times
throughout a year. The fσ vector contained three random full-day
occurrences per 28 days while fϕ was given five days. Occurrences in fε were
two hours in the morning for three randomly chosen days a week. For each
occurrence of these secondary effects, an intensity of 50-100% was assigned.
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Table 9.2: Time-dependent vector inputs for used to simulate the virtual
patient, noting that the simulation uses 1 minute resolution
Vector Description Value Unit
PX meals
{































0 1200 to 1530 hours
1 0830 hours






0 1530 to 0830 hours
1 1200 hours






0 0830 to 1200 hours
1 1530 hours
0 < g3 < 1 otherwise
∗
∗triangular basis function forms are pictured in Figure 9.1
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9.2.3 Data acquisition
Diary-like data was sampled’ from the glucose simulation to mimic daily
finger-prick measurements. Meal carbohydrate estimates, insulin doses, as
well as instances and intensity of exercises, stress and fatigue were also
recorded.
Blood glucose measurements were sampled randomly from G at 6
non-adjacent times per day between the hours of 6am and 12 midnight.
This random distribution yields a more conservative approach than if
sampling was limited to around mealtimes. In particular, mealtime
sampling would capture dynamic responses to meal perturbations and thus
would maximise practical identifiability of metabolic parameters (Docherty
et al., 2011). The sampling frequency could also be considered a
conservative estimate for fastidious individuals with poor blood glucose
control.
There is significant measurement error and variation associated with blood
glucose measurements (Freckmann et al., 2013). To mimic this error, 10%
normally distributed noise was applied to the blood glucose data.
Misrepresentation and error are also common in a patient’s carbohydrate
estimates (Wong et al., 2009). Thus, the acquired data neglected the snacks
(PC) and 10% uniformly distributed noise was applied to PX . Hence, PS
calculated during parameter identification was different from that of the
true simulated patient. The Q, fε, fσ and fϕ vector profiles used in
parameter identification were equal to those used to simulate the virtual
patient.
9.3 Parameter identification
The identification set included circadian SI parameters, basal blood glucose
and parameters for exercise, stress and fatigue:
x = [SI1, SI2, SI3, G0, εmax, σmax, ϕmax]
T. The Gauss-Newton method for
gradient descent was used to minimise the least-squares residual between
the data and a forward simulation of G using the current parameter
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estimates, xi. This residual is given by:
Ψi = Gi(tS)−GS (9.20)
where GS is the sampled data and Gi(tS) is the modelled blood glucose at
the sample times (tS) for the present iteration (i). S denotes the samples
1 . . . n, where n is the number of samples.
The first iteration parameter set was defined as
x0 = [10
−3, 10−3, 10−3, G(t0), 10, 0.1, 0.1]. Iterations continued until the
tolerance criteria were satisfied: ||xi+1 − xi||2 < 10−8 and i > 10.
9.4 Analysis methodology
A two-part Monte Carlo approach was used to evaluate the estimation of
the behaviours present in the simulation. To investigate the convergence of
parameter values in increasing data, identification was conducted in data
subsets of one week up to one year. To capture long-term drift in SI, Part
II identifies parameters in 90 day data subsets whose start dates shift by
ten days at a time, for a total of two years. Figure 9.3 shows a flowchart of
the Monte Carlo analytical process for both parts.
All analyses were undertaken on a 64-bit Intel R© CoreTM i7-2600 (3.4 GHz)
CPU personal computer with 32GB of RAM using MATLAB (2013b
Version 8.2.0.701).
9.4.1 Part I
Data was sampled from a one year simulation of glucose that contained no
long-term drift in SI (D(%) = 0). The parameter set x was identified for
increasing subsets of this data (GS) for 7, 14, 21, 35, 56, 91, 147, 238 and
365 days.
When a data subset did not contain any randomly generated days of stress
or fatigue, σmax and ϕmax were set to zero and excluded from identification.
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When both stress and fatigue effects occurred concurrently and thus yielded
a structurally non-identifiable system, both parameters were excluded from
identification, as their effects can only be quantified when there are
separate instances recorded (Docherty et al., 2011; Bellu et al., 2007).
The parameter set x was identified in 2000 simulations of the patient for
each data set length (n). The CV, mean, and 95% confidence interval (CI)
were calculated for each data size (n) for each parameter. The CV values








where y1 denotes the magnitude of the CV and y2 allows an offset to account
for when effects are not present in early data.
9.4.2 Part II
Part II measured the ability of the identification method to accurately
capture all parameters in data that contained insulin sensitivity drift over a
2 year data collection period. In this analysis, SI was set to increase
linearly by 10% during the first year (D(%) = 10), then decline by 20% in
the second year (D(%) = −20). Neither the magnitude nor shape of SI
drift were treated as a priori. Thus, the drift could not be identified
directly. Instead, the analysis used subsets of data that shifted through
time to capture all identified parameters in a moving average.
A 90 day data subset was taken starting each successive 10 days until the
full 730 days was used. This process was repeated for 2000 virtual patient
simulations, with mean and 95% CI calculated for each data subset across
the simulations.
To attenuate apparent periodicity in the drift patterns, the parameter
identification method was adjusted to penalise SI1 − SI3 values that
142
strayed too far from values obtained in the previous data subset. This
attenuation was achieved by modifying Equation (9.20) to include












where i is the present iteration of identification in a 90 day data subset (w)
and G1...n is the data contained within that subset. α is a factor that
determines the magnitude of penalisation of changes in insulin sensitivity
across subsets. The ability to capture long-term drift in SI was compared
with α = 0, 2 × 104 and 4 × 104; where the 104 converts SI to values to
between 1 and 10, thus, comparable in scale to the G(t) values.
Singular values of εmax, σmax and ϕmax for the full two year period were
found using an average over every 90 day data subset. This was carried out
for α = 2 × 104 only. These values were analysed across the population for
mean, 95% CI and CV.
9.5 Results
9.5.1 Part I
Figure 9.4 shows that the CV in each parameter converged with increasing
days of data. The function of Equation (9.21) was fitted to the parameter
CV values, and values for y1,2 and R
2 are presented in Table 9.3. G0 had
the lowest variation coefficients of all the identified parameters while εmax
had the greatest, followed by ϕmax and σmax. R
2 was over 99.9% for all
parameters thus indicating strong adherence to the 1/
√
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subsets        
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S = 61-600      






I II Part 
randomised 
parameters     
PX, PC, fε, fσ, fφ 
sampling + noise 
fixed 
parameters 
Figure 9.3: The Monte Carlo analysis, showing the distinction between
Parts I and II for data subset selection. Note that the actual data is not
interchanged between the two parts, since Part II contains long-term drift in
SI while Part I does not
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Table 9.3: Trend-line parameters for CVx(n) and the R
2 value
Parameter y1 y2 R
2
SI1 0.531 -1.537 1.000
SI2 0.677 -1.029 1.000
SI3 0.498 -0.814 1.000
G0 0.116 -0.317 0.999
εmax 0.921 -6.906 1.000
σmax 1.854 -9.730 1.000
ϕmax 4.746 -7.998 1.000
Ball, 2002). The higher y2 values for the secondary effects implied greater
offsets with respect to days. Figure 9.5 shows that the precision of each
parameter improved with increasing days of data although some small biases
were observed. The biases were relatively small by day 385 (SI1, 0.9%; SI2,
0.9%; SI3, 0.6%; G0, 0.9%; εmax, 0.04%; , σmax, 0.2%; ϕmax, 0.2%). To
evaluate convergence, CV was evaluated for repeat sets of size 1950, 1951,
1952, . . ., 2000 repeats. These values were within 0.5% of the 2000 repeat
CV for every parameter, indicating that the Monte Carlo simulation cohort
had converged suitably.
9.5.2 Part II
Figure 9.6 shows that the long-term drift in insulin sensitivity was readily
captured over the data sets tested, but lagged the true drift. Furthermore,
the drift in insulin sensitivity caused some drift to occur in the secondary
effect parameters (εmax, ϕmax and σmax) that was not present in the
underlying behaviour of the virtual patient. Figure 9.7 shows that
increasing the α value smoothed out the oscillating patterns in insulin
sensitivity, but Figure 9.6 shows that higher α values caused greater
variation in other parameters and increased the lag in the mean identified
SI profile.
Values for εmax, ϕmax and σmax obtained with α = 2 × 104, yielded
relatively small 95% confidence intervals and all biases were below 1%
(Table 9.4). Figure 9.7 shows a typical example of the effect of α on drift
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Figure 9.4: CVx(n) for each identified parameter over 2000 repeats for each
data subset length fitted with the trend-lines of 9.21. Note the different
magnitude of the secondary effect parameters
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identified mean and 95% CI
Figure 9.5: Convergence of identified parameter values compared to true
values as days of data increased for 2000 repeats
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Table 9.4: Average of secondary effects over every 90 day data subset for
α = 2× 104 with 2000 repeats
Parameter True value Mean 95%CI Relative bias CV
εmax 6.5 6.44 (6.43,6.45) -0.9% 3.7%
σmax 0.3 0.299 (0.298,0.300) -0.2% 7.6%
ϕmax 0.1 0.0995 (0.0986,0.1004) -0.5% 19.6%
patterns in daily SI mean for an individual simulation and identification
process. Greater values of α attenuated the random drift in SI, allowing
the method to better emulate the original drift pattern.
Using Equation (9.21) and the parameters in Table 9.3, the variation
coefficient in the secondary effects for Part II was compared with Part I for
α = 2 × 104. To achieve the same variation coefficient as that of 100 days
with no drift effects, it would require 118, 120 and 123 days of data with
drift present for the εmax, σmax and ϕmax parameters, respectively.
A single 91 day period required an average of 3.4 seconds of computational
time and one 730-day, 65-data subset repeat of the drift analysis required
an average of 578 seconds.
9.6 Discussion
The accuracy of the model parameters for the individual virtual patients
and the precision of model parameters of the in silico cohort increased in
accuracy as more data accumulated. Some small bias (< 1%) occurred in
each parameter across the virtual cohort by day 385 (Figure 9.5). These
small biases were due to the log-normal parameter distributions that result
from identifying the effects from 1st order models in data that have
normally distributed measurement error. In accordance with expectations,
the CVX values reduced in proportion to 1/
√
n (9.4) (Whitley and Ball,
2002) with R2 values all exceeding 99.9%. As sparse measurement data
accumulates, failure to adhere to 1/sqrtn would imply instability during
parameter identification or significant parameter trade-off. The strong
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Figure 9.6: The effect of increasing α on parameter identification of 90 day


























Figure 9.7: An example of a typical run showing identification of the mean
of SI1−3 at the end of each 90 day data subset for increasing values of α
correlation to the trend in the results validates the identification method as
well as the robustness of the parameters.
Identifying y2 in Equation (9.21) was necessary as the randomised
occurrences of some parameters meant that some identification sets did not
have any stress or fatigue in the early stages. Both σmax and ϕmax are on
28 day alternations and therefore appeared anywhere between 0 and 3
times in the first 7, 14 and 21 days. These three data subset lengths were
therefore excluded from trend-fitting for σmax and ϕmax because these data
subsets are shorter than might be used in practice and it was more useful to
capture the long-term trends than initial transience. Overall, the results
indicate that noise in blood glucose and food intake, in addition to
instances of unreported food intake, can be overcome by an accumulation of
data and robust parameter identification, even in the presence of sparse,
irregular data.
It is well established that insulin sensitivity undergoes long-term drift due
to changes in a patient’s metabolism (Abate et al., 1995; Mayer-Davis
et al., 1998; Wu, 2005). For that reason, it would be misguided to identify
single values of SI1−3 for periods that are longer than a few months. Insulin
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sensitivity can increase or decrease at any time and while it is likely to drift
in a steady manner, it was important that the identification method did not
make any assumptions of the drift profile. Using consecutive data subsets
to observe the drift pattern fulfilled this requirement, but caused some lag
in identification. While the modelling approach used in Part II of this
analysis yielded transient parameter values, it was effectively a traditional
constant parameter approach. In particular, constant values for each of the
SI and secondary effect parameters were determined for a particular 90 day
window. The outcomes of Part I implied reasonably robust parameter
values could be obtained in 90 days of data. Part II showed that it is
possible to identify parameters that influence glycaemia in the presence of
SI drift that would inevitably occur in free-living individuals.
The Monte Carlo simulation implied that drift in insulin sensitivity was
easily inferred, but that this identification also lagged the underlying true
behaviour. This lag should be expected due to the need to accumulate
enough sparse, irregular data to identify the trend. While Figure 9.6
appears to show no advantage and increased lag due to the penalisation of
changes in SI, Figure 9.7 shows the need for this parameter to limit the
systematic oscillation in measured insulin sensitivity and allowing for more
practical inference of the underlying trends. The optimal α out of the few
examined was 2 × 104 because it attenuated much of the noise, but did not
flatten the SI trends excessively. Further refinement of the α value is
necessary prior to further implementation of the method.
The secondary effects (εmax, σmax and ϕmax) remained identifiable in the
presence of SI drift. Table 9.4 shows high precision (CV< 20%) and small
biases (< 1%). Note that the secondary parameters were effectively
identified over the whole period and thus built up precision due to the
number of data points available. The validity of this assumption relies on
the consistency of secondary effects on glycaemia, which has not been
investigated.
To assess the robustness of the secondary parameters to drift, an analysis
151
was undertaken to estimate how many days of data with SI drift would be
needed to match 100 days of data without drift. The PART I CVX values
for the secondary parameters were similar to the PART II CVX values for
the equivalent number of days. In particular, the CV values after 100 days
without drift was equivalent to the CV of 118-123 days with drift. This
outcome indicates a high level of robustness that allows the methods to
capitalise on the majority of the information collected over 2 years, despite
the presence of drift.
While using virtual patients limits the explicit clinical relevance of the
outcomes of this study in real patients, it was sensible to carry out this
stage of the investigation in silico. The advantages of an initial in silico
study are the ability to control exactly what the model entails and compare
the identified parameters to true values. This method also facilitated
effective statistical analysis through repeated generation of the model.
Hence, any outcomes were a factor of the input data that were controllable
and thus it was possible to determine the robustness of the mathematics in
the presence of noise and a known level of confounding behaviour. In vivo,
the level of confounding behaviour would not be known, and thus the origin
of parameter variance would remain ambiguous.
In the simulated model, basis function shapes perfectly matched the input
model shapes. However, in real data, basis functions will give the
identification scheme some freedom to emulate the circadian rhythm, but
cannot be any more than an approximation to the true shape that is
currently unknown. Likewise in the model, perfect interstitial insulin
profiles were used during identification, but diary data will not contain
measurements of insulin but will have dose descriptions instead. Hence,
insulin pharmacokinetics will need to be estimated using currently available
models. While there is general knowledge available of the pharmacokinetics
of different insulin products, the patient- and dose- specific behaviour is
much more variable and unknown (Wong et al., 2008a,b). Regardless, this
computational study proves the concepts to justify focused clinical trials
where these profiles can be optimised.
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There are likely to be many confounding effects for a real system that
cannot be directly accounted for, such as low patient compliance, errors in
insulin dosing or dose recording, and errors in meal records. Thus, the in
silico analysis mimicked this type of behaviour by including an unrecorded
snack intake, the effect of which was still favourably offset by the 1/
√
n
convergence rate of the parameter values. However, if similar un-modelled
effects are substantial and frequent, the quality of results would deteriorate.
In reality, the group that may gain advantage from this type of model
based glycaemic regulation is a subgroup of people with T1DM who are
willing to undergo relatively stricter control regimens and are more
meticulous at diary recording. In particular, the diary data taken by such
individuals must include information on exercise, stress and fatigue.
However, new software and technology can ease and improve this process
by augmenting and even replacing traditional diary-taking methods.
The glycaemic model used was relatively simple but allowed the key
governing dynamics to be captured. There are a few quantitative models of
the impact of exercise on metabolism in diabetes (Dalla Man et al., 2009;
Roy and Parker, 2007; Breton, 2008), but none that examine a wider range
of secondary influences on glycaemic behaviour. The evidence suggests that
moderate-intensity exercise causes non-insulin mediated glucose uptake
(Yardley et al., 2013) and thus the linear glucose depletion model used in
this analysis represents a valid estimate for the true dynamics. Likewise,
with stress and sleep-deprivation, both are known to reduce insulin
sensitivity (Rizza et al., 1982; Räikkönen et al., 1996; González-Ortiz et al.,
2000), but the specific dynamics are unknown. In particular, it is unknown
whether the conditions interact additively or multiplicatively and how the
physiological strength of the conditions increases with perceived intensity.
The chosen model used additive stress and fatigue effects that increased in
strength linearly with perceived intensity. All approximations served to
validate the identification methods used and were thus acceptable at this
stage in the research process. Due to the large number of assumptions
made in silico, observational tests must be undertaken in vivo to validate
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and improve this model.
A single 91 day data subset required 3.4 seconds to identify all parameters
using the Gauss-Newton approach, and thus could be used in real time
control. The full 730 day analysis required 578 seconds and would be
cumbersome in real-time control. Ideally, secondary effects would only need
to be identified once and could be used in concert with recent insulin
sensitivity values, thus speeding up the process. Equally, a faster code than
MATLAB could speed up this computation by 10-100×.
Inference of long-term drift in SI was enhanced by the penalisation of
changes in SI across data subsets. In some cases, the random oscillations in
SI drift patterns created some difficulty in establishing the underlying
trends for individual runs. The penalisation process succeeded in reducing
the oscillations. However it is also anticipated that changes in SI could be
steeper than in this simulation. Studies have reported an average drop in
insulin sensitivity of 50% for pubescent individuals (Hannon et al., 2006),
and a 34% average drop over 3.3 years in pre-diabetics (Aizawa et al.,
2014). Another study reports a 50% drop in insulin resistance (inversely
related to SI) after 6 months dieting in obese individuals (Montastier
et al., 2014). There are also significant changes in SI during pregnancy
(Cousins, 1991) and even changes correlated to intake of certain spices
(Kouzi et al., 2015). With larger changes compared to the impact of noise,
the SI drift would be easier to discern.
Identification restrictions sometimes applied when fatigue and stress
occurred concurrently such to create a non-identifiable problem in time
periods of less than 4 weeks. Non-identifiability existed when σmax and
ϕmax occurred concurrently. However, cases of non-identifiability ceased to
occur for larger time periods due to the difference in timing of stressful and
fatigued days. However, in an organic system there is very likely to be
crossover between fatigue and stress, thus generating the need for a robust
algorithm in real world application. While computational parameter
identification will remain stable so long as there is at least some distinction
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between periods of stress and fatigue, the validity of the results will be
inclined to decrease with greater degrees of crossover.
While it is common knowledge that emotional stress causes hyperglycaemia
(Surwit et al., 1992; Lloyd et al., 1999), parameter identification and
control in this area has not effectively been attempted in outpatients and
not in a self-reported data style presented in this research (Ward et al.,
2011). Some people living with T1DM find continuous control of blood
glucose arduous. This research is less aimed at meticulous persons who test
often and maintain good control, either reactionary or proactive, but at
those who consistently struggle to avoid hypo- and hyper- glycaemia and
who are willing to adhere to dietary regimes and control protocols. For
these people, secondary effects such as stress and exercise may play a huge
role and to be able to quantify the strength of each secondary effect to even
some degree of accuracy has real potential to improve their quality and
length of life for this subgroup.
This analysis only considered a few of the many factors that are known to
affect glycaemia. However, the methods developed in this chapter could be
used to incorporate a larger number of additional secondary effects. For
example, menstrual cycles affect blood glucose levels in women with
diabetes (Lunt and Brown, 1996; Ramalho et al., 2009), and depression has
an equivalent effect to that of stress (Nathan et al., 1981; Lustman et al.,
2000) and other not yet investigated effects could also be tested.
9.7 Summary
This study presented and tested the robustness of a method to identify
parameters for insulin sensitivity, exercise, stress and fatigue in the
presence of sparse, irregular data that is noisy and includes errors of
omission and accuracy typical of self-managed blood glucose diary data. It
showed that sparse, irregular and noisy data could be overcome as such
data accumulated to provide a clearer picture of patient status. Part I of
this analysis showed that the reduction in CV for parameters in increasing
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data was in accordance with the rule 1/
√
n and thus provided evidence that
measurement error and other sources of noise cannot obscure the estimation
of key glycaemic factors. Part II allowed for identification of secondary
effects over longer time periods by capturing an anticipated long term drift
in SI. Based on the results presented, the methods developed appear
capable of measuring secondary effects in glycaemic control in patients
living with T1DM. However, an in vivo observational trial should be
undertaken to validate these findings with the ultimate purpose of
providing tools to improve glycaemic control and quality of life of
individuals that have T1DM.
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Chapter X
Low road: a-posteriori identifiability
This chapter presents an evaluation of the practical identifiability of patient-
specific parameters identified in sparse diary data from the virtual patient
in the previous chapter. This work was published as a conference paper
and presented at the 2015 World Congress for the International Federation
of Automatic Control (Mansell et al., 2015b). The ’Low road’ refers to the
method being numerical rather than purely analytical, which by comparison
would be substantially more difficult to derive.
10.1 Motivation
In the previous chapter seven glycaemic parameters were identified in
sparse blood glucose data from a virtual patient. The results of the Monte
Carlo analyses proved the parameters were all observable, and that
measurement noise and un-modelled effects could be overcome as data size
increased, with CV across the population reducing in proportion to 1/
√
(n)
and only small (< 1%) biases resulting after one year. To observe long-term
drift in SI, a 90 day data window was progressed along a 2 year period to
identify parameters in a moving average. Information for stress, fatigue and
exercise parameters were still able to be captured with biases remaining less
than 1% and CV being approximately equivalent to drift-free outcomes.
Practical non-identifiability occurs when experimental data is of insufficient
quality or quantity compared to the size of a model Raue et al. (2009);
Docherty et al. (2011) as explained in Section 3.3.2. This chapter
investigates identifiability in the six most variable parameters from the
original seven-parameter model. Specifically, the aim is to determine the




All computation was carried out in MATLAB R2014a. The virtual patient
in this chapter was modelled and simulated the same as that of Section 9.2.1.
10.2.1 Parameter identification
Like the previous chapter, the Gauss-Newton method of gradient descent was
used to identify the least squares solution of variable set x by minimising
the residual error between the sampled and forward-simulated blood glucose
(Equation (9.20)) over several iterations. This time, however, parameters of
interest were subsets of those in the set:
x = [SI1, SI2, SI3, εmax, σmax, ϕmax]
T (10.1)
where between 2 and all 6 of these parameters were identified as variables
when required. Variables were initially set to relevant subsets of
x0 = [10
−3, 10−3, 10−3, 1, 0.1, 0.1]T and Gauss-Newton iterations were
continued until the tolerance criteria
∣∣∣∣∣∣xi−1−xix0 ∣∣∣∣∣∣2 < 10−4 yielded
approximately 4 significant figures of convergence precision on parameter
estimates.
10.2.2 Structural identifiability and stability checks
When instances of exercise, stress or fatigue were not present in an
identified period of time, εmax, σmax and ϕmax were set to zero and
excluded from identification. When both stress and fatigue effects occurred
concurrently yielding a structurally non-identifiable system, both
parameters were excluded, as their effects can only be quantified when there
are distinguishable instances (Docherty et al., 2011; Bellu et al., 2007).
For occasional instances in small sets of data where noise and un-modelled
effects rendered Gauss-Newton identification unstable (when singular
matrix occurred or i > 30), latter variables were removed from the process
every 20 iterations until successful identification occurred.
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10.2.3 Error analysis proof of concept
The broad concept behind this method of evaluating practical identifiability
begins by considering the error between simulated and identified values in
parameters for an increasing dataset size, similar to the previous chapter
(Mansell et al., 2015d). However, to evaluate whether or not to identify a
new, previously a priori parameter without reducing practical
identifiability, the error in the original identified variables is considered
both with and without the new parameter identified in increasing dataset
size. A new specification, the norm error, was created to singularly quantify
the effect of the introduced parameter on the full set of previously identified
variables.
Forty days of data was simulated, and this data was broken up into subsets
of 0-1, 0-2, 0-3, to 0-40 days. Initially only SI1−2 was identified with
incorrect ’a priori ’ values set for the remaining parameters:
SI3 = 0.4 × 10−3, εmax = σmax = ϕmax = 0. Then SI3 was also included as
an identified variable. Figure 10.1 shows the SI parameter estimates when
identifying two versus three variables for a particular virtual patient, to
demonstrate the error analysis concept. Note that the 3-variable set yielded
larger error in SI2 for days 1-10 compared to the 2-variable set. This shows
the trade-off that SI3 causes in SI2 for small datasets.
The combined specification of norm error for the 2-variable subset






where xtrue is the original model input. Norm error was calculated for these
two variables both for 2-variable and 3-variable identification. Figure 10.2
shows how e changes for the increasing dataset sizes. After approximately
23 days of data, the combined norm-error for SI1−2 is reduced with the
introduction of SI3 into the variable set.
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Figure 10.1: Identification for a data set with 2 variables plus one a priori
parameter (a) and all 3 as variables (b).
identification period (days)




























Figure 10.2: Norm-error of SI1−2 for 2 and 3 variable identification sets. Prior
to 23 days the least error is achieved by treating SI3 as a priori, afterwards
it is better identified as a variable.
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10.2.4 Monte Carlo analysis
A more thorough error analysis was carried in a Monte Carlo population of
virtual patients, investigating the effect of each new parameter addition:
SI3, εmax, σmax, and ϕmax.
This time, 89 days of data was simulated for 1000 patients. These datasets
were broken into subsets from zero to [2, 3, 5, 8, 13, 21, 34, 55, 89] days.
SI1−2 were identified for all data subsets for all patients. SI3, εmax, σmax,
and ϕmax were all added to the variable set one at a time, with new
identification occurring at each addition. Norm-error was calculated for
variable subsets x1−2 for all results, x1−3 when 3 or more variables were
identified, and so on up to norm-error of x1−5 for 5 and 6 variable cases.
The specific day when an increase in the number of variables yielded
improved precision in each previous variable subset were located for the
population mean.
To quantify the effects of variability on the population outcomes, the 89
day subset was used to calculate mean reduction in norm-error for each
variable subset from x1−2 to x1−5 for each variable introduction. This




The fraction of non-improved cases was also calculated.
10.3 Results
Figure 10.3 is the population equivalent of Figure 10.2, extended to show
the effect of further parameter introductions on SI1−2. For the Monte Carlo
population mean, the point at which a 3-variable set favoured the precision
of SI1−2 was at four days. Introducing εmax, σmax, and ϕmax as variables
reduced the SI1−2 norm-error at three, nine and 34 days, respectively.
Further consideration was taken into to the norm-error of variable sets
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Figure 10.3: Norm error of SI1−2 as 2-6 variables are identified over a
population. Reduced error for variable introductions 3-6 occurs at 4, 3, 9
and 34 days.
greater than just SI1−2. Table 10.1 shows that for the population mean,
crossover days for beneficially introducing certain parameters into the
variable set were comparable across all norm-error sets (e.g. εmax improves
norm-error of both SI1−2 and SI1−3 after 3 days). Additionally, the
crossover days generally increased for subsequent variable additions (e.g.
the 5th parameter, σmax, can be introduced as a variable on average 3 days
after the 4th parameter, εmax).
Table 10.1: Mean day for an introduced parameter to improve precision in
other variable sets.
parameter variable subset evaluated
introduced x1−2 x1−3 x1−4 x1−5 average
x3 = SI3 4 4
x4 = εmax 3 3 3
x5 = σmax 9 5 5 6
x6 = ϕmax 34 27 27 26 29
Table 10.2 gives statistics for the degree of norm-error improvement after
89 days for each increase in variable number. Identifying SI3 reduced
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norm-error in SI1−2 by 29% on average, only failing to improve the error in
1% of cases. Introducing the exercise parameter, εmax, produced greater
mean error reductions (28 and 41% for SI1−2 and SI1−3), but also had a
greater no-benefit rate of 6-18%. Introducing stress, σmax, and fatigue,
ϕmax, as variables had less benefit in error reduction, especially for ϕmax,
where mean reductions ranged from an increase in error of 6% to a
reduction of 6% and no-benefit rates were 28-40%.
Table 10.2: Population variability statistics for 89 days of data with mean
reduction in norm-error for parameter sets as subsequent parameters were












reduction 9.0% 23% 16%
no-benefit 20% 8.6% 16%
x6 = ϕmax
reduction -6.2% 6.2% 3.7% 2.6%
no-benefit 40% 28% 34% 36%
10.4 Discussion
Introducing a new parameter into the identified set of variables can reduce
the error of the original variables due to the ability of the introduced
parameter to assume a value that has less associated error than an a priori
estimate. In the example virtual patient, a comparison of Figure 10.1a and
10.1b shows that by the end of 40 days, the error in SI1−3 was less when
SI3 was identified as a variable, rather than taken as an incorrect a priori
parameter. However, too little data results negates this beneficial effect.
Figure 10.1b shows that identifying SI3 introduced large error in SI2 for
small n. This outcome demonstrates that, at first, the data was not
sufficient to support all the variables with any degree of accuracy, and
reduced practical identifiability resulted in variable interference (Raue
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et al., 2009; Docherty et al., 2011).
SI1−3 are equivalent parameters that peak at different times of the day.
Hence the times at which data points were taken would influence accuracy
in SI1−3 estimates. For example, if data points have largely been sampled
in the morning, then the effect of the afternoon SI is not easily
distinguishable, and the resulting error may propagate particularly strongly
into the midday SI, as was the likely case in Figure 10.1b. As more data
accumulated, with more random additions inevitably occurring in the
afternoon, the afternoon SI began to achieve accuracy and all variables
were benefited. This illustrates the concept of the contribution of data to
practical identifiability.
While mean population results appear to clearly indicate when parameters
should be introduced as variables (Figure 10.3), the trends fail to capture
variability effects and thus represent an ideal case rather than average. In
particular the population value averages out y-dimensional error in
Figure 10.3 but thus misrepresents the x-dimensional location of mean
crossover day, the sought after property. In fact, for individual sets of data
there were frequently multiple crossovers points or none at all in the first 89
days. This reality cannot be captured by the mean, thus the statistical data
of Table 10.2 was calculated.
Based on results for variability effects, SI3 appears beneficial to introduce
by day 89 since it reduced norm-error of SI1−2 in 99% of cases. Since the
appearance of SI3 was daily, its accuracy weighed heavily on the outcomes
of other variables. Comparatively, stress occurred much less frequently and
had lower gains for greater risk (no-benefit rate 9-20%). Exercise, εmax, also
appears to introduce large benefits (28-41%) but also represents a moderate
no-benefit rate (6-18%). Since the model includes frequent exercise at the
same time of day, not identifying εmax is likely to skew at least one SI peak
value, thus the risk from including the parameter in the model could be
deemed acceptable.
Like stress, fatigue was relatively infrequent. Thus, many more days of data
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were required to achieve accuracy and minimise interference with other
variables. This can be seen in the higher no-benefit rates (28-40%) and
lower gains (-6% to 6% error reduction). This indicates that both the σmax
and ϕmax parameters should not be identified due to their tendency for
error propagation in other parameters.
Of course, while introducing some parameters is likely to increase error in
other parameters, this detriment must be weighed against the benefit
identifying the new parameter itself. A small error increase could be an
acceptable price for the advantageous information. However, a best case for
all parameters could be achieved by identifying a base parameter set of
regular and highly identifiable parameters, then fixing some or all of these
parameters while performing a second identification round to ascertain the
less frequent parameters.
An in silico analysis was the best platform for investigating the research
presented in this paper since true parameter values are non-existent in real
data. Therapeutic glycaemic modelling can be difficult due to the presence
of measurement noise, un-modelled effects and sometimes practical
non-identifiability. It has been shown that much of these effects can be
accounted for in a stable manner through the timely addition of new
parameters into the identified set of variables. It remains unknown how real
data would respond to equivalent parameter introductions. However, the
concepts explored in this chapter are foundational to development and and
testing the efficacy of other analysis methods independent of error and
perhaps instead evaluating properties such as variability in specific datasets.
There are many factors that can significantly affect the glycaemic dynamics
of people with diabetes, not limited to those modelled in this report. The
ability to identify a large number of such parameters in one set of data
would be valuable. However, if certain parameters are introduced too soon
during data accumulation, they can seriously reduce the precision of the
other parameter estimates. If introduced too late, then un-modelled
behaviour, or grey’ noise, is the limiting factor on the precision of identified
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variables. Hence the importance of this type of identifiability analysis.
10.5 Summary
Identification of increasing numbers of parameters generally improves error
in the parameter group by capturing otherwise un-modelled effects.
However insufficient data can reduce practical identifiability, increasing
parameter interference and error. The point at which data does become
sufficient was diagnosed through analysis of error in equivalent variable sets
before and after parameter introduction.
Specific to this model and analysis, the two parameters SI3 and εmax
appear reasonably beneficial to introduce after 89 days, while σmax and
ϕmax may be better excluded until the other parameters can be well
established and fixed.
Error-based analysis was ideal for exploring the effect of practical
identifiability on the model, but will ultimately be ineffective for in vivo
data, requiring improved methods. Identifying large numbers of parameters
with known confidence would be useful in diabetes. Greater knowledge of




High road: a priori identifiability
The content of this chapter is a more theoretical vein of research,
developing an a priori practical identifiability evaluation method. This
work was published as a conference paper and presented at the 2015 World
Congress for the International Federation of Automatic Control (Mansell
et al., 2015c) with a small investigation on additive noise included as
further work. The ’High road’ refers to the development of a more pure
analytical method. Analytical methods are often more complicated to
ascertain than their numerical counterparts.
11.1 Motivation
Physiological modelling is becoming a standard approach to investigating
complex biological systems to recover parameter values that cannot be
directly measured (Saccomani, 2013). Nonetheless, outcomes of such
parameter identification should not necessarily be accepted without
evaluation of the credibility of the results and models. Structural
identifiability is a discernible binary model property that states that under
ideal data conditions the unknown parameters can be uniquely and exactly
recovered from input-output relationships (Bellu et al., 2007). However,
affirmation of structural identifiability is not in itself sufficient to ensure
precision in identifying true parameter values.
In recent years, analysis methods have emerged to detect and evaluate
practical rather than structural non-identifiability. These methods
determine when the data quantity and quality is insufficient for the size of a
model, resulting in mutual interference of two or more parameters
(Docherty et al., 2011; Raue et al., 2009; Saccomani, 2013). The result of
such interference is increased parameter variability and bias with no clear
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cause. Thus, practical identifiability analyses are greatly beneficial when
designing and utilising models identified from noisy data, since they can
diagnose problems that structural identifiability analyses cannot (Docherty
et al., 2011).
This chapter presents preliminary research into a new method of practical
identifiability analysis that aims to link properties of a model, data size and
measurement error to variance in results expected from a population of
data. Information about population variance can be captured by a
Principal Component Analysis (PCA), which is a multivariate analysis that
reduces data variability to a new set of variables calculated from an
eigen-decomposition problem (Jolliffe, 1986). Thus, MC simulations were
carried out in silico to find the connections from a priori model and data
information to PCA outcomes.
11.2 Methods
11.2.1 The model
To prevent complex effects from obscuring underlying behaviours, a simple
model was used as a precursor to larger physiological models. The output,
b(t), for discrete time steps, t = (1, tn), was produced from the superposition
of step and ramp functions (pictured Figure 11.1):




where n is the number of discrete time steps, H is the Heavyside function
that forms a binary step, tn/2 is rounded up to the nearest integer, and α











Figure 11.1: A graphical representation of the model
11.2.2 Parameter identification
Linear regression of the model for discrete output data gives:









































Random multiplicative white noise was introduced to b to create an imperfect
data set (b̂):
b̂ = b (1 + e) for e ⊂ N(0, σ2) (11.5)
where the  symbol indicates element-wise vector multiplication.
The least-squares solution (x̂) of the variables for α and β to the noisy data
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Table 11.1: Variable definitions for Monte Carlo simulation schemes, where
n = data size, x is the true solution to the parameters, σ = output error
standard deviation, and γ is an arbitrary variable.
scheme constants variables
1a n = 10,x = [1, 1]T,σ = 0.1 none
1a n = 10,x = [1, 1]T,σ = 0.2 none
1a n = 50,x = [1, 1]T,σ = 0.1 none
2 n = 10,x = [1, 1]T σ = 0, 0.1, 0.2, . . . , 1
3a n = 10,σ = 0.1 x = [1, γ]T, γ = 4, 8, . . . , 100
3b n = 10,σ = 0.1 x = [γ, γ]T, γ = 4, 8, . . . , 100
3c n = 10,σ = 0.1 x = [1, γ1.5]T, γ = 4, 8, . . . , 100
4 σ = 0.1,x = [1, 1]T n = 4, 8, . . . , 100
set was calculated as:
x̂ = (ATA)−1 ATb̂ (11.6)
11.2.3 Monte Carlo simulation and variables
Parameter outcomes from multiple data sets 1 through r, each with random
multiplicative white noise of variance σ2, were stored in a matrix:
X = [x̂1 x̂2 · · · x̂r]T (11.7)
This process was carried out using 106 repeats for each combination of noise
variance (σ2), true parameter values (x), and data length (n). Several testing
schemes, described in Table 11.1, were investigated. Schemes 1a-c used single
combinations of these properties while schemes 2-4 used variable inputs over
a range in order to capture trends.
11.2.4 Analysis
For schemes 1a-c, two dimensional objective surfaces were created over a
range of α and β of -0.5 to 2.5 by taking the norm of residual error between
the output created by these combinations of x and that of true output (b):
ψ(x1, x2) = ||Ax− b||2 (11.8)
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Correlation between the matrix equation and resulting MC scatter was sought
by carrying out eigen-decomposition on the 2×2 ATA matrix, and comparing
it to outcomes of the PCA on the X matrix. PCA first involves calculation of
a mean-centred matrix (X̄) that contains both columns of X in Equation 5
with their mean value subtracted. This is followed by an eigen-decomposition





Both PCA and ATA eigenvectors were compared and eigenvalue trends
correlated to other independent variables.
11.2.5 Additive noise model validation
The majority of modelling and analysis for this investigation utilises
multiplicative white noise. Multiplying the noise significantly complicates
the relationship between a priori information and PCA outcomes compared





To validate this eigenvalue relationship on the step-ramp model, PCA
outcomes were compared to the a priori modelled PCA eigenvalues from
Equation (11.10) for a 106 Monte Carlo population with additive noise. For
this population, α = β = 1 was assigned, although another arbitrary
parameter combination was also tested. A range of n from 2 to 100 was
used.
11.3 Results
All analysis were carried out using MATLAB R2014a. Eigen-decomposition
analysis showed that the ATA eigenvectors were parallel with the principal
components of the parameter distribution from the MC analysis of scheme
1a, Figure 11.2. PCA produced the greatest eigenvalue in the direction of
greatest spread, while the smallest eigenvalue of ATA was in this direction.
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Principle components of scatter
Figure 11.2: A comparison of ATA eigenvectors and principal components
of parameter identification scatter, pictured on an error objective surface.
σ = 0.1, n = 10.
Doubling the standard deviation of noise in the output data (scheme 1b)
did not affect the eigenvector direction but created a larger distribution of
parameters, as seen in Figure 11.3. The change in output noise did not
affect the ATA eigenvalues but PCA eigenvalues were both quadrupled in
value.
Increasing the data quantity by 5 times (scheme 1c) reduced the parameter
spread to a comparable width of scheme 1a although the output noise was
still that of scheme 1b. In this case, increased steepness in the objective
surface was accompanied by greater ATA eigenvalues, 533% and 435% of
their scheme 1a-b values, and decreased PCA eigenvalues, at 13% and 23%
of their scheme 1b values, respectively. There was also a reduced
eccentricity of the elliptical contours in the objective surface and an
alteration in both the eigenvalue ratios (λ1/λ2), increasing for A
TA and
decreasing for PCA, which in both cases corresponded to a reduced
difference between λ1 and λ2.
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Principle components of scatter
Figure 11.3: A comparison of ATA and PCA eigenvectors with double the
noise from Figure 11.2. σ = 0.2, n = 10.
β

















Principle components of scatter
Figure 11.4: A comparison of ATA and PCA eigenvectors now with five
times the data points compared to Figure 11.3. σ = 0.2, n = 50.
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Scheme 2 investigated the effects of changing the relative contribution of
model parameters (x) when A and therefore the ATA eigenvalues were
unaffected. The results gave a strong linear correlation between PCA
eigenvalues and noise variance (R2 = 1.0000 for λ1−2), with the full
relationships listed in Table 11.3. The eigenvalues had zero-value for zero
noise and the ratio between eigenvalues, λ1/λ2, was consistent at
approximately 11.8 through all noise values.
Like the effect of noise, changes to the parameter values in x influenced
PCA and also had no effect on the properties of ATA. Scheme 3a and 3b
both resulted in strong linear correlation between the eigenvalues of the
PCA and the square of the variable γ (relationships listed in Table 11.3, R2
= 1.0000). However, eigenvalues λ1−2 for scheme 3b were approximately 4-5
times greater than those of 3a. In scheme 3c, where one parameter was
equal to γ1.5, the PCA eigenvalues were now proportional to γ3 (Table 11.3,
R2 = 1.000). The ratio PCA eigenvalues fitted well with a two-term power
model: λ1/λ2 = aγ
b + c for both schemes 3a and 3c while 3b showed no
changes in the ratio, seen in C11.5. Table 11.2 gives the value of these
power model parameters and the R2 values.
The results of scheme 4 showed that the ATA eigenvalues were linearly
proportional to data size while the PCA eigenvalues were inversely so
(Table 11.3, R2 = 1.000). Ratios of λ1/λ2 were affected by data size in both
cases. A two-term power model was fitted to this trend, Figures 11.6-11.7
(PCA R2 = 1.0000, ATA R2 = 0.997). However, the residual error (not
shown), particularly for ATA data, reveals behaviour uncaptured by these
models.
Figure 11.8 shows the performance of this model for a range of n in 106
repeats of a Monte Carlo simulation. The a priori model appears to fit well
with the PCA outcomes and the residual shows no systemic bias.
Equivalent outcomes occurred with arbitrary choices of x (data not shown).
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Figure 11.5: Results for PCA eigenvalue ratio compared with changes in γ,
which influences x. Schemes 3a and 3c are fitted to two-term power models
while 3b is fitted to a horizontal function.
data size, n






























 = -0.039n-0.55 + 0.043
Figure 11.6: Results for PCA eigenvalue ratio against n.
Table 11.2: Model fits for eigenvalue ratio compared to the variable γ for two
schemes where x = f(γ).
model scheme a b c R2
λ1
λ2
= aγb + c
3a -4.74 -0.674 14.7 0.993
3b 0 - 11.8 -
3c -5.46 -0.124 16.8 0.994
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data size, n































 = 121n-1.3 + 6.1
Figure 11.7: Results for ATA eigenvalue ratio against n.
Table 11.3: Relationships found between model and data variables against
the eigenvalues of PCA and ATA eigenvalues against variables for schemes
2-4.
scheme PCA relations ATA relations
2
λ1 = 3.88σ
2 λ1 = 0.30
λ2 = 0.33σ
2 λ2 = 9.6
3a
λ1 = 0.0090γ
2 + 0.35 λ1 = 0.30
λ2 = 0.00062γ
2 + 0.035 λ2 = 9.6
3b
λ1 = 0.039γ
2 − 0.041 λ1 = 0.30
λ2 = 0.0033γ
2 + 0.0017 λ2 = 9.6
3c
λ1 = 0.011γ
3 + 65 λ1 = 0.30
λ2 = 0.00079γ
3 + 6.0 λ2 = 9.6
4
λ1 = (4.4n− 19)−1 λ1 = 0.032n− 0.027
λ2 = (26n− 41)−1 λ2 = 0.80n+ 1.5
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Figure 11.8: PCA eigenvalue outcomes for parameters identified in datasets
of increasing size, alongside the a priori PCA eigenvalue model from
Equation (11.10). Note the differing scales in the plots, especially for residual
error (Ψ) which is relatively small compared to the respective eigenvalues.
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11.4 Discussion
The relationships between eigenvectors of the model equation matrix
(ATA) and Monte Carlo parameter spread shown in Figures 11.2-11.4,
show deterministic behaviour that could contribute to advances in a priori
model identifiability analyses. Should all the factors determining PCA
eigenvalues be ascertained in a usable and broadly applicable manner, then
there is potential to estimate wider outcomes of a population of data when
only a single set is processed, as in some cases with real data. Several
linearised relationships have been discerned for a simple model (R2 = 1).
Principal component information could be further processed into useful
statistical measures such as variance or confidence limits on identified
parameters a priori. For physiological models and analysis, these, in turn,
could be used to evaluate the certainty of outcomes for diagnosis or control,
or the degree of practical identifiability of model parameters with assumed
data. Infinite confidence intervals indicate practical non-identifiability
(Raue et al., 2009) and since identifiability is a continuous artefact
(Docherty et al., 2011), smaller finite intervals could be useful in evaluating
whether the degree of identifiability is acceptable, subject to the needs of
the research or application. Where multiple models of a system are
available, the practical identifiability of each could be compared to
determine the best model for the data.
It is a useful outcome that the effect of noise in the output data on the
resulting data spread was linearly correlated with noise variance by the
relationship: λPCA ∝ σ2 with no changes to the ratio between eigenvalues.
This result makes intuitive sense since noise drives the spread of identified
parameters. With no noise, the true parameters would be identified and the
spread would be zero in all directions, even for a practically
non-identifiable, but structurally identifiable model. This relationship is
likely applicable over a range of models where noise is confined to output
data and is zero-mean.
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The results clearly indicate a relationship between the PCA eigenvalues and
the value of x. This outcome was expected since the identified parameter
set, x̂, is dependent on the noisy b̂ vector, defined Equation 3, which can
also be defined as a function of the original parameter set:
b̂ = Eb = EAx (11.11)
where E is a diagonal matrix of (1 + e). Thus substitution into Equation 4
yields an identified parameter definition of:
x̂ = (ATA)−1 ATEAx (11.12)
The parameters x are further propagated into the data storage matrix, X,
and into the covariance matrix, C, before eigen-decomposition where the










where Tr and D are the trace and determinant of the matrix respectively.
The calculation of these eigenvalues therefore appears to be deterministic,
especially since it has already been shown that the effect of the noise can be
described purely by the variance. Given the convolution involved in the
substitution of full definitions of x̂ into the PCA eigenvalue equation,
results drawn instead from MC simulations were highly valuable.
The evidence in Table 11.3 suggests that the eigenvalues are scaled by the
dot product of x with itself, which is the sum of squared parameters:




Both eigenvalues in each case are affected in the same manner
proportionally and the order of that proportionality is the square of the
highest order by which an x parameter changes. When one or both
parameters was equal to γ then λPCA were strongly proportional to γ
2,
though with greater magnitude for scheme 3b than 3a which shows an
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accumulative effect of changes in the two parameters. Further, when one
parameter was equal to γ1.5 then λPCA were strongly proportionality to γ
3.
In addition to this relationship, changing x-parameters altered eigenvalue
ratios but only when parameters were affected to different orders than each
other, otherwise the ratio was constant, as with scheme 3b when
x = [γ, γ]T. For cases 3a and 3c, the eigenvalue ratio changes fitted well
with two-term power models where the exponent term on γ was between -1
and 0 in both cases. This outcome indicates that the eigenvalue ratio is
related to the relative difference in appearance or in this case magnitude of
the two species in the model: the step and ramp.
The relationships of ATA and PCA eigenvalues to n and n− 1 respectively
for the step-ramp model (Table 11.3) highlights the inverse nature of the
two. The PCA eigenvalues describe the level of spread in the direction of
the principal components while the ATA eigenvalues could be described as
evaluating the steepness of the objective surface in the principal directions
of the surface geometry. As the quantity of data increases, the steepness of
the objective surface increases, confining the MC spread to a smaller area.
There was also an n-dependence for both ATA and PCA eigenvalue ratios,
λ1/λ2, the latter of which fitted well to a two-term power model
(Figure 11.6) where the exponent of n was -1.32. Similar to the case with
the changing parameter values, the ratio change may be related to the
relative changes in magnitude of the step and ramp as they appear in the
matrix. For this model, as n increases, the norm of each column in A
increases but at different rates due to the different forms of the species.
There are several limitations to this first analysis based on our findings.
The foremost limitation is its restriction to systems with separable
parameters where a matrix equation Ax = b can be defined. There may
also be issues with parameter models that yield non-elliptical objective
surfaces, as they are poorly described by PCA. This issue could, in some
cases, be remedied by identifying related parameters and inferring the
desired parameter, for example identifying and evaluating 1/xi instead of
xi. Another small limitation is that true noise variance may not be be
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known in real data, though an estimate would likely be sufficient in most
cases. Since PCA eigenvalues are dependent on x, systems with low levels
of practical identifiability and subsequent reduced accuracy in x̂ will likely
influence how the identifiability of the system is perceived by the analysis.
Model systems with A = f(x) have been shown in unpublished results to
introduce much larger error than could be accounted for by this analysis.
Using a simple model was extremely useful for discerning some of the
relationships between ATA and PCA, all of which could contribute in some
way to fundamental relations for more complex biological models.
Ultimately, PCA eigenvalues could be robustly calculated with ATA,
circumventing the need for population-wide data. There is still a missing
link between changes in the properties of the A matrix and the resultant
scaling of the eigenvalues and the altered eigenvalue ratio. All relationships
must be found for the simple case prior to a deterministic approach for all
models can be developed. Furthermore, direct links between PCA and
parameter confidence estimates require research, though there appears to
be deterministic relationships between the two.
Though the deterministic relationship is not yet fully defined for
multiplicative white noise, additive white noise yields a much simpler
relationship, described in Equation (11.10) where the variance in the
scatter is inverse to the model eigenvalues, further scaled by the noise
variance. It is clear that this eigenvalue model is valid for the step-ramp
model (Figure 11.8) and is valid for arbitrary n and x. The relationship
may indeed be more widely applicable to other similarly simple models and
perhaps even more complex models with linearly separable variables. The
implication is that for such models, assuming additive white noise, it is easy
to estimate the variation in population outcomes based on only the model,
some data, and an estimate of the noise variance.
The simplicity of the additive model, while encouraging, is not directly
applicable in the context of physiological modelling. In particular, blood
glucose measurements generally have multiplicative error as opposed to
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additive or mixed (Werner et al., 1978). In some situations, the magnitude
of a measured species compared to its variation might allow for an additive
noise approximation to be valid. However, this is not the case for blood
glucose, especially in individuals with diabetes, since glucose can easily vary
between 4 and 20 mmol/L. Nevertheless, the additive noise model will be
useful as a reference for further work in defining the eigenvalue relationship
with multiplicative noise.
Models can be used to measure, diagnose and predict the behaviour of
many phenomenon. However, even well justified model formulations can
cause failure of model-based analyses. Structural non-identifiability occurs
when multiple model parameters trade off to describe the same behaviour.
While some methods for determining model structural identifiability have
been in existence for many decades (Pohjanpalo, 1978; Bellman and
Åström, 1970; Ritt, 1950), there remains a consistent stream of research in
this field (Audoly et al., 1998, 2001; Bellu et al., 2007).
This research is driven, in part, by the ambiguous identifiability of a
particular model of glycaemic dynamics (Bergman et al., 1979; Cobelli
et al., 1998; Pillonetto et al., 2002, 2003). More recently it has been
discovered that the cause of this failure was practical rather than structural
identifiability (Docherty et al., 2011). The Docherty et al. approach to
practical identifiability analysis was descriptive rather than predictive but
the relationships found, and deterministic nature of the MC analyses
implies that the concept could become a predictive a priori practical
non-identifiability analysis.
11.5 Summary
There are deterministic links between properties of the step-ramp model
equation, data size and measurement noise to the resulting principal
component analysis of a Monte Carlo simulation. Eigenvectors for ATA
and PCA line up directly and the eigenvalues are inversely related. ATA
eigenvalues describe magnitude of steepness in the objective error surface,
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increasing linearly with data size for the model, and PCA eigenvalues
describe the magnitude of spread from a population of data, with an inverse
relationship to data size. Noise in output data increased PCA eigenvalues
in proportion to noise variance. Principal component eigenvalues also
appear to be a scaled dot product of the parameter set, x · x, and differing
orders of change between parameters alters eigenvalue ratio, likely due to
different comparative magnitudes of the step and ramp in the model. Data
size also produced eigenvalue ratio changes, but in both PCA and ATA,
likely also related to comparative step-ramp magnitude.
Most but not all factors for direct PCA eigenvalue calculation have been
ascertained for the simple step-ramp model. However, using additive rather
than multiplicative noise yields a simple and deterministic relationship,
though this has limited usefulness compared to multiplicative noise. Future
research will include aims to find the missing links to multiplicative noise,
as well as to research more complex biological models, and interval
estimation on the basis of PCA. Confidence intervals estimated for a single
parameter identification outcome, as opposed to a whole population, would
be useful where little information is available. The level of confidence in
parameters for diagnosis and control would be useful, along with the ability
to evaluate the practical identifiability of a model and, where applicable,
choose the best model for a set of data.
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Chapter XII
Noise and gestational diabetes diagnosis
This chapter presents an in silico analysis exploring the extent that
pre-analytical glucose decay in clinical OGTTs results in underdiagnosis of
gestational diabetes. This work was done in collaboration with the
Canterbury District Health Board who kindly provided de-identified OGTT
data for a local population of pregnant women. The content of this chapter
has been published in the Journal of Clinical Biochemistry (Mansell et al.,
2017a)
12.1 Motivation
The two-hour OGTT is a standard method for clinical diagnosis of
gestational diabetes (GDM). During the procedure, the fasted patient
ingests a 75g oral glucose load. Venous blood samples are taken
immediately before ingestion, at one hour after ingestion and two hours
afterwards. These samples are assayed for blood glucose concentration and
the values are then compared to diagnostic criteria for GDM. While many
diagnostic levels exist, a commonly used criteria for GDM was defined by
the International Association of Diabetes and Pregnancy Study Group
(IADPSG). The IADPSG recommends diagnoses of GDM when any one of
the thresholds are exceeded: fasting glucose ≥ 5.1 mmol/L; one-hour
glucose ≥ 10.0 mmol/L; or two-hour glucose ≥ 8.5 mmol/L (Duran et al.,
2014).
In typical clinical practice, tubes containing blood samples are treated with
sodium-fluoride in order to preserve glucose concentration until laboratory
analysis can take place. However, research has suggested that GDM is
systematically underdiagnosed as the use of fluoride tubes to store blood
prior to assays leads to significantly lower readings than gold standard
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methods (Daly et al., 2016; Carey et al., 2016; Uchida et al., 1988). In
particular, Uchida et al. (1988) found that fluoride tubes attenuate glucose
decay but a minor reduction in serum glucose still occurs. This decay was
on the order of 8% glucose and plateaued after approximately two hours at
room temperature. Hence, the measurable glucose levels from samples
stored in fluoride tubes reduces over the time between the sampling time
and the laboratory process time. Since fasting, one-hour and two-hour
samples tend to be batched and processed together, there is differing
measured glucose bias in the three samples (Carey et al., 2016; Daly et al.,
2016).
This investigation determines the likelihood of misdiagnosis of GDM in the
presence of fluoride-induced bias in glucose measurement. Understanding
the limitations of a diagnostic test is critical to applying it effectively and




A cohort of 1 million virtual test subjects was simulated using glucose
distributions that were summarised in a prior study by Hypoglycaemia and
Adverse Pregnancy Outcomes (HAPO) (The HAPO Study Cooperative
Research Group, 2008). Fasting (G0), one hour (G1) and two hour (G2)
glucose values were drawn from the distributions described by the following
equations and pictured in Figure 1:
G0 = 3.9 + e
N(−0.8,0.6) (12.1)
G1 = 2.1G0 + N(−1.9, 1.5) (12.2)
G2 = 0.2G0 + 0.52G1 − 2.3 + eN(1.3,0.24) (12.3)























Figure 12.1: The probability distributions for fasting, 1 and 2 hour glucose in
the simulated cohort. Solid lines indicate gold standard; dashed lines indicate
fluoride tubes; dotted lines show the diagnostic thresholds.
These distributions were designed to create plausible OGTT results within
±2% of reported target values for mean (G0 = 4.5 mmol/L, G1 = 7.4
mmol/L, G2 = 6.2 mmol/L), inter-sample correlation (R0−1 = 0.38,
R0−2 = 0.30, R1−2 = 0.68) and standard deviations (0.4, 1.7, 1.3 mmol/L)
based on the large (n > 23, 000) HAPO study (The HAPO Study
Cooperative Research Group, 2008).
Published intra-individual CV on glucose measurement reported by the
HAPO study was 4.4% (Nesbitt et al., 2006). Hence, to mimic results from
the gold standard (GS) glucose analysis methods used by HAPO, the
simulated glucose values were multiplied by a normal distribution of values,
Gh,GS = GhN(1, 0.044) for h = 0, 1 and 2 hours.
Both Daly et al. (2016) and Carey et al. (2016) demonstrated differences in
glucose results associated with using test tube preservatives with typical
batching processes compared to research-grade methods equivalent to the
gold standard methods utilised in HAPO. In the larger of the two studies
by Daly et al., the mean error between fluoride tubes and the gold standard
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method were -0.5, -0.4, and -0.2 mmol/L for G0, G1 and G2 respectively. In
the Carey et al. data, the standard deviations in the errors between fluoride
and gold standard were approximately 4% of the mean measured
fluoride-tube value. Hence, fluoride-tube glucose outcomes (G0−2,F ) were
created with the following equations:
G0,F = (G0,GS − 0.5)N(1, 0.04) (12.4)
G1,F = (G1,GS − 0.4)N(1, 0.04) (12.5)
G2,F = (G2,GS − 0.2)N(1, 0.04) (12.6)
12.2.1.2 Real-virtual hybrid cohort
A hybrid cohort was created with real fluoride-tube glucose assays from
pregnant women in New Zealand (n = 1305) that were used to simulate
corresponding gold-standard data. The HAPO population on which the
fully virtual cohort are based were randomly selected and thus
representative of a typical population of pregnant women. In contrast, this
cohort represents a population more typically administered this OGTT in a
clinical context, who have first screened positive in the one-hour 50g
OGTT. The typical New Zealand diagnostic criteria requires one glucose
threshold to be exceeded out of G0 ≥ 5.5 and G2 ≥ 9.0 mmol/L.
The gold standard simulated values were created with the following
equations, and both the real and simulated cohorts are pictured in
Figure 12.2.
G0,GS = G0,FN(1, 0.04
√
2) + 0.5 (12.7)
G2,GS = G2,FN(1, 0.04
√
2) + 0.2 (12.8)
12.2.2 Analysis
The fluoride and true simulated OGTT results were evaluated against the
IGADSG diagnosis criteria (Duran et al., 2014). By this criteria, patients
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blood glucose (mmol/L)



















Figure 12.2: The n = 1305 cohort for fasting and two hour glucose. Dashed
lines are real fluoride-preserved data; solid lines are the simulated gold
standard cohort; dotted lines show the diagnostic threshold.
must exceed just one of the three glucose thresholds for a positive
diagnosis. The thresholds are G0 ≥ 5.1,G1 ≥ 10.0,G2 ≥ 8.5 mmol/L. A
confusion matrix was created to calculate the rate of true positive (TP),
true negative (TN), false positive (FP) and false negative (FN) diagnostic
outcomes using the fluoride tubes compared to gold standard methods.





) of glucose measurements that were stored in fluoride tubes with
respect to findings of the gold standard tubes.
Fluoride and gold standard outcomes were compared for each of fasting,
one-hour and two-hour glucose with respect to the IGADSG thresholds on
scatter plots. Receiver operating characteristic (ROC) curves were also
created for fluoride against gold standard. To determine the glucose
thresholds from fluoride tubes that match gold standard diagnostics, the
optimal sensitivity and specificity obtainable from the fluoride tubes was
determined. This optimal point was defined as the point closest to 100%
sensitivity and specificity (the point closest to the top-left of the ROC
curves), i.e. when min (||[1− sensitivity, 1− specificity]||2) is true.
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All computational analysis were carried out in MATLAB R2015a on a
64-bit Intel R© CoreTM i7-4770 CPU @ 3.40GHz with 16.0 GB of RAM.
12.3 Results
Based on the OGTT results with the gold standard methods, 14% of the
cohort met the requirements for a diagnosis of GDM (Table 12.1). Under
two thirds of these individuals were also identified by the fluoride-tube
OGTT. Hence the sensitivity was calculated as 57.5%. There were very few
individuals (0.3%) diagnosed with GDM based on fluoride tubes who were
not diagnosed with gold standard methods. Hence, the specificity was near
100%.
Figure 12.3 shows that fasting glucose has the lowest sensitivity with many
FN outcomes (pink quadrant). One and two hour glucose have similar ROC
curves, with reasonably high sensitivity. In contrast, the fasting glucose
stored in the fluoride tube yielded poor sensitivity. table 12.2 shows that
the fluoride-tube glucose thresholds with the optimum combination of
sensitivity and specificity are 4.4, 9.2 and 7.9 mmol/L for G0−2 respectively.
The results for the hybrid cohort with NZ diagnostic criteria are very
similar to those of the large in silico population with the IADPSG
diagnostic criteria. The sensitivity of the test was 48.4% (Table 12.3),
indicating approximately half of diagnosable patients were overlooked.
Fasting glucose had very low sensitivity with many false negative outcomes,
more so than two-hour glucose. Optimum glucose thresholds to achieve
diagnostic equivalence were 4.8 and 8.5 mmol/L for and respectively
(Table 12.4).
12.4 Discussion
The use of in silico modelling was effective in estimating and visualising the
effect of glucose decay in fluoride tubes on clinical diagnosis outcomes on a
large population of individuals. The results demonstrated that the typical
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Table 12.1: The confusion matrix for the overall diagnostic outcomes, and
each sample time, of fluoride-tube OGTT compared to OGTT with gold
standard tube treatment in the virtual cohort. Note: contrary to typical
confusion matrices, the orientation of the different boxes to gain consistency
with Figure 12.3.
OVERALL G0
Gold Gold Gold Gold
-ve +ve -ve +ve
Fluoride FP TP FP TP
+ve 0.3% 7.8% 0.0% 1.8%
Fluoride TN FN TN FN
-ve 86.2% 5.8% 93.9% 4.3%
Specificity Sensitivity Specificity Sensitivity
99.6% 57.5% 100% 29.4%
G1 G2
Gold Gold Gold Gold
-ve +ve -ve +ve
Fluoride FP TP FP TP
+ve 0.2% 4.5% 0.2% 3.5%
Fluoride TN FN TN FN
-ve 93.0% 2.3% 94.7% 1.6%
Specificity Sensitivity Specificity Sensitivity
99.8% 66.3% 99.8% 68.6%
Table 12.2: Diagnostic characteristics at the point on the ROC curve closest
to the top left corner for each sample time in the virtual cohort.
sample original original
c-ROC
new threshold optimal optimal
time sensitivity specificity (mmol/L) sensitivity specificity
0 hour 29.4% 100% 0.990 4.4 95.5% 94.5%
1 hour 66.3% 99.8% 0.994 9.2 96.5% 96.3%
2 hour 68.6% 99.8% 0.995 7.9 97.0% 96.8%
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gold standard (mmol/L)


































































































































Figure 12.3: ROC curves for fluoride tubes vs gold standard in the virtual
cohort, with the point of diagnostic threshold marked •, and optimal
threshold marked ◦ (top row). Scatter plots of fluoride tubes vs gold standard
glucose for a representative cohort of 1000, with the optimal threshold shown
by the dotted line (bottom row).
Table 12.3: The confusion matrix for the diagnostic outcomes of fluoride-
tube OGTT compared to OGTT with gold standard tube treatment for the
hybrid n = 1305 cohort. Note: contrary to typical confusion matrices, the
orientation of the different boxes to gain consistency with Figure 12.4.
OVERALL G0 G2
Gold Gold Gold Gold Gold Gold
-ve +ve -ve +ve -ve +ve
Fluoride FP TP FP TP FP TP
+ve 7 171 2 78 9 113
Fluoride TN FN TN FN TN FN
-ve 945 182 1033 192 1152 31
Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity
99.3% 48.4% 99.8% 28.9% 99.2% 78.5%
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gold standard (mmol/L)


















































































Figure 12.4: ROC curves for fluoride tubes vs gold standard in the hybrid n =
1305 cohort, with the point of diagnostic threshold marked •, and optimal
threshold marked ◦ (top row). Scatter plots of fluoride tubes vs gold standard
glucose for a representative cohort of 1000, with the optimal threshold shown
by the dotted line (bottom row).
Table 12.4: Diagnostic characteristics at the point on the ROC curve closest
to the top left corner for each sample time in the hybrid cohort.
sample original original
c-ROC
new threshold optimal optimal
time sensitivity specificity mmol/L sensitivity specificity
0 hour 28.9% 99.8% 0.954 4.8 91.1% 85.6%
2 hour 78.5% 99.2% 0.992 8.5 95.1% 96.9%
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clinical procedure of batching blood samples in fluoride-preserved tubes had
a noticeable effect on diagnosis outcomes in silico. Table 12.1shows that in
the virtual cohort over a third of samples that led to a positive diagnosis
with the gold standard methods were not diagnosed when fluoride tubes
were used. This false negative rate was even greater (over half) in the
hybrid cohort of local pregnant women. Low sensitivity is a clinically
relevant outcome as false negatives will lead to a lack of medical
intervention for at-risk individuals.
Figure 12.3 shows that fasting glucose had a particularly low sensitivity. In
batched samples, fasting glucose has the longest wait before processing and
thus the greatest extent of glucose decay. One-hour glucose was less
susceptible to glucose decay than two-hour glucose due to the overall higher
glucose values and the absolute, rather than proportional decay, caused by
the fluoride tubes. However, the selection of an absolute decay of glucose in
this simulation is justified by the fact that the decay in both Daly et al.
(2016) and Carey et al. (2016) populations appeared to depend only on
time in the sense of strictly increasing population error for earlier samples,
i.e. 0.5, 0.4 and 0.2 mmol/L for (Daly et al., 2016). This does not rule out a
dependency of glucose decay on nominal glucose concentration, but the
assumption is valid in the absence of more direct evidence.
Table 12.2 suggests that optimal diagnosis rates in the virtual cohort with
fluoride tubes are achieved with glucose thresholds at 4.4, 9.2 and 7.9
mmol/L rather than 5.1, 10 and 8.5 mmol/L. The difference in threshold
values is remarkable, especially for fasting glucose since 4.4 mmol/L is
considered a healthy fasting concentration. However, a batched
fluoride-tube fasting glucose of 4.4 mmol/L implies much higher actual
fasting glucose. Additionally, it must be accepted that a shift in diagnostic
threshold towards markedly improved sensitivity trades off with a small
increase in specificity. Table 12.2 shows that rates of specificity remain
above 94% when the optimal threshold increases sensitivity to > 95%. An
equivalent outcome was found in the hybrid cohort with the optimal fasting
threshold at 4.8 from 5.5 mmol/L and two hour at 8.5 from 9.0 mmol/L.
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The simulated populations were successfully created with similar
characteristics to those published for the large HAPO cohort. Laboratory
process effects were implemented in the data. Reported intra-individual
variation on glucose assay by the gold standard method was applied
(Nesbitt et al., 2006). The effect of glucose decay in fluoride tubes when the
three blood samples are batched together and processed at once was also
easily applied (Carey et al., 2016). Using a large virtual population of 1
million mitigated the influence of discrete patient numbers influencing the
false-positive and false-negative rates at the diagnosis thresholds.
The disadvantage of using the published summary of the HAPO cohort
characteristics is that mean, standard deviation and correlation does not
fully describe the shape of non-normal distributions. This means that there
is a great range of possible variations, especially in the shape and size of
the tails. In particular, many different distribution shapes meet the listed
criteria. Since the nature of the tail distributions is most critical in
diagnostic outcomes, the exact applicability of these in silico analyses is
limited by the uncertainty of the true shapes (Figure 12.3). However, the
use of log-normal distributions for these distributions has been found in a
number of studies (Peplies et al., 2014; Kirchsteiger et al., 2015; Kovatchev
et al., 1997).
The hybrid cohort demonstrated similar outcomes to the fully virtual
cohort. This equivalence in outcomes is largely due to the replication of
simulation strategy, despite the underlying real cohort. However, since the
literature provides good evidence for the effect of batched fluoride samples
(Carey et al., 2016; Daly et al., 2016), this analysis is equally valid.
Moreover, the hybrid cohort overcomes some of the limitations of unknown
distribution shapes in the HAPO populations. Additionally, the extension
to a more realistic clinical cohort is useful, compared to HAPO which was
intentionally more inclusive in its selection criteria for other research
purposes.
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The present analysis builds on the work of the small in vivo study by Carey
et al. (2016) which directly compared glucose assay outcomes with
fluoride-tube batching to the gold standard methods used in HAPO. This
in silico study demonstrates on a larger scale the potential for this current
common practice to have a clinically relevant diagnostic impact on the
OGTTs of pregnant women. While the findings of this study strongly imply
that there is a lack of sensitivity when fluoride tubes are used for diagnosis
of GDM, further research in a prospective human study must be
undertaken to confirm the findings and determine the relevant equivalent
diagnostic thresholds.
12.5 Summary
Both the in silico and hybrid populations analysed in this chapter suggest
that the typical practice of assaying batches of fluoride-preserved OGTT
samples results in a markedly low diagnostic sensitivity compared to gold
standard practices. In particular, fluoride-tube sensitivity with the 75g
OGTT using the IADPSG criteria was 57.5% in the simulated cohort,
indicating over a third of diagnosable patients would be overlooked.
Similarly, the hybrid cohort had an overall diagnostic sensitivity of 48.4%
with more than half of diagnosable patients overlooked.
The duration of glucose decay was most significant for a fasting samples,
and thus noticeably reduced the apparent glucose concentration. Hence,
optimum diagnosis rates would require lower glucose thresholds when using
fluoride as a preservative compared to thresholds based on gold standard
glucose assays. Likewise, but to a progressively lesser extent the one and
two hour sample thresholds should be lower to gain diagnostic equivalence
to gold standard samples.
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Part IV
Conclusions and future work
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Chapter XIII
Summary and concluding remarks
13.1 Summary
Type 1 diabetes is an autoimmune disease affecting an increasing number
and proportion of people worldwide. The primary clinical characteristic of
the disease is hyperglycaemia due to a lack of endogenously produced
insulin. Autoimmune destruction of the insulin-producing β cells in the
pancreas tends to be absolute, especially in younger individuals.
Fortunately, the widespread availability of manufactured insulin provides
viable treatment. However, insulin administration only mitigates some
symptoms of diabetes and is not a cure for the disease. Presently T1DM is
managed, not cured. Insulin treatment is daily and ongoing, and therefore
burdensome for the individual. This is particularly due to the delicate
balance required to treat hyperglycaemia but avoid hypoglycaemia.
The appropriate doses of insulin required to achieve euglycaemia are
uncertain during the everyday life of some outpatients with diabetes.
Hence, individuals are often not able to engage in the fullness of activities
enjoyed by the healthy. For example, a strict routine for mealtimes can
substantially improve glycaemic control, improving quality of life. However,
the routine is kept at the expense of flexibility, which can negatively impact
on social and psychological freedoms, thereby reducing the quality of life.
This example demonstrates both the inherent difficulties of accounting for
all influences on glucose metabolism in the everyday, as well as the need for
treatment to be a good compromise between improving glycaemic control
and decreasing the burden of the disease. Each of these factors contributes
positively to the perceived quality of life.
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Much of the current research in diabetes management is focused on
achieving a successfully automated closed-loop control solution to diabetes,
termed the artificial pancreas. This would be the most ideal treatment
solution for individuals with T1DM since it could potentially achieve near
normal glycaemia with minimal human input. An effective closed-loop
controls system would negate some or much of the need for anticipating the
effect of certain everyday factors, by observing and directly influencing the
target species, blood glucose concentration, at a higher sampling frequency
than for self-managed methods.
However, the yet unresolved problem for the artificial pancreas is the
inability to obtain high enough quality glucose measurements at a high
sampling frequency. Meters that use finger-pricking are reasonably reliable
but require effort, pain and long term scarring. Hence, the maximum
frequency of use is only a few times daily in self-managed individuals.
Continuous glucose monitoring (CGM) systems are able to achieve high
frequency data (typically every 5 minutes) but do not measure blood
glucose directly, resulting in both delay and damping of observed dynamics.
Additionally, CGMs are prone to unpredictable spikes and jumps in error,
along with a steady error drift. These problems are ameliorated with
frequent recalibration to finger-prick measurement (e.g. once daily) and
recommendations to confirm some measurements (particularly
hypoglycaemic) before adjusting treatment. Nevertheless, the performance
of CGMs are at present insufficient to ensure safe and effective closed-loop
control.
In contrast to a closed-loop control focus, the present work falls into the
vein of research that aims to inform and improve self-managed blood
glucose control. Glucose metabolism is complex, multifaceted, and subject
to a wide range of influences arising in everyday life. Some factors have
very minor and clinically insignificant effects while others can severely
impact on glycaemic control, but these differentiations vary widely across
individuals. Some patients are termed ”brittle” by clinicians due to their
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sensitivity to external factors and inability to achieve good glycaemic
control despite rigorous effort. These individuals in particular would benefit
from model-based decision support that is personalised and includes as
many factors as are both relevant and observable. Even without
model-based decision support, greater personalised knowledge of these
factors would be beneficial.
Four major categories of everyday life factors have been studied in depth in
the literature, presented in Chapter 4: nutrition, psychological effects,
physical activity and metabolic rhythms. These areas were considered to
encompass many factors that have recognised effects on glycaemia but lack
consensus around modelling. This chapter collated and compared various
models of these effects in outpatients to reduce undesirable systemic and
non-random grey noise affecting model outcomes. The analysis considered
how the measurement of such factors affect the model. However, with the
right tools, data and models, it can be expected that observable signals
from a variety of factors are separable and quantifiable.
Developing and selecting the right model is a major theme of the present
work. Ultimately, personalisable models would need to be used with data
from the outpatient environment to capture that glimpse of the everyday.
However, the data used in the present work, described in Chapter 5, is an
effective stepping stone toward such a goal. The data is of very high
research quality but introduces some of the variability of the everyday in a
prescribed manner, and in a heterogeneous cohort. The resulting richly
descriptive and dynamic data has been ideal for developing an
understanding of the physiological aspects of some of the effects being
considered. The subsequent model development has thus been informed by
the breadth and depth of the behaviour and the variability that can also be
expected outpatients.
Models fully informed by the breadth and depth of information in the
research data are also an intermediary stage. Indeed, the development of a
subcutaneous model in Chapter 6 highlighted that even best choice of
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model with respect to the research data was not that which contained the
most detail that the data could afford. This work was valuable in part
because of the lack of subcutaneous models specific to a continuous infusion
of insulin aspart. Therefore, the model(s) developed fulfil a particular
demand. But perhaps more valuable still was a demonstration of the
rigorous analysis process for assessing relative model performance.
While some models appear to be designed with a poor understanding of
some of the mathematical limitations in physiological modelling around the
issue of robustness and practical non-identifiability, the subcutaneous
model analyses of Chapter 6 made every effort to consider more than just
model fitting ability. A model in itself may be pioneering in its
physiological descriptiveness and accuracy. But if it cannot be used
effectively in the context of its intended purpose due to insufficient data
quality and quantity, then the descriptiveness and accuracy are wasted.
Hence, it is not surprising that one of the much simpler subcutaneous
insulin models was found to be best when considering these clinically
relevant metrics. When poor understanding of this problem prevails, the
confidence placed in the descriptiveness and accuracy (or a long legacy of
use) can lead to poor or dangerous model interpretation for a clinical
context. Hence, the methodology and outcomes of Chapter 6 are an
important addition to the research field.
Development of a model for the effect of moderate aerobic exercise on
insulin and glucose did not include the same level of rigorous analysis as the
subcutaneous model. Nonetheless, a unique and perhaps novel approach
was taken in this model development process. The use of autoregressive
modelling to retrieve information on underlying behaviours (Chapter 7) is
uncommon in itself. Usually, NARX models are used as a black box, where
the correlative information is not sought after so much as the model’s
ability to make output predictions based on the same type of inputs as are
encountered in the training stage. By uncovering the correlative
information for exercise, the present method can instead be considered
grey-box modelling, not being as physiologically rigorous in definition as
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most differential glycaemic models, but not just about the inputs to
outputs performance either. This method was an effective step in the
development process as it allowed the data to inform the model more
directly than if guess and check iterations were carried out.
Additionally, the exercise-effect behaviour uncovered was remarkably
consistent across the heterogeneous cohort. Therefore, despite the
limitations of NARX modelling, the results were interesting and persuasive
at a descriptive level at least. To illustrate this, there was found to be
contention in the literature over whether exercise influenced the
concentration of exogenous insulin in the plasma positively, negatively, or
not at all. The NARX analysis demonstrates that there was a positive
effect during exercise and negative afterwards, for the type of exercise
carried out and in the experimental conditions prescribed. Indeed, the
further work in Chapter 8 showed that the magnitude of this excursion
appears correlated to subcutaneous concentration, especially relating to
insulin boluses. This observation would further explain the contention in
the literature, since some experiments would inevitably aim to increase
repeatability by removing insulin boluses. Evidently, such an experimental
design would likely not see the same effect as observed amongst an everyday
routine that contains boluses. This notion further highlights the value of
NARX in being able to deconvolute the exercise effect from other dynamics.
Beyond the NARX and in anticipation of an outpatient context, the basis
models presented in Chapter 8 were designed as a simplistic
implementation of a model containing the effect of exercise. The underlying
plasma insulin model neglects some known physiological features such as
saturated clearance and interaction with interstitium. These simplifications
were intentional since the sophisticated insulin pharmacokinetics are not
likely to be observable in outpatients. Still, the model performed well as
the exercise basis is an effective addition to the model. The basis function
used in the model is easier to apply than attempting to alter subcutaneous
uptake rates, which is the likely physiological mechanism. Correlation of
the magnitude of the exercise-induced insulin excursion to prior insulin
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concentration appears significant, though cautionary, but represents work
towards a more extensively a priori insulin model, which would be most
appropriate for outpatients given the limitations in observability.
A basis model was also created for the effect of exercise on glucose. The
glucose model was also relatively simple, which noticeably limited its fitting
performance, particularly due to unmodelled effects in the appearance of
food and in the physiological responses to intravenous glucose bolus.
However, the exercise basis itself performed well and improved the model
fit. The model featured an increasing but saturated rate of glucose disposal
as exercise was carried out in response to an increase in peripheral glucose
demand. This exercise-induced glucose disposal remained post-exercise,
possibly representing a refuelling of peripheral glycogen stores, but
eventually returned to zero.
Chapter 9 demonstrates in silico that though the data quality expected
from outpatients is poor, this limitation is overcome with time. As data
accumulates, parameter estimates for everyday effects tend towards the true
underlying value with minimal bias. This result emerged despite the various
sources of error that were introduced, such as glucose measurement noise,
unrecorded food intake and carbohydrate misestimation. Additionally, it
was found that longer-term changes in insulin sensitivity could be
accounted and compensated for, further increasing the viability of this type
of data collection. This finding represents a pathway toward personalisable
glycaemic models that can be fit to the individual, for the individual.
Further work was carried out in consideration of practical identifiability for
model recovery in outpatient data. Chapter 10 presented an analysis for
evaluating the value of identifying increasing parameter sets. The caution is
that identifying too many parameters in insufficient data can result in
substantial parameter trade-off, unknowingly introducing large errors.
While the analysis in its current form only works in silico where the true
parameter values are known, the results provide insight into the likely
capabilities of the model and data. On the other hand, an analysis
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developed from the initial work of Chapter 11 would be able to evaluate the
likely confidence intervals of parameters with only the information expected
from real data. However carried out, an analysis around the practical
identifiability of the parameter estimates is crucial if the identified
parameters are to be fed back into control strategies and systems.
Chapter 12 provides an interesting case-study of the influence of a
particular form of grey-noise on clinical interpretation of diagnostic
outcomes in gestational diabetes. This work is somewhat tangential to the
main focus of the present work in T1DM. However, it is valuable to
clinicians in highlighting the limitations of the typical laboratory processing
techniques used, and the implication for getting appropriate treatment to
those in need. Though some assumptions have been made in the simulation
of test cohorts, the evidence of poor test sensitivity in typical practice is
unambiguous. This outcome also generally highlights the possible effect of
measurement noise on the observability of behaviours, particularly systemic
grey-noise in small data quantities.
Overall, the present work takes great strides towards an improvement in
glycaemic control for individuals with diabetes by modelling the effects of
everyday life factors. There is a distinct value in modelling such factors, so
long as the models are effective and robust. The ability to use models in an
outpatient context would be beneficial for a large number of individuals,
since there the unique effects of a unique set of everyday life factors would
be observed. Hence, the models have been developed with consideration to
the practical identifiability constraints of outpatient data. Furthermore, an
in silico investigation of the efficacy of model recovery in outpatients shows
positive preliminary results, and further work was carried out addressing
identifiability analyses specifically. Ultimately, sound modelling of everyday
life factors would improve the quality of life for sufferers of diabetes by
improving control and decreasing the burden of disease management.
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13.2 Concluding remarks
Three broad conclusions can be drawn from this work. The first is that the
literature demonstrates numerous factors present in the outpatient
environment that can noticeably affect glucose metabolism and thus
glycaemic control. These factors include physical activity, psychological
stress and depression, daily metabolic rhythms, menstrual cycles, food
variability and so on. Furthermore, technologies are increasingly being
developed to measure the presence or effect of some of these factors.
Without accounting for these everyday life factors, model-based control
techniques are limited in their effectiveness, reliability and safety. Hence
there is a need to model such factors, specific to individual patients.
The second broad conclusion is the need to consider practical identifiability.
This type of identifiability is as valid to ensure as the traditional structural
identifiability, perhaps even more so given its subtler presentation. In
practice this means that although everyday life effects for outpatients
should be modelled, they can only be modelled to the degree of complexity
allowed by the quality of information present. Patient-specific variables
should be identified with sufficient confidence to ensure safety and
effectiveness.
The final broad conclusion is that despite the challenges of outpatient data
quality, it appears entirely possible to identify the patient-specific
parameters sought, if enough data can be collected over a longer period of
time. Preliminary computational simulations suggest that it is possible to
identify everyday life factors and other metabolic variables modelled in a
virtual patient, even with sparse data, noise and unmodelled effects. Since
everyday life effects cannot all be controlled and simulated in the inpatient





The present work demonstrates the scientific foundation for advances in
interventional treatment. However, further advances are necessary before
such an intervention. With the current data, there is yet more model
development and evaluation that could be carried out. A highly functional
glucose model is the main goal as blood glucose is the target species for
control and is readily measured in outpatients.
Glucose dynamics are considerably more complex than insulin due to the
large variety of regulatory influences. Since several hormones other than
insulin affect glycaemia, there is potential to improve understanding and
physiological modelling of the dynamic effects of these hormones, and to
generally improve the physiological accuracy of the glucose model as
necessary. However, keeping in mind the substantial practical identifiability
constraints of outpatient data, advancing the glucose model would likely
need to be followed by wise simplifications. This may seem redundant,
however not all simplifications or complications of modelled behaviour are
beneficial. Like the process carried out with the subcutaneous insulin
model, it would be beneficial to be able to model all reasonable behaviours
and evaluate which simplifications of these behaviours will be the best
compromise of fit, prediction ability and parameter robustness.
Some aspects of the glucose model will need improving, beyond what the
current data can inform. This is particularly true for forms of exercise other
than moderate aerobic exercise, or at greater durations (given the influence
of glycogen depletion). Moreover, the medium term influence of physical
activity on insulin sensitivity spanning multiple days needs some viable
model pathways. Other everyday life effects such as stress will require some
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model development as well. These model developments could be built on
information from the literature and tested on outpatient data directly.
Additional in silico analysis of model recovery could be carried out. These
would include updated versions of the models since the model recovery
work pre-dated the model-building. On the other hand, the model recovery
analysis was always intended as a proof of concept for the overall research
goals. The concept appears to be proved well by the results. Additionally,
preliminary in vivo testing of the models would be low cost and low risk.
The data would be collected using a diary template distributed and
recollected by a primary healthcare provider. No intervention would be
carried out during this observations stage of the research. Only small
numbers of patients would need to be recruited due to the individualised
application of the work.
A rigorous testing of models in the outpatient data would then need to be
carried out. This process would include evaluation of the robustness and
reliability of all identified parameters. This stage of the research would be
pivotal. Though all prior research has and would be valuable in some
capacity, these tests would confirm whether the everyday effects considered
are actually observable in the type of data collected. If not, then steps
could be taken to improve the quality of the data for another next attempt.
This could include an increase in the number of easily wearable sensors for
heart rate, temperature, sympathetic nerve activity and so on. These would
provide clearer input parameters for certain everyday effects and would
improve model outcomes compared to subjective diary recordings.
Pending successful identification of everyday life effects, considerable in
silico analysis would need to be carried out to evaluate whether
interventional treatment could be safely and effectively implemented.
Multiple control strategies would be tested with the information provided,
and a suitable user interface would be required for the model-based insulin
recommendations. These analyses would inform ethical applications for
recruitment of patients to test interventions. Experimental design would
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need to be rigorous to evaluate whether the intervention is successful.
Crossover would be necessary to compare intervention periods versus
non-intervention periods. A combination of metrics would be used for the
evaluation including HbA1c measurement, number of hypoglycaemic events,
percentage of blood glucose in the target band, and patient interviews. The
patients would need to be well instructed, especially to check that
intervention-recommended insulin doses are reasonable compared with their
intuition and past experience.
The present scope of the future work ends at determining if patient trials
were successful. If interventional treatment performs well enough, then the
research could increase the scope to larger trials and ultimately
implementation to unstudied individuals.
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